<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Treatment with disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis - Filippini, G - 2017 | Cochrane Library</title> <meta content="Treatment with disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis - Filippini, G - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012200.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Treatment with disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis - Filippini, G - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012200.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012200.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Treatment with disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis" name="citation_title"/> <meta content="Graziella Filippini" name="citation_author"/> <meta content="Fondazione IRCCS, Istituto Neurologico Carlo Besta" name="citation_author_institution"/> <meta content="graziella.filippini@istituto-besta.it" name="citation_author_email"/> <meta content="Cinzia Del Giovane" name="citation_author"/> <meta content="University of Modena and Reggio Emilia" name="citation_author_institution"/> <meta content="Marinella Clerico" name="citation_author"/> <meta content="AOU San Luigi Gonzaga" name="citation_author_institution"/> <meta content="Omid Beiki" name="citation_author"/> <meta content="Miriam Mattoscio" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="Federico Piazza" name="citation_author"/> <meta content="AOU San Luigi Gonzaga" name="citation_author_institution"/> <meta content="Sten Fredrikson" name="citation_author"/> <meta content="Karolinska Institutet" name="citation_author_institution"/> <meta content="Irene Tramacere" name="citation_author"/> <meta content="Fondazione IRCCS, Istituto Neurologico Carlo Besta" name="citation_author_institution"/> <meta content="Antonio Scalfari" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="Georgia Salanti" name="citation_author"/> <meta content="University of Bern" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD012200.pub2" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/04/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012200.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012200.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012200.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Adjuvants, Immunologic [adverse effects, *therapeutic use]; Cladribine [adverse effects, therapeutic use]; Cohort Studies; Crotonates [adverse effects, therapeutic use]; Disease Progression; Glatiramer Acetate [adverse effects, therapeutic use]; Hydroxybutyrates; Immunosuppressive Agents [adverse effects, *therapeutic use]; Interferon beta‐1a [adverse effects, therapeutic use]; Multiple Sclerosis [*drug therapy]; Nitriles; Publication Bias; Randomized Controlled Trials as Topic; Recurrence; Time Factors; Toluidines [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012200.pub2&amp;doi=10.1002/14651858.CD012200.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="mV7VuqgF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012200\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012200\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012200.pub2",title:"Treatment with disease\\u2010modifying drugs for people with a first clinical attack suggestive of multiple sclerosis",firstPublishedDate:"Apr 25, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012200.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012200.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012200.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012200.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012200.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012200.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012200.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012200.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012200.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012200.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4313 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012200.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-sec-0157"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-sec-0033"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-sec-0034"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-sec-0071"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-sec-0127"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/appendices#CD012200-sec-0162"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/table_n/CD012200StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/table_n/CD012200StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Treatment with disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information#CD012200-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Graziella Filippini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information#CD012200-cr-0003">Cinzia Del Giovane</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information#CD012200-cr-0004">Marinella Clerico</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information#CD012200-cr-0005">Omid Beiki</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information#CD012200-cr-0006">Miriam Mattoscio</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information#CD012200-cr-0007">Federico Piazza</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information#CD012200-cr-0008">Sten Fredrikson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information#CD012200-cr-0009">Irene Tramacere</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information#CD012200-cr-0010">Antonio Scalfari</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information#CD012200-cr-0011">Georgia Salanti</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information/en#CD012200-sec-0167">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 April 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012200.pub2">https://doi.org/10.1002/14651858.CD012200.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012200-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012200-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012200-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012200-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012200-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012200-abs-0001" lang="en"> <section id="CD012200-sec-0001"> <h3 class="title" id="CD012200-sec-0001">Background</h3> <p>The treatment of multiple sclerosis has changed over the last 20 years. The advent of disease‐modifying drugs in the mid‐1990s heralded a period of rapid progress in the understanding and management of multiple sclerosis. With the support of magnetic resonance imaging early diagnosis is possible, enabling treatment initiation at the time of the first clinical attack. As most of the disease‐modifying drugs are associated with adverse events, patients and clinicians need to weigh the benefit and safety of the various early treatment options before taking informed decisions. </p> </section> <section id="CD012200-sec-0002"> <h3 class="title" id="CD012200-sec-0002">Objectives</h3> <p>1. to estimate the benefit and safety of disease‐modifying drugs that have been evaluated in all studies (randomised or non‐randomised) for the treatment of a first clinical attack suggestive of MS compared either with placebo or no treatment; </p> <p>2. to assess the relative efficacy and safety of disease‐modifying drugs according to their benefit and safety; </p> <p>3. to estimate the benefit and safety of disease‐modifying drugs that have been evaluated in all studies (randomised or non‐randomised) for treatment started after a first attack ('early treatment') compared with treatment started after a second attack or at another later time point ('delayed treatment'). </p> </section> <section id="CD012200-sec-0003"> <h3 class="title" id="CD012200-sec-0003">Search methods</h3> <p>We searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group Trials Register, MEDLINE, Embase, CINAHL, LILACS, clinicaltrials.gov, the WHO trials registry, and US Food and Drug Administration (FDA) reports, and searched for unpublished studies (until December 2016). </p> </section> <section id="CD012200-sec-0004"> <h3 class="title" id="CD012200-sec-0004">Selection criteria</h3> <p>We included randomised and observational studies that evaluated one or more drugs as monotherapy in adult participants with a first clinical attack suggestive of MS. We considered evidence on alemtuzumab, azathioprine, cladribine, daclizumab, dimethyl fumarate, fingolimod, glatiramer acetate, immunoglobulins, interferon beta‐1b, interferon beta‐1a (Rebif®, Avonex®), laquinimod, mitoxantrone, natalizumab, ocrelizumab, pegylated interferon beta‐1a, rituximab and teriflunomide. </p> </section> <section id="CD012200-sec-0005"> <h3 class="title" id="CD012200-sec-0005">Data collection and analysis</h3> <p>Two teams of three authors each independently selected studies and extracted data. The primary outcomes were disability‐worsening, relapses, occurrence of at least one serious adverse event (AE) and withdrawing from the study or discontinuing the drug because of AEs. Time to conversion to clinically definite MS (CDMS) defined by Poser diagnostic criteria, and probability to discontinue the treatment or dropout for any reason were recorded as secondary outcomes. We synthesized study data using random‐effects meta‐analyses and performed indirect comparisons between drugs. We calculated odds ratios (OR) and hazard ratios (HR) along with relative 95% confidence intervals (CI) for all outcomes. We estimated the absolute effects only for primary outcomes. We evaluated the credibility of the evidence using the GRADE system. </p> </section> <section id="CD012200-sec-0006"> <h3 class="title" id="CD012200-sec-0006">Main results</h3> <p>We included 10 randomised trials, eight open‐label extension studies (OLEs) and four cohort studies published between 2010 and 2016. The overall risk of bias was high and the reporting of AEs was scarce. The quality of the evidence associated with the results ranges from low to very low. </p> <p><b>Early treatment versus placebo during the first 24 months' follow‐up</b> </p> <p>There was a small, non‐significant advantage of early treatment compared with placebo in disability‐worsening (6.4% fewer (13.9 fewer to 3 more) participants with disability‐worsening with interferon beta‐1a (Rebif®) or teriflunomide) and in relapses (10% fewer (20.3 fewer to 2.8 more) participants with relapses with teriflunomide). Early treatment was associated with 1.6% fewer participants with at least one serious AE (3 fewer to 0.2 more). Participants on early treatment were on average 4.6% times (0.3 fewer to 15.4 more) more likely to withdraw from the study due to AEs. This result was mostly driven by studies on interferon beta 1‐b, glatiramer acetate and cladribine that were associated with significantly more withdrawals for AEs. Early treatment decreased the hazard of conversion to CDMS (HR 0.53, 95% CI 0.47 to 0.60). </p> <p><b>Comparing active interventions during the first 24 months' follow‐up</b> </p> <p>Indirect comparison of interferon beta‐1a (Rebif®) with teriflunomide did not show any difference on reducing disability‐worsening (OR 0.84, 95% CI 0.43 to 1.66). We found no differences between the included drugs with respect to the hazard of conversion to CDMS. Interferon beta‐1a (Rebif®) and teriflunomide were associated with fewer dropouts because of AEs compared with interferon beta‐1b, cladribine and glatiramer acetate (ORs range between 0.03 and 0.29, with substantial uncertainty). </p> <p><b>Early versus delayed treatment</b> </p> <p>We did not find evidence of differences between early and delayed treatments for disability‐worsening at a maximum of five years' follow‐up (3% fewer participants with early treatment (15 fewer to 11.1 more)). There was important variability across interventions; early treatment with interferon beta‐1b considerably reduced the odds of participants with disability‐worsening during three and five years' follow‐up (OR 0.52, 95% CI 0.32 to 0.84 and OR 0.57, 95% CI 0.36 to 0.89). The early treatment group had 19.6% fewer participants with relapses (26.7 fewer to 12.7 fewer) compared to late treatment at a maximum of five years' follow‐up and early treatment decreased the hazard of conversion to CDMS at any follow‐up up to 10 years (i.e. over five years' follow‐up HR 0.62, 95% CI 0.53 to 0.73). We did not draw any conclusions on long‐term serious AEs or discontinuation due to AEs because of inadequacies in the available data both in the included OLEs and cohort studies. </p> </section> <section id="CD012200-sec-0007"> <h3 class="title" id="CD012200-sec-0007">Authors' conclusions</h3> <p>Very low‐quality evidence suggests a small and uncertain benefit with early treatment compared with placebo in reducing disability‐worsening and relapses. The advantage of early treatment compared with delayed on disability‐worsening was heterogeneous depending on the actual drug used and based on very low‐quality evidence. Low‐quality evidence suggests that the chances of relapse are less with early treatment compared with delayed. Early treatment reduced the hazard of conversion to CDMS compared either with placebo, no treatment or delayed treatment, both in short‐ and long‐term follow‐up. Low‐quality evidence suggests that early treatment is associated with fewer participants with at least one serious AE compared with placebo. Very low‐quality evidence suggests that, compared with placebo, early treatment leads to more withdrawals or treatment discontinuation due to AEs. Difference between drugs on short‐term benefit and safety was uncertain because few studies and only indirect comparisons were available. Long‐term safety of early treatment is uncertain because of inadequately reported or unavailable data. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012200-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012200-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012200-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012200-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012200-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012200-abs-0006">Français</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012200-abs-0004" lang="en"> <h3>Disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis </h3> <p>This summary presents data about the benefit and side effects of some disease‐modifying drugs used at the time when multiple sclerosis is diagnosed after a first clinical attack. We reviewed the available evidence to answer three questions: 1) is early treatment beneficial and safe? 2) which drug is best for early treatment? 3) is early treatment better than later treatment? </p> <p>Sufficient data were available from 22 studies on the following drugs: cladribine (Movectro), glatiramer acetate (Copaxone), interferon beta‐1b (Betaferon), interferon beta‐1a (Rebif; Avonex), and teriflunomide (Aubagio). </p> <p><b>First question: is early treatment beneficial and safe?</b> </p> <p><b>Disability‐worsening</b> <br/> Among people who took Aubagio or Rebif, 28 people out of 100 experienced disability‐worsening over two years’ treatment compared to 34 people out of 100 who took placebo (6% absolute benefit). The overall quality of the included studies is very low, so our confidence in this result is low. </p> <p><b>Relapse</b> <br/> Early treatment was associated with lower proportions of people who had a second attack ‐ ie who received a diagnosis of MS ‐ during the first two years' treatment, compared to people who took placebo. Among people who took Aubagio, 32 people out of 100 experienced recurrent relapses over two years’ treatment compared to 42 people out of 100 who took placebo (10% absolute benefit). Again, the overall quality of evidence is very low. </p> <p><b>Serious side effects</b> <br/> Among people who took Aubagio, Avonex, Betaferon, Copaxone, Movectro, or Rebif, there is probably little or no difference in serious side effects over two years’ treatment compared with people who took placebo. </p> <p><b>Side effects</b> <br/> Among people who took Betaferon, 11 people out of 100 experienced side effects compared to one person out of 100 people who took placebo (10% absolute harm). Among people who took Movectro, seven people out of 100 experienced side effects compared to two out of 100 people who took placebo (5% absolute harm). Among people who took Copaxone, six people out of 100 experienced a side effect compared to two out of 100 people who took placebo (4% absolute harm). </p> <p><b>Second question: which drug is best for early treatment?</b> </p> <p><b>Disability‐worsening</b> <br/> Indirect comparison of Rebif with Aubagio did not show any difference on reducing disability‐worsening over two years’ treatment. However, there were few studies and the overall quality of evidence is very low. </p> <p><b>Relapse</b> </p> <p>Only one study on Aubagio was available, so we cannot compare the effects of each drug compared with one other. </p> <p><b>Side effects</b> <br/> Rebif and Aubagio were associated with fewer dropouts because of side effects compared with Betaferon, Copaxone, or Movectro. </p> <p><b>Third question: is early treatment better than later treatment?</b> </p> <p><b>Disability‐worsening</b> <br/> Among people who received early treatment with Avonex, Betaferon, Copaxone, or Rebif, 37 people out of 100 experienced disability‐worsening at a maximum of five years’ follow‐up compared with 40 people out of 100 who received later treatment (3% absolute benefit). However, the great variability between the studies and the low quality of the evidence make our confidence in this result low. </p> <p><b>Relapse</b> <br/> Early treatment was associated with lower proportions of people who had a second attack at any follow‐up up to 10 years, compared to people who received later treatment. Among people who received early treatment with Betaferon, Copaxone, or Rebif, 64 people out of 100 experienced recurrent relapses at a maximum of five years’ follow‐up compared to 83 people out of 100 who received these drugs later (19% absolute benefit). </p> <p><b>Side Effects</b> <br/> We did not draw any conclusions on long‐term serious side effects or treatment discontinuation due to side effects because of inadequacies in the available data in the included studies. </p> <p><b>Conclusion</b> </p> <p>The low‐quality evidence of the included studies suggests a small and uncertain benefit with early treatment compared with placebo or later treatment in reducing disability‐worsening and relapses. </p> <p>We cannot draw conclusions on the long‐term safety of these drugs when administered as early treatment because of inadequately reported or unavailable data. </p> <p>Until convincing evidence of any difference on benefit between disease‐modifying drugs becomes available, the drugs that have been in use in clinical practice for many years and whose safety profile is better understood are probably the most sensible choice for early treatment. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012200-sec-0157" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012200-sec-0157"></div> <h3 class="title" id="CD012200-sec-0158">Implications for practice</h3> <section id="CD012200-sec-0158"> <p>Our study has several important findings but some conservative interpretation of the results is warranted, since most of the included treatments have been evaluated in few trials compared with placebo and the overall quality of evidence is low or very low. </p> <p>Weak evidence of low to very low quality suggests that early treatment reduces the chances of recurrence or relapse compared to placebo, no treatment or delayed treatment both in short‐ and long‐term follow‐up. The benefit of early treatment for disability‐worsening both in short‐ and long‐term follow‐up remains unclear. </p> <p>There are indications that there might be differences in the short‐term safety of the disease‐modifying drugs included in this review, but it is not possible to pinpoint them with the available studies. This review cannot conclude on long‐term safety of these drugs when administered as early treatment because of inadequately‐reported or unavailable data. Until convincing evidence of any difference on benefit between disease‐modifying drugs becomes available, the drugs that have been in use in clinical practice for many years and with a safety profile that is well understood, are probably the most sensible choice for early treatment. </p> </section> <h3 class="title" id="CD012200-sec-0159">Implications for research</h3> <section id="CD012200-sec-0159"> <p>There are two needs that the research agenda should address. First, randomised trials of direct comparisons between active agents would be useful, avoiding further placebo‐controlled studies that do not now comply with the principle of clinical equipoise for treatment of multiple sclerosis (MS). Second, long‐term benefit and safety of early treatment with disease‐modifying drugs and comparative benefit and safety of different disease‐modifying drugs should be mandatory. As the number of disease‐modifying drugs that are available for treatment of MS increases, more options are available to people with MS and clinicians. In the absence of comparative trials, national and international registries and other types of large databases may be relevant sources for providing complementary data regarding the long‐term benefit and safety of disease‐modifying drugs for MS. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012200-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012200-sec-0022"></div> <div class="table" id="CD012200-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Are disease‐modifying drugs for a first attack suggestive of multiple sclerosis (MS) effective and safe compared to placebo?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> adults with first attack suggestive of MS<br/> <b>Setting:</b> MS centres<br/> <b>Intervention:</b> early disease‐modifying drug treatment<br/> <b>Comparison:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>With early disease‐modifying drugs treatment</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Disability‐worsening</b> </p> <p>Proportion of participants with disability‐worsening, assessed by EDSS** during 24 months of treatment<br/> Participants: N = 927<br/> (2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.74<br/> (0.49 to 1.14) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.7%</p> <p>(20.2 to 37.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4% fewer (13.9 fewer to 3 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The risk of disability‐worsening is less with disease‐modifying drugs than with placebo, but there is a lot of uncertainty in the effect </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse</b> </p> <p>Proportion of participants with relapse during 24 months of treatment<br/> Participants: N = 618<br/> (1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.65<br/> (0.38 to 1.12) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.7%</p> <p>(21.3 to 44.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0% fewer (20.3 fewer to 2.8 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The risk of relapse is less with disease‐modifying drugs than with placebo, but there is a lot of uncertainty in the effects </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Occurrence of at least one serious adverse event</b> Proportion of participants with at least one serious adverse event during 24 months of treatment<br/> Participants: N = 3385<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.78<br/> (0.60 to 1.03) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3%<br/> (5.0 to 8.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6% fewer<br/> (3 fewer to 0.2 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, disease‐modifying drugs were associated with less risk of serious adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawls or drug discontinuation due to adverse events</b> </p> <p>during 24 months of treatment<br/> Participants: N = 2693<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 2.43<br/> (0.91 to 6.49) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0%<br/> (3.2 to 18.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6% more<br/> (0.3 fewer to 15.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,f,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo interferon beta 1‐b, glatiramer acetate, and cladribine were associated with higher risk of withdrawals due to adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>**<b>EDSS:</b> expanded disability status scale<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>High risk of bias for blinding of participants and outcome assessment and incomplete outcome data.<br/> <sup>b</sup>Surrogate outcome in both studies contributing to this estimate.<br/> <sup>c</sup>The confidence interval does not rule out a null effect or benefit.<br/> <sup>d</sup>Only one study contributed to this estimate.<br/> <sup>e</sup>Definition and methods of monitoring and detecting serious adverse events not reported in most trials.<br/> <sup>f</sup>High heterogeneity (I² = 78%, P = 0.001) not explained; high subgroup differences (I² = 75%, P = 0.003).<br/> <sup>g</sup>Definition and methods of monitoring and detecting adverse events not reported in most trials. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012200-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Is early treatment with disease‐modifying drugs more efficacious and safer than delayed treatment?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> adults with first attack suggestive of MS<br/> <b>Setting:</b> MS centres<br/> <b>Intervention:</b> early disease‐modifying drug treatment<br/> <b>Comparison:</b> delayed disease‐modifying drug treatment; after the second attack or diagnosis with clinically definitive MS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Without early disease‐modifying drug treatment</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>With early disease‐modifying drug treatment</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability‐worsening</b> </p> <p>Proportion of participants with disability‐worsening at a maximum of five years' follow‐up (assessed by EDSS**)<br/> Participants: N = 1868<br/> (4 open‐label extension studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.88<br/> (0.50 to 1.57) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.2%<br/> (25.2 to 51.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0% fewer<br/> (15 fewer to 11.1 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c, d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant effect of early treatment compared to delayed treatment during five years' follow‐up; however there is a significant heterogeneity between the studies </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> </p> <p>Proportion of participants with relapse at a maximum of five years' follow‐up<br/> Participants: N = 1485<br/> (3 open‐label extension studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.35<br/> (0.26 to 0.48) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.8%<br/> (56.7 to 70.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.6% fewer<br/> (26.7 fewer to 12.7 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early treatment reduced the risk of relapses compared to delayed treatment during five years' follow‐up </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **<b>EDSS:</b> expanded disability status scale<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>High risk of bias for allocation concealment, blinding of outcome assessment and incomplete outcome data.<br/> <sup>b</sup>Surrogate outcome in two out of four studies contributing to this estimate.<br/> <sup>c</sup>High heterogeneity (I² = 67%, P = 0.03).<br/> <sup>d</sup>The confidence interval fails to exclude important benefit or important harms. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012200-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012200-sec-0023"></div> <section id="CD012200-sec-0024"> <h3 class="title" id="CD012200-sec-0024">Description of the condition</h3> <p>Since the revision of the McDonald criteria in 2010 (<a href="./references#CD012200-bbs2-0106" title="PolmanC , ReingoldS , BanwellB , ClanetM , CohenJ , FilippiM , et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology2011;69(2):292‐302. [PUBMED: 21387374] ">Polman 2011</a>), multiple sclerosis (MS) can be diagnosed at the time of a first clinical attack when magnetic resonance imaging (MRI) shows the presence of focal lesions in the white matter of the central nervous system, which are considered typical for MS in terms of distribution, morphology, evolution and signal abnormalities on conventional MRI sequences (<a href="./references#CD012200-bbs2-0081" title="FilippiM , RoccaMA , CiccarelliO , DeStefanoN , EvangelouN , KapposL , et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurology2016;15(3):292‐303. [DOI: 10.1016/S1474‐4422(15)00393‐2] ">Filippi 2016</a>). Opinion leaders have recommended early action as "treating at first clinical attack may be the most effective strategy to manage disease progression" (<a href="./references#CD012200-bbs2-0083" title="FreedmanMS , ComiG , DeStefanoN , BarkhofF , PolmanCH , UitdehaagBM , et al. Moving toward earlier treatment of multiple sclerosis: findings from a decade of clinical trials and implications for clinical practice. Multiple Sclerosis and Related Disorders2014;3(2):147‐55. [PUBMED: 25878002] ">Freedman 2014</a>). Revised guidelines of the Association of British Neurologists (<a href="./references#CD012200-bbs2-0114" title="ScoldingN , BarnesD , CaderS , ChatawayJ , ChaudhuriA , ColesA , et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease‐modifying treatments in multiple sclerosis. Practical Neurology2015;15(4):273‐9. [PUBMED: 26101071] ">Scolding 2015</a>) and NHS England (<a href="./references#CD012200-bbs2-0102" title="NHS England Clinical Reference Group for Neurosciences. Clinical commissioning policy: disease modifying therapies for patients with multiple sclerosis (MS). www.england.nhs.uk/wp‐content/uploads/2013/10/d04‐p‐b.pdf (accessed 13 April 2016). ">NHS England 2014</a>) suggest that treatment should be advised for patients within 12 months of a first attack, if MRI establishes a diagnosis of MS according to the 2010 McDonald criteria or predicts a high likelihood of recurrent attacks. The benefit of starting early treatment with disease‐modifying drugs has been demonstrated by some short‐term trials that showed delay of a second attack in participants given interferons beta (<a href="./references#CD012200-bbs2-0011" title="ComiG , FilippiM , BarkhofF , DurelliL , EdanG , FernándezO , et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet2001;357(9268):1576‐82. [PUBMED: 11377645] ">ETOMS 2001</a>) or glatiramer acetate (<a href="./references#CD012200-bbs2-0017" title="ComiG , MartinelliV , RodegherM , MoiolaL , BajenaruO , CarraA , et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double‐blind, placebo‐controlled trial. Lancet2009;374(9700):1503‐11. [PUBMED: 19815268] ">PRECISE 2009</a>) compared with those on placebo. On the basis of these results, interferons beta and glatiramer acetate were approved by national regulatory agencies for treating MS at clinical onset (<a href="./references#CD012200-bbs2-0066" title="European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. Committee for Medicinal Products for Human Use (CHMP). EMA/CHMP/771815/2011, Rev. 2. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500185161.pdf (accessed 05 April 2017). ">EMA 2015a</a>). However, the available evidence does not indicate that the prevention of recurrent attacks has an effect on disability (<a href="./references#CD012200-bbs2-0010" title="KinkelRP , DontchevM , KollmanC , SkaramagasTT , O'ConnorPW , SimonJH , et al. Association between immediate initiation of intramuscular interferon beta‐1a at the time of a clinically isolated syndrome and long‐term outcomes: a 10‐year follow‐up of the Controlled High‐Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Archives of Neurology2012;69(2):183‐90. [PUBMED: 21987393] SimonJH , KinkelRP , KollmanC , O'ConnorP , FisherE , YouX , et al. Ten‐year follow‐up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial. Multiple Sclerosis2015;21(4):415‐22. [PUBMED: 25344370] ">CHAMPS 2012 (10 years FU)</a>; <a href="./references#CD012200-bbs2-0084" title="FrischerJM , BramowS , Dal‐BiancoA , LucchinettiCF , RauschkaH , SchmidbauerM , et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain2009;132:1175‐89. [PUBMED: 19339255] ">Frischer 2009</a>), and large variability of long‐term disability‐worsening has been reported, even among people with frequent early relapses (<a href="./references#CD012200-bbs2-0110" title="ScalfariA , NeuhausA , DaumerM , DelucaG , MuraroP , EbersG . Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurology2013;70(2):214‐22. [PUBMED: 23407713] ">Scalfari 2013</a>).<br/> Once the decision for early treatment is made, patients and their healthcare providers need to select one of several disease‐modifying drugs. Most of the evidence about the relative efficacy and safety of interventions is non‐specific to early treatment. In a previously published review, moderate‐ to high‐quality evidence suggested that alemtuzumab, natalizumab and fingolimod were associated with greater benefit for preventing recurrent attacks compared with placebo, and evidence of moderate quality indicated that natalizumab was associated with greater benefit for preventing disability‐worsening among all treatments evaluated (<a href="./references#CD012200-bbs2-0121" title="TramacereI , DelGiovaneC , SalantiG , D'AmicoR , FilippiniG . Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis. Cochrane Database of Systematic Reviews2015, Issue 9. [DOI: 10.1002/14651858.CD011381] ">Tramacere 2015</a>). Despite alemtuzumab and natalizumab having been proven to exert higher relapse suppression, because of safety concerns, the guidelines of the Association of British Neurologists recommended their use as second‐line treatment, or as treatment for people with rapidly evolving relapsing‐remitting MS. Beta interferons, glatiramer acetate, teriflunomide, dimethyl fumarate and fingolimod are recommended as first‐line agents (<a href="./references#CD012200-bbs2-0114" title="ScoldingN , BarnesD , CaderS , ChatawayJ , ChaudhuriA , ColesA , et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease‐modifying treatments in multiple sclerosis. Practical Neurology2015;15(4):273‐9. [PUBMED: 26101071] ">Scolding 2015</a>). Australian and New Zealand guidelines allow neurologists the discretionary use of all disease‐modifying drugs as first‐line treatments (<a href="./references#CD012200-bbs2-0053" title="BroadleySA , BarnettMH , BoggildM , BrewBJ , ButzkuevenH , HeardR , et al. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 3 treatment practicalities and recommendations. MS Neurology Group of the Australian and New Zealand Association of Neurologists. Journal of Clinical Neuroscience2014;21(11):1857‐65. [PUBMED: 24993136] ">Broadley 2014</a>). </p> </section> <section id="CD012200-sec-0025"> <h3 class="title" id="CD012200-sec-0025">Description of the intervention</h3> <p>We considered all disease‐modifying drugs that are used, approved or off‐label, or are currently under marketing authorisation or investigation for people with a first clinical attack. We considered that all agents used or under investigation for relapsing‐remitting MS could be given to people with a first attack complying with the 2010 McDonald criteria. More specifically, we are interested in drugs that have been approved for a first attack complying with 2010 McDonald criteria. </p> <p> <ul id="CD012200-list-0001"> <li> <p>Beta interferons (Betaferon/Betaseron<sup>®</sup>; Extavia<sup>®</sup>; Rebif<sup>®</sup>; Avonex<sup>®</sup>) and glatiramer acetate (Copaxone<sup>®</sup>) (<a href="./references#CD012200-bbs2-0066" title="European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. Committee for Medicinal Products for Human Use (CHMP). EMA/CHMP/771815/2011, Rev. 2. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500185161.pdf (accessed 05 April 2017). ">EMA 2015a</a>; <a href="./references#CD012200-bbs2-0074" title="U.S.Food , DrugAdministration . Avonex® (interferon beta‐1a) intramuscular injection. Prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2012/103628s5191lbl.pdf (accessed 05 April 2017). ">FDA 2012a</a>; <a href="./references#CD012200-bbs2-0075" title="U.S.Food , DrugAdministration . Betaseron® (interferon beta‐1b). Prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2012/103471s5063s5067s5079s5088s5120s5124s5136s5138lbl.pdf (accessed 05 April 2017). ">FDA 2012b</a>; <a href="./references#CD012200-bbs2-0076" title="U.S.Food , DrugAdministration . Copaxone® (glatiramer acetate injection) solution for subcutaneous injection. www.accessdata.fda.gov/drugsatfda_docs/label/2013/020622s087lbl.pdf (accessed 05 April 2017). ">FDA 2013</a>). These medications are administered subcutaneously, except for beta interferon 1a (Avonex<sup>®</sup>), which is administered via intramuscular injections. Approved for relapsing‐remitting MS </p> </li> <li> <p>Natalizumab (Tysabri<sup>®</sup>) (<a href="./references#CD012200-bbs2-0059" title="European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Tysabri. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000603/wapp/Post‐authorisation/human_wapp_000166.jsp&amp;mid=WC0b01ac058001d128 (accessed 05 April 2017). ">EMA 2006</a>; <a href="./references#CD012200-bbs2-0071" title="U.S.Food , DrugAdministration . FDA approves resumed marketing of Tysabri under a special distribution program. www.fda.gov/ohrms/dockets/ac/06/briefing/2006‐4208b1_02_01biogenbriefingmaterial.pdf (accessed 05 April 2017). ">FDA 2006</a>) administered by intravenous infusion at a dose of 300 mg every four weeks </p> </li> <li> <p>Fingolimod (Gilenya<sup>®</sup>) (<a href="./references#CD012200-bbs2-0060" title="European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Gilenya. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002202/human_med_001433.jsp&amp;mid=WC0b01ac058001d124 (accessed 05 April 2017). ">EMA 2011</a>; <a href="./references#CD012200-bbs2-0072" title="U.S.Food , DrugAdministration . Gilenya (Fingolimod) Product Approval Information 2010. www.accessdata.fda.gov/drugsatfda_docs/appletter/2010/022527s000ltr.pdf (accessed 05 April 2017). ">FDA 2010</a>) given at an oral dose of 0.5 mg once daily </p> </li> <li> <p>Teriflunomide (Aubagio<sup>®</sup>) (<a href="./references#CD012200-bbs2-0061" title="European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Aubagio. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002514/human_med_001645.jsp&amp;mid=WC0b01ac058001d124 (accessed 05 April 2017). ">EMA 2013a</a>; <a href="./references#CD012200-bbs2-0073" title="U.S.Food , DrugAdministration . Aubagio (Teriflunomide) Product Approval Information 2012. www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/202992Orig1s000ltr.pdf (accessed 05 April 2017). ">FDA 2012</a>) given at an oral dose of 7 mg or 14 mg once daily </p> </li> <li> <p>Dimethyl fumarate (Tecfidera<sup>®</sup>) (<a href="./references#CD012200-bbs2-0063" title="European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Tecfidera. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002601/human_med_001657.jsp&amp;mid=WC0b01ac058001d124 (accessed 05 April 2017). ">EMA 2014a</a>; <a href="./references#CD012200-bbs2-0076" title="U.S.Food , DrugAdministration . Copaxone® (glatiramer acetate injection) solution for subcutaneous injection. www.accessdata.fda.gov/drugsatfda_docs/label/2013/020622s087lbl.pdf (accessed 05 April 2017). ">FDA 2013</a>) given at an oral dose of 240 mg twice daily </p> </li> <li> <p>Alemtuzumab (Lemtrada<sup>®</sup>) (<a href="./references#CD012200-bbs2-0062" title="European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Lemtrada. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003718/human_med_001678.jsp&amp;mid=WC0b01ac058001d124 (accessed 05 April 2017). ">EMA 2013b</a>; <a href="./references#CD012200-bbs2-0077" title="U.S.Food , DrugAdministration . Alemtuzumab (Lemtrada) Product Approval Information. Licensing action 2014. www.accessdata.fda.gov/drugsatfda_docs/label/2014/103948s5139lbl.pdf (accessed 05 April 2017). ">FDA 2014a</a>) administered intravenously in two annual treatment courses ‐ the first at a dose of 12 mg daily on five consecutive days (60 mg total dose), and the second, 12 months later, on three consecutive days (36 mg total dose) </p> </li> <li> <p>Daclizumab (Zinbryta<sup>®</sup>) administered by subcutaneous or intravenous injections and approved by the European Medicines Agency (EMA) (<a href="./references#CD012200-bbs2-0068" title="EMA . Marketing authorisation for the medicinal product Zinbryta. www.ema.europa.eu/docs/en_GB/document_library/EPAR_‐_Product_Information/human/003862/WC500210598.pdf (accessed 05 April 2017). ">EMA 2016</a>) and the Food and Drug Administration (FDA) (<a href="./references#CD012200-bbs2-0079" title="U.S.Food , DrugAdministration . Zinbryta™ (daclizumab) injection, for subcutaneous use. Prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2016/761029s000lbl.pdf (accessed 13/04/2017). ">FDA 2016</a>) </p> </li> <li> <p>Ocrelizumab (Ocrevus®) (<a href="./references#CD012200-bbs2-0080" title="U.S.Food , DrugAdministration . Ocrevus™ (ocrelizumab) injection, for intravenous use. Prescribing information. www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf (accessed 13/04/2017). ">FDA 2017</a>) administered intravenously at an initial single dose of 300 mg followed two weeks later by a second 300 mg intravenous infusion. Subsequent doses of 600 mg intravenously every six months. Approved for relapsing forms of MS and primary progressive MS </p> </li> <li> <p>Pegylated interferon beta‐1a (Plegridy<sup>®</sup>) (<a href="./references#CD012200-bbs2-0064" title="European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Plegridy. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002827/human_med_001782.jsp&amp;mid=WC0b01ac058001d124 (accessed 05 April 2017). ">EMA 2014b</a>; <a href="./references#CD012200-bbs2-0078" title="U.S.Food , DrugAdministration . Peginterferon beta‐1a (Plegridy) Product Approval Information. Licensing action 2014. www.accessdata.fda.gov/drugsatfda_docs/label/2014/125499lbl.pdf (accessed 05 April 2017). ">FDA 2014b</a>) given by subcutaneous injection at a dose of 125 µg every 14 days </p> </li> <li> <p>Cladribine (Movectro<sup>®</sup>) approved in Russia and Australia in 2010 (<a href="./references#CD012200-bbs2-0100" title="MurphyJA , HarrisJA , CrannageAJ . Potential short‐term use of oral cladribine in treatment of relapsing‐remitting multiple sclerosis. Neuropsychiatric Disease and Treatment2010;5(6):619‐25. [PUBMED: 20957121] ">Murphy 2010</a>). EMA (<a href="./references#CD012200-bbs2-0067" title="European Medicines Agency. Refusal of the marketing authorization for Movectro (cladribine): outcome of re‐examination. www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_‐_Initial_authorisation/human/001197/WC500101072.pdf (accessed 05 April 2017). ">EMA 2015b</a>) and FDA in 2011 did not approve it because of a suspected increase in cancer risk. A meta‐analysis failed to confirm these concerns (<a href="./references#CD012200-bbs2-0104" title="PakpoorJ , DisantoG , AltmannDR , PavittS , TurnerBP , MartaM , et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurology Neuroimmunology &amp; Neuroinflammation2015;2(6):e158. [PUBMED: 26468472] ">Pakpoor 2015</a>) </p> </li> <li> <p>Mitoxantrone (Novantrone<sup>®</sup>) approved in 2000 in the USA (<a href="./references#CD012200-bbs2-0070" title="U.S.Food , DrugAdministration . Mitoxantrone (Novantrone) Product Approval Information ‐ Licensing Action 2000. www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21120.pdf_Novantrone_Approv.pdf (accessed 05 April 2017). ">FDA 2000</a>), Europe and other countries for relapsing‐remitting and progressive MS. It is administered as a short intravenous infusion every three months. Safety concerns include cardiotoxicity and acute leukaemia </p> </li> <li> <p>Azathioprine (Imuran<sup>®</sup>) used in many countries on the basis of placebo‐controlled randomised controlled trials (RCTs) published more than two decades ago. However, since interferons beta were approved, azathioprine is no longer recommended as first‐line therapy (<a href="./references#CD012200-bbs2-0085" title="GoodinDS , FrohmanEM , GarmanyGPJr , HalperJ , LikoskyWH , LublinFD , et al. Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology2002;58(2):169‐78. [PUBMED: 11805241] ">Goodin 2002</a>). It is taken orally, 2 mg/kg or 3 mg/kg per day. Intravenous immunoglobulins are used for people with severe and frequent relapses, for whom other treatments were contraindicated (<a href="./references#CD012200-bbs2-0114" title="ScoldingN , BarnesD , CaderS , ChatawayJ , ChaudhuriA , ColesA , et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease‐modifying treatments in multiple sclerosis. Practical Neurology2015;15(4):273‐9. [PUBMED: 26101071] ">Scolding 2015</a>) </p> </li> <li> <p>Rituximab (Rituxan<sup>®</sup> or Mabthera<sup>®</sup>) administered intravenously. Currently under marketing authorisation or investigation </p> </li> <li> <p>Laquinimod (Nerventra<sup>®</sup>) given at an oral dose of 0.6 mg daily. The drug received a negative opinion from EMA (<a href="./references#CD012200-bbs2-0065" title="European Medicines Agency. Refusal of the marketing authorisation for Nerventra (laquinimod). www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_‐_Initial_authorisation/human/002546/WC500160120.pdf (accessed 05 April 2017). ">EMA 2014c</a>). Studies of laquinimod in relapsing‐remitting MS are ongoing (<a href="./references#CD012200-bbs2-0051" title="ActiveBiotech . Teva and Active Biotech remain committed to the development of NERVENTRA® (laquinimod) for multiple sclerosis following the negative opinion from the EMA's CHMP. www.activebiotech.com/press‐releases‐1?pressurl=http://cws.huginonline.com/A/1002/PR/201401/1756936.xml. (accessed 05 April 2017). ">Active Biotech 2014</a>). </p> </li> </ul> </p> </section> <section id="CD012200-sec-0026"> <h3 class="title" id="CD012200-sec-0026">How the intervention might work</h3> <p>Immunosuppressive or immunomodulatory effects are common to all treatments included in the review. </p> <p> <ul id="CD012200-list-0002"> <li> <p>Approved interventions</p> </li> </ul> <ul class="plain" id="CD012200-list-0003"> <li> <ul id="CD012200-list-0004"> <li> <p>Beta interferons are naturally occurring cytokines that possess antiviral activity and a wide range of anti‐inflammatory properties. Recombinant beta interferons are believed to directly increase expression and concentration of anti‐inflammatory agents, while downregulating expression of pro‐inflammatory cytokines (<a href="./references#CD012200-bbs2-0094" title="KieseierBC . The mechanism of action of interferon‐β in relapsing multiple sclerosis. CNS Drugs2011;25(6):491‐502. [PUBMED: 21649449] ">Kieseier 2011</a>). </p> </li> <li> <p>Glatiramer acetate exerts an immunomodulatory action by inducing tolerance or anergy of myelin‐reactive lymphocytes (<a href="./references#CD012200-bbs2-0111" title="SchmiedM , DudaPW , KriegerJI , TrollmoC , HaflerDA . In vitro evidence that subcutaneous administration of glatiramer acetate induces hyporesponsive T cells in patients with multiple sclerosis. Clinical Immunology2003;106(3):163–74. [PUBMED: 12706402] ">Schmied 2003</a>). Glatiramer acetate may promote neuroprotective repair processes (<a href="./references#CD012200-bbs2-0052" title="AharoniR . Immunomodulation neuroprotection and remyelination. The fundamental therapeutic effects of glatiramer acetate: a critical review. Journal of Autoimmunity2014;54:81‐92. [PUBMED: 24934599] ">Aharoni 2014</a>). </p> </li> <li> <p>Natalizumab is a humanised monoclonal antibody directed against the alfa4 integrin. This integrin is essential in the process by which lymphocytes gain access to the brain by allowing cells to penetrate the blood‐brain barrier. Natalizumab binds alfa4β1 and alfa4β7 integrin on the surface of circulating T lymphocytes, preventing interaction with cellular adhesion molecules that facilitate extravasation and migration from the circulation to the central nervous system (CNS) (<a href="./references#CD012200-bbs2-0099" title="MillardM , OddeS , NeamatiN . Integrin targeted therapeutics. Theranostics2011;17(1):154‐88. [PUBMED: 21547158] ">Millard 2011</a>). </p> </li> <li> <p>Fingolimod is a sphingosine‐1‐phosphate (S1P) receptor modulator that prevents lymphocyte egress from lymphoid tissues, thereby reducing autoaggressive lymphocyte infiltration into the CNS. S1P receptors are also expressed by many CNS cell types and have been shown to influence cell proliferation, morphology and migration. Fingolimod crosses the blood–brain barrier and therefore may have direct CNS effects (<a href="./references#CD012200-bbs2-0054" title="ChunJ , HartungHP . Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clinical Neuropharmacology2010;33(2):91‐101. [PUBMED: 20061941] ">Chun 2010</a>). </p> </li> <li> <p>Teriflunomide acts as an inhibitor of dihydroorotate dehydrogenase (DHODH), a mitochondrial enzyme involved in pyrimidine synthesis for DNA replication in rapidly proliferating cells. The drug reduces T lymphocyte and B lymphocyte activation and proliferation, and may attenuate the inflammatory response to autoantigens in MS. However, the exact mechanism of action for teriflunomide is not fully understood. Some observations suggest that the drug may have immunological effects outside of its ability to inhibit pyrimidine synthesis in rapidly proliferating cells (<a href="./references#CD012200-bbs2-0055" title="ClaussenMC , KornT . Immune mechanisms of new therapeutic strategies in MS: teriflunomide. Clinical Immunology2012;142:49‐56. [PUBMED: 21367665] ">Claussen 2012</a>; <a href="./references#CD012200-bbs2-0103" title="OhJ , O’ConnorPW . An update of teriflunomide for treatment of multiple sclerosis. Therapeutics and Clinical Risk Management2013;9:177‐90. [PUBMED: 23761970] ">Oh 2013</a>). </p> </li> <li> <p>Dimethyl fumarate derives from fumaric acid, promotes anti‐inflammatory activity and can inhibit expression of pro‐inflammatory cytokines and adhesion molecules. Actions of neuroprotective and myelin‐protective mechanisms have been proposed (<a href="./references#CD012200-bbs2-0097" title="LinkerRA , LeeDH , RyanS , VanDamAM , ConradR , BistaP , et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain2011;134(3):678‐92. [PUBMED: 21354971] ">Linker 2011</a>; <a href="./references#CD012200-bbs2-0125" title="WilmsH , SieversJ , RickertU , Rostami‐YazdiM , MrowietzU , LuciusR . Dimethyl fumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL‐1beta, TNF‐alpha and IL‐6 in an in‐vitro model of brain inflammation. Journal of Neuroinflammation2010;7(30):2‐8. [PUBMED: 20482831] ">Wilms 2010</a>). </p> </li> <li> <p>Alemtuzumab is a monoclonal antibody to CD52 on the cell surface of lymphocytes and monocytes. Its effects are thought to be mediated by extended B and T lymphocyte depletion followed by a distinctive pattern of T and B cell repopulation that begins within weeks of treatment and leads to a rebalanced immune system, including an increased percentage of regulatory and memory T cells. Effects of alemtuzumab persisted after it was cleared from the circulation (<a href="./references#CD012200-bbs2-0098" title="LyckeJ . Monoclonal antibody therapies for the treatment of relapsing‐remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Therapeutic Advances in Neurological Disorders2015;8(6):274‐93. [PUBMED: 26600872] ">Lycke 2015</a>). </p> </li> <li> <p>Daclizumab is a monoclonal antibody to the interleukin‐2 receptor CD25 that is expressed on immune cells. The exact mechanism is not well understood. Daclizumab interrupts interleukin‐2‐mediated cell activation, thereby preventing expansion of autoreactive T lymphocytes and inhibiting survival of activated T cells (<a href="./references#CD012200-bbs2-0127" title="WuestSC , EdwanJH , MartinJF , HanS , PerryJS , CartagenaCM , et al. A role for interleukin‐2 trans‐presentation in dendritic cell‐mediated T cell activation in humans, as revealed by daclizumab therapy. Nature Medicine2011;17(5):604‐9. [PUBMED: 21532597] ">Wuest 2011</a>). </p> </li> <li> <p>Ocrelizumab is a recombinant monoclonal antibody designed to selectively target CD20‐positive B lymphocytes, a specific type of immune cell thought to be a key contributor to myelin and axonal nerve cell damage. The drug depletes CD20 B cells, it increases antibody‐dependent cell‐mediated cytotoxicity effects and reduces complement‐dependent cytotoxicity effects (<a href="./references#CD012200-bbs2-0093" title="KapposL , CalabresiPA , O'ConnorP , Bar‐OrA , BarkhofF , YinM , et al. Ocrelizumab in relapsing‐remitting multiple sclerosis: a phase 2, randomised, placebo‐controlled, multicentre trial. Lancet2011;378(9805):1779‐87. [PUBMED: 22047971] ">Kappos 2011</a>). </p> </li> <li> <p>Pegylated interferon beta‐1a (PEG‐IFN) is the drug obtained by PEGylation of IFN beta‐1a (Avonex<sup>®</sup>) (i.e. joining of a polyethylene glycol group (PEG) molecule to the IFN beta‐1a molecule). PEGylation has been applied to increase IFN stability, solubility and half‐life, and to reduce dosing frequency (<a href="./references#CD012200-bbs2-0091" title="HuX , MillerL , RichmanS , HitchmanS , GlickG , LiuS , et al. A novel PEGylated interferon beta‐1a for multiple sclerosis: safety, pharmacology, and biology. Journal of Clinical Pharmacology2012;52(6):798‐808. [PUBMED: 21680782] ">Hu 2012</a>). </p> </li> <li> <p>Cladribine is a chemotherapeutic drug approved for treatment of people with hairy‐cell leukaemia, a subtype of chronic lymphoid leukaemia. Short courses of cladribine induce prolonged lymphopenia by selectively interfering with DNA synthesis and repair in T and B lymphocytes lasting months to years (<a href="./references#CD012200-bbs2-0096" title="LeistTP , WeissertR . Cladribine: mode of action and implications for treatment of multiple sclerosis. Clinical Neuropharmacology2011;34(1):28‐35. [PUBMED: 21242742] ">Leist 2011</a>). </p> </li> <li> <p>Mitoxantrone is a cytotoxic drug that intercalates with DNA and inhibits both DNA and RNA synthesis, thus reducing the number of lymphocytes (<a href="./references#CD012200-bbs2-0082" title="FoxE . Mechanism of action of mitoxantrone. Neurology2004;12(12 Sppl 6):15‐8. [PUBMED: 15623664] ">Fox 2004</a>). </p> </li> </ul> </li> </ul> <ul id="CD012200-list-0005"> <li> <p>Interventions used off‐label</p> </li> </ul> <ul class="plain" id="CD012200-list-0006"> <li> <ul id="CD012200-list-0007"> <li> <p>Azathioprine is a cytotoxic immunosuppressive drug that acts as a prodrug for mercaptopurine, inhibiting an enzyme required for DNA synthesis. Thus it most strongly affects proliferating cells, such as T cells and B cells of the immune system (<a href="./references#CD012200-bbs2-0120" title="TiedeI , FritzG , StrandS , PoppeD , DvorskyR , StrandD , et al. CD28‐dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. The Journal of Clinical Investigation2003;111:1133–45. [PUBMED: 12697733] ">Tiede 2003</a>). </p> </li> <li> <p>Intravenous immunoglobulins may improve remyelination of demyelinated axons through mediation of cytokines. However, their mechanism of action in MS remains unclear (<a href="./references#CD012200-bbs2-0117" title="StangelM , ToykaK , GoldR . Mechanisms of high‐dose intravenous immunoglobulins in demyelinating diseases. Archives of Neurology1999;56(6):661–3. [PUBMED: 10369303] ">Stangel 1999</a>). </p> </li> <li> <p>Rituximab is a monoclonal antibody to CD20 expressed on pre‐B and mature B cells; it acts by depleting these cells in the circulation and the CNS. Although MS was traditionally considered a T cell‐mediated disease, accumulating evidence suggests that B cells may play a role (<a href="./references#CD012200-bbs2-0098" title="LyckeJ . Monoclonal antibody therapies for the treatment of relapsing‐remitting multiple sclerosis: differentiating mechanisms and clinical outcomes. Therapeutic Advances in Neurological Disorders2015;8(6):274‐93. [PUBMED: 26600872] ">Lycke 2015</a>; <a href="./references#CD012200-bbs2-0101" title="NaismithR , PiccioL , LyonsJ , LauberJ , TutlamN , ParksB , et al. Rituximab add‐on therapy for breakthrough relapsing multiple sclerosis: a 52‐week phase II trial. Neurology2010;74(23):1860–7. [PUBMED: 20530322] ">Naismith 2010</a>). </p> </li> </ul> </li> </ul> <ul id="CD012200-list-0008"> <li> <p>Interventions currently under marketing authorisation or investigation</p> </li> </ul> <ul class="plain" id="CD012200-list-0009"> <li> <ul id="CD012200-list-0010"> <li> <p>Laquinimod may have an immunomodulatory effect on the peripheral and central nervous systems. This drug modulates the function of various myeloid antigen‐presenting cell populations, which then downregulate pro‐inflammatory T cell responses. Furthermore, data indicate that laquinimod acts directly on resident cells within the CNS to reduce demyelination and axonal damage. However, exactly how the drug works remains unknown (<a href="./references#CD012200-bbs2-0122" title="Varrin‐DoyerM , ZamvilSS , Schulze‐TopphoffU . Laquinimod, an up‐and‐coming immunomodulatory agent for treatment of multiple sclerosis. Experimental Neurology2014;262:66‐71. [PUBMED: 24731945] ">Varrin‐Doyer 2014</a>). </p> </li> </ul> </li> </ul> </p> </section> <section id="CD012200-sec-0027"> <h3 class="title" id="CD012200-sec-0027">Why it is important to do this review</h3> <section id="CD012200-sec-0028"> <h4 class="title">Uncertainty</h4> <p>Many treatment options are available, and patients and their clinicians may choose to start with a drug of moderate efficacy and general safety or with a drug of high efficacy and a complex safety profile. Consequently, a comprehensive appreciation of the benefits and risks of all treatment approaches is urgently needed (<a href="./references#CD012200-bbs2-0114" title="ScoldingN , BarnesD , CaderS , ChatawayJ , ChaudhuriA , ColesA , et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease‐modifying treatments in multiple sclerosis. Practical Neurology2015;15(4):273‐9. [PUBMED: 26101071] ">Scolding 2015</a>; <a href="./references#CD012200-bbs2-0126" title="WingerchukDM , CarterJL . Multiple sclerosis: current and emerging disease‐modifying therapies and treatment strategies. Mayo Clinic Proceedings2014;89(2):225‐40. [PUBMED: 24485135] ">Wingerchuk 2014</a>). </p> <section id="CD012200-sec-0029"> <h5 class="title">Early treatment</h5> <p>Interferons and glatiramer acetate are indicated by the FDA and the EMA for treatment of people who have experienced a first attack and are at high risk of recurrent attacks. Other immunotherapies have been reported to delay recurrent attacks, although their effect on disability prevention remains unclear. In addition, various national guidelines provide conflicting information about effects of these treatments and their use as first‐line or second‐line therapy (see <a href="#CD012200-sec-0024">Description of the condition</a>). This uncertainty results from several factors, including intermediate outcomes and short follow‐up periods in the clinical trials included in published reviews. Immunotherapies administered early in the disease can delay intermediate outcomes (i.e. short‐term relapses), but suppression of early relapses may not necessarily correlate with long‐term disability prevention (<a href="./references#CD012200-bbs2-0084" title="FrischerJM , BramowS , Dal‐BiancoA , LucchinettiCF , RauschkaH , SchmidbauerM , et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain2009;132:1175‐89. [PUBMED: 19339255] ">Frischer 2009</a>; <a href="./references#CD012200-bbs2-0110" title="ScalfariA , NeuhausA , DaumerM , DelucaG , MuraroP , EbersG . Early relapses, onset of progression, and late outcome in multiple sclerosis. JAMA Neurology2013;70(2):214‐22. [PUBMED: 23407713] ">Scalfari 2013</a>). Therefore an effect on disability cannot be claimed solely on the basis of relapse prevention (<a href="./references#CD012200-bbs2-0066" title="European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. Committee for Medicinal Products for Human Use (CHMP). EMA/CHMP/771815/2011, Rev. 2. www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/03/WC500185161.pdf (accessed 05 April 2017). ">EMA 2015a</a>). Given that most evidence has been derived from short‐term trials with low power to investigate rare adverse events, safety outcomes have not been extensively investigated. Consequently, a demonstration and quantification of the benefit and safety of the early treatment versus delayed treatment is still required. </p> </section> <section id="CD012200-sec-0030"> <h5 class="title">Choice of interventions for early treatment</h5> <p>Patients and their doctors must be given information about the relative benefit and safety of the various treatment options if they are to make informed decisions. Various disease‐modifying drugs have been shown to have different benefit/acceptability profiles. Differences in benefit are as important to consider as differences in safety. For example, local injection site reactions and flu‐like symptoms have emerged as the main adverse effects of interferons beta, and cardiotoxicity and acute leukaemia as major safety issues for mitoxantrone. Investigators have described fatal cases of progressive multi‐focal leucoencephalopathy in people treated with natalizumab (<a href="./references#CD012200-bbs2-0059" title="European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Tysabri. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000603/wapp/Post‐authorisation/human_wapp_000166.jsp&amp;mid=WC0b01ac058001d128 (accessed 05 April 2017). ">EMA 2006</a>), fingolimod (<a href="./references#CD012200-bbs2-0060" title="European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Gilenya. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002202/human_med_001433.jsp&amp;mid=WC0b01ac058001d124 (accessed 05 April 2017). ">EMA 2011</a>) and dimethyl fumarate (<a href="./references#CD012200-bbs2-0063" title="European Medicines Agency. Committee for proprietary medicinal products European public assessment report: Tecfidera. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002601/human_med_001657.jsp&amp;mid=WC0b01ac058001d124 (accessed 05 April 2017). ">EMA 2014a</a>). To support informed decision‐making, there is a need to identify, systematically collect and synthesise information about relative safety and efficacy between interventions administered to people with the first attack suggestive of MS. </p> </section> </section> <section id="CD012200-sec-0031"> <h4 class="title">Relevance</h4> <p>In July 2014, Cochrane Multiple Sclerosis launched a ‘Priority Setting Survey’ and invited consumers and MS societies to answer a questionnaire identifying priority research questions considered to have the most relevant impact for all stakeholders. The question ‐ "Early onset of treatment may avoid disease progression?" ‐ was one of the most frequently reported by people with MS and family members. The question ‐ "Does early treatment with aggressive disease‐modifying drugs improve the prognosis for people with MS?" ‐ addresses one of the top 10 MS priorities reported by the <a href="http://www.jla.nihr.ac.uk/priority-setting-partnerships/multiple-sclerosis" target="_blank">James Lind Alliance</a> in collaboration with the <a href="https://www.mssociety.org.uk/ms-research/how-we-decide-what-we-fund/Setting-MS-research-priorities" target="_blank">UK MS Society 2012</a>. This review aims to answer these two questions by comparing all disease‐modifying drugs with placebo; it also plans to provide an assessment of the relative effects of each drug compared with one other and a ranking of treatments according to benefit and safety. The significance of this project is underlined by the fact that evaluation of disease‐modifying drugs for people with a first clinical attack has been identified as a priority and is featured in the <a href="http://editorial-unit.cochrane.org/cochrane-priority-reviews-list-2015-16" target="_blank">Cochrane Priority Review List 2015/16</a>. </p> <p>Most published reviews have compared a single treatment versus placebo and have made inferences about benefits and safety. This information is unlikely to be useful in practice, as people with MS have several treatment options. Network meta‐analysis (NMA), which is an extension of the traditional pairwise meta‐analysis, collates information from studies comparing different treatments in order to form a ‘network of interventions’. This provides information about the relative effects of all interventions included in the network, even those not directly compared in any trial and a hierarchy of treatments ordered by efficacy and safety. None of the existing comparative effectiveness reviews have specifically addressed disease‐modifying drugs in early treatment. As the number of people who choose to start treatment soon after diagnosis increases, it is important for healthcare providers to know the relative benefit and safety of the various treatment options in this particular setting. </p> <p>Another important limitation of existing reviews is that all include randomised controlled trials. Although this study design is theoretically associated with low risk of bias, it has several shortcomings. First, randomised trials do not provide patient follow‐up for a long period; consequently, this design is not appropriate when rare safety outcomes are of interest. Second, randomised trials are typically undertaken in highly selected conditions and do not represent real‐world settings. Consequently, the generalisability of findings is doubtful. For these reasons, interest in including non‐randomised studies in the decision‐making process is growing (<a href="./references#CD012200-bbs2-0069" title="FariaR , Hernandez AlavaM , MancaA , WailooAJ . NICE DSU technical support document 17: the use of observational data to inform estimates of treatment effectiveness in technology appraisal: methods for comparative individual patient data. www.nicedsu.org.uk/TSD17%20‐%20DSU%20Observational%20data%20FINAL.pdf (accessed 05 April 2017). ">Faria 2015</a>), and innovative methods have been developed for combining data obtained through different study designs (<a href="./references#CD012200-bbs2-0112" title="SchmitzS , AdamsR , WalshC . Incorporating data from various trial designs into a mixed treatment comparison model. Statistics in Medicine2013;32(17):2935‐49. [PUBMED: 23440610] ">Schmitz 2013</a>; <a href="./references#CD012200-bbs2-0123" title="VerdePE , OhmannC . Combining randomized and non‐randomized evidence in clinical research: a review of methods and applications. Research Synthesis Methods2015;6(1):45‐62. [PUBMED: 26035469] ">Verde 2015</a>). </p> <p>Overall, we believe that despite the wealth of information and the plethora of studies and reviews on treatments for MS, uncertainty surrounds the relative ranking of disease‐modifying drugs when treatment starts early. In particular, the issue of safety is less well studied, as evidence from non‐randomised studies that provide useful information on adverse events has not been systematically considered. We believe that having access to high‐quality health information is an essential component of good decision‐making processes and helps people take control of their health. Our certainty comes from the results of studies previously undertaken by Cochrane Multiple Sclerosis, wherein people with MS and their family members told us that they want access to high‐quality information about MS provided by sources they can trust (<a href="./references#CD012200-bbs2-0057" title="ColomboC , MosconiP , ConfalonieriP , BaroniI , TraversaS , HillSJ , et al. Web search behavior and information needs of people with multiple sclerosis: focus group study and analysis of online postings. Interactive Journal of Medical Research2014;3(3):e12. [PUBMED: 25093374] ">Colombo 2014</a>; <a href="./references#CD012200-bbs2-0058" title="ColomboC , FilippiniG , SynnotA , HillS , GuglielminoR , TraversaS , et al. Development and assessment of a website presenting evidence‐based information for people with multiple sclerosis: the IN‐DEEP project. BMC Neurology2016;16(1):30. [PUBMED: 26934873] ">Colombo 2016</a>; <a href="./references#CD012200-bbs2-0090" title="HillS , FilippiniG , SynnotA , SummersM , BeecherD , ColomboC , et al. Presenting evidence‐based health information for people with multiple sclerosis: the IN‐DEEP project protocol. BMC Medical Informatics and Decision Making2012;12:20. [PUBMED: 22424304] ">Hill 2012</a>; <a href="./references#CD012200-bbs2-0119" title="SynnotAJ , HillSJ , GarnerKA , SummersMP , FilippiniG , OsborneRH , et al. Online health information seeking: how people with multiple sclerosis find, assess and integrate treatment information to manage their health. Health Expectations2016;19(3):727‐37. [PUBMED: 25165024] ">Synnot 2014</a>). </p> </section> <section id="CD012200-sec-0032"> <h4 class="title">Potential to change or influence clinical practice or health policy</h4> <p>The review aimed to provide critical information necessary in making informed healthcare decisions on treatments for people with MS, their neurologists and family members. Notably, marked variability in treatment decisions has been reported, likely as the result of physician preference and opinion (<a href="./references#CD012200-bbs2-0105" title="PalaceJ . Partnership and consent in MS treatment choice. Journal of the Neurological Sciences2013;335:5‐8. [PUBMED: 24090756] ">Palace 2013</a>). Disease‐modifying drugs are expensive and their use has significant economic implications for the healthcare system. These treatments are associated with high risk of adverse events, which indirectly further increases treatment costs. Identifying treatment that offers a better benefit and safety profile, with particular attention to safety, may help to reduce costs. </p> </section> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012200-sec-0033" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012200-sec-0033"></div> <p>The review aimed to answer three research questions:</p> <p> <ul id="CD012200-list-0011"> <li> <p>is early treatment efficacious and safe compared to placebo or no treatment?</p> </li> <li> <p>are there differences in efficacy and safety between the various drugs administered for early treatment? </p> </li> <li> <p>is early treatment better than delayed treatment?</p> </li> </ul> </p> <p>Consequently, the objectives were:</p> <p> <ul id="CD012200-list-0012"> <li> <p>to estimate the benefit and safety of disease‐modifying drugs that have been evaluated in all studies (randomised or non‐randomised) for the treatment of a first clinical attack suggestive of MS compared either with placebo or no treatment; </p> </li> <li> <p>to assess the relative efficacy and safety of disease‐modifying drugs according to their benefit and safety; </p> </li> <li> <p>to estimate the benefit and safety of disease‐modifying drugs that have been evaluated in all studies (randomised or non‐randomised) for treatment started after a first attack ('early treatment') compared with treatment started after a second attack or at another later time point ('delayed treatment'). </p> </li> </ul> </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012200-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012200-sec-0034"></div> <section id="CD012200-sec-0035"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012200-sec-0036"> <h4 class="title">Types of studies</h4> <p>We included RCTs, open‐label extension (OLE) studies, controlled clinical trials, cohort studies and registries. Inclusion of non‐randomised controlled studies was supported by the aim to provide additional evidence about long‐term outcomes (in particular safety outcomes) and populations that are typical of real world practice. </p> <p>An OLE study follows on from a RCT. At the end of the RCT or after the occurrence of a primary outcome event (e.g. conversion to MS), participants receiving placebo were offered the option to switch to the active treatment during an ‘open‐label’ follow‐up. In these studies efficacy and safety were evaluated comparing the early‐treatment group with the delayed‐treatment group. </p> <p>We included studies with follow‐up of at least one year. We excluded non‐comparative studies. </p> </section> <section id="CD012200-sec-0037"> <h4 class="title">Types of participants</h4> <p>Adults (aged 18 years or older) with a first clinical attack suggestive of MS as defined in the original articles. We included participants with optic neuritis, isolated brainstem or cerebellar syndrome or spinal cord or other clinical syndrome as a first attack and monofocal or multi‐focal first attacks. </p> </section> <section id="CD012200-sec-0038"> <h4 class="title">Types of interventions</h4> <p>The following interventions administered as monotherapy were eligible for inclusion: alemtuzumab, azathioprine, cladribine, daclizumab, dimethyl fumarate, fingolimod, glatiramer acetate, immunoglobulins, interferon beta‐1b (Betaseron®), subcutaneous interferon beta‐1a (Rebif®), intramuscular interferon beta‐1a (Avonex®), laquinimod, mitoxantrone, natalizumab, ocrelizumab, pegylated interferon beta‐1a, rituximab and teriflunomide. We included regimens irrespective of their dose and assumed that treatments are 'jointly randomisable' across trial participants (<a href="./references#CD012200-bbs2-0109" title="SalantiG . Indirect and mixed‐treatment comparison, network, or multiple‐treatments meta‐analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods2012;3(2):80. [PUBMED: 26062083] ">Salanti 2012</a>). To address the first two review questions we included studies comparing disease‐modifying drugs with placebo, no treatment or another active treatment. To address the third question we included studies comparing early treatment versus delayed treatment with disease‐modifying drugs. We excluded combination treatments, non‐pharmacological treatments, and interventions consisting of over‐the‐counter drugs. </p> </section> <section id="CD012200-sec-0039"> <h4 class="title">Types of outcome measures</h4> <section id="CD012200-sec-0040"> <h5 class="title">Primary outcomes</h5> <section id="CD012200-sec-0041"> <h6 class="title">Primary efficacy outcomes</h6> <section id="CD012200-sec-0042"> <p><b>Disability‐worsening</b></p> <p>We measured this as the proportion of participants who experienced disability‐worsening (as defined by the study authors) at 24 months, 36 months or at the end of the study. Most investigators used the expanded disability status scale (EDSS) (<a href="./references#CD012200-bbs2-0095" title="KurtzkeJ . Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology1983;33(11):1444‐52. [PUBMED: 6685237] ">Kurtzke 1983</a>). EDSS is based on the results of a neurological examination and the patient’s ability to walk. Scores range from 0 (no neurological abnormality) to 10 (death from multiple sclerosis). Disability‐worsening is often defined as a sustained (3 months or 6 months) increase of at least one point in EDSS recorded over a relapse‐free period. </p> </section> <section id="CD012200-sec-0043"> <p><b>Relapses</b></p> <p>We measured this as the proportion of participants who experienced new relapses over 12 months, 24 months and 36 months or at the end of the study. A relapse is defined as a newly developed or recently worsened symptom of neurological dysfunction that lasted more than 24 hours with or without objective confirmation and that stabilised or resolved either partly or completely. </p> </section> </section> <section id="CD012200-sec-0044"> <h6 class="title">Primary safety outcomes</h6> <section id="CD012200-sec-0045"> <p><b>Occurrence of at least one serious adverse event</b></p> <p>We measured this as the proportion of participants with at least one serious adverse event during the study. </p> </section> <section id="CD012200-sec-0046"> <p><b>Withdrawing from the study or discontinuing the drug due to adverse events</b></p> <p>We measured this as the proportion of participants who withdrew from the study or discontinued the drug due to adverse events during the study. </p> </section> </section> </section> <section id="CD012200-sec-0047"> <h5 class="title">Secondary outcomes</h5> <section id="CD012200-sec-0048"> <h6 class="title">Time to conversion to clinically definite multiple sclerosis (CDMS)</h6> <p>As defined by Poser diagnostic criteria (<a href="./references#CD012200-bbs2-0107" title="PoserCM , PatyDW , ScheinbergL , McDonaldWI , DavisFA , EbersGC , et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Annals of Neurology1983;13:227–31. [PUBMED: 6847134] ">Poser 1983</a>). </p> </section> <section id="CD012200-sec-0049"> <h6 class="title">Withdrawing from the study or discontinuing the drug for any reason</h6> <p>We measured this as the proportion of participants who discontinued treatment and were followed‐up to the end of the study or who were lost to follow‐up for any reason. </p> </section> </section> </section> </section> <section id="CD012200-sec-0050"> <h3 class="title">Search methods for identification of studies</h3> <p>We did not apply any language restrictions to the search.</p> <section id="CD012200-sec-0051"> <h4 class="title">Electronic searches</h4> <p>The Information Specialist searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Trials Register , which, among other sources, contains trials from: </p> <p> <ul id="CD012200-list-0013"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2016, issue 12);</p> </li> <li> <p>MEDLINE (PubMed) (1966 to 31 December 2016);</p> </li> <li> <p>Embase (Embase.com) (1974 to 31 December 2016);</p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL) (EBSCOhost) (1981 to 31 December 2016); </p> </li> <li> <p>Latin American and Caribbean Health Science Information Database (LILACS) (Bireme) (1982 to 31 December 2016); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); and </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>). </p> </li> </ul> </p> <p>Information on the Trials Register or the Review Group and details of the search strategies used to identify trials can be found in the 'Specialised Register' section within the Cochrane Multiple Sclerosis and Rare Diseases of the CNS <a href="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/MS/frame.html" target="_blank">module</a>. We described in <a href="./appendices#CD012200-sec-0163">Appendix 1</a> the keywords that we used to search for trials. We performed an expanded search to identify articles of non‐randomised studies in MEDLINE (<a href="./appendices#CD012200-sec-0164">Appendix 2</a>) and Embase (<a href="./appendices#CD012200-sec-0165">Appendix 3</a>). </p> </section> <section id="CD012200-sec-0052"> <h4 class="title">Searching other resources</h4> <p> <ul id="CD012200-list-0014"> <li> <p>We handsearched the reference lists of all retrieved articles, texts and other reviews on the topic. </p> </li> <li> <p>We contacted study authors and researchers active in this field to ask for additional data, if necessary. </p> </li> <li> <p>We searched for FDA and EMA reports.</p> </li> </ul> </p> </section> </section> <section id="CD012200-sec-0053"> <h3 class="title" id="CD012200-sec-0053">Data collection and analysis</h3> <section id="CD012200-sec-0054"> <h4 class="title">Selection of studies</h4> <p>Two teams of three authors each (MC, MM and AS; OB, FP and GF) independently assessed titles and abstracts to identify relevant studies for inclusion. We obtained the full text of the study when necessary to confirm inclusion. All completed RCTs, OLEs, CCTs, and cohort studies were included if the studies contained clinically relevant benefit and safety outcomes for any of the drugs included in the review and met the inclusion criteria. The reference lists of the articles were screened to identify any studies missed by the electronic database search. Discrepancies in judgement were resolved by discussion between review authors. </p> </section> <section id="CD012200-sec-0055"> <h4 class="title">Data extraction and management</h4> <p>The six review authors extracted data independently and in duplicate using an Excel sheet piloted on three articles. We resolved disagreements on extractions by discussion. </p> <section id="CD012200-sec-0056"> <h5 class="title">Outcome data</h5> <p>For all dichotomous outcomes, we extracted arm‐level data (number of participants with events and number of participants). For time to conversion to CDMS we extracted hazard ratios (HR) and relative standard errors. When timing of outcome measure was not reported at selected time points, we extracted data as close as possible to that time point. When outcome data were not reported or were unclear in the original article we checked reports from the FDA or EMA. If necessary, we sought additional information from the trial investigators. For non‐randomised and OLE studies, we preferred adjusted relative treatment effects to unadjusted. </p> </section> <section id="CD012200-sec-0057"> <h5 class="title">Other extracted data</h5> <p> <ul id="CD012200-list-0015"> <li> <p>Study design: year of publication, monocentric or multicentric, recruitment period, time between onset of first attack and randomisation method; </p> </li> <li> <p>Participants: age, gender, monofocal or multi‐focal onset presentation, type of first attack, baseline EDSS, baseline MRI lesions, proportion of participants treated with steroids at the first attack; </p> </li> <li> <p>Definitions of relapse and disability‐worsening;</p> </li> <li> <p>Interventions: route, dose, frequency or duration of treatment/follow‐up.</p> </li> </ul> </p> <p>In OLE studies we also extracted the number of participating centres, and the number of participants who entered and completed the study during different follow‐up times. For each non‐randomised study, we recorded the analysis method used to reduce confounding. </p> </section> </section> <section id="CD012200-sec-0058"> <h4 class="title">Assessment of risk of bias in included studies</h4> <section id="CD012200-sec-0059"> <h5 class="title">RCTs and OLEs</h5> <p>We assessed the risk of bias of each included study using the Cochrane recommendations for assessment (<a href="./references#CD012200-bbs2-0089" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). These included: random sequence generation, allocation concealment, blinding of personnel and participants, blinding of outcome assessors, incomplete outcome data, selective outcome reporting, and evidence of major baseline imbalance. We explicitly judged the risk of bias on each criterion as 'low', 'high' or 'unclear'. We judged attrition as having low risk of bias when numbers and causes of dropouts were balanced between arms. To summarise the quality of evidence we considered allocation concealment, blinding of outcome assessors and incomplete outcome data to classify each study as having low risk of bias (when all three criteria were judged at low risk of bias), high risk of bias (when at least one criterion was at high risk of bias), unclear risk of bias when all three criteria were judged as having unclear risk of bias, and moderate risk of bias in the remaining cases. </p> <p>Participants in OLE studies were informed at the time they were recruited into the RCT that they could be enrolled into an OLE study. Then the participants taking placebo had the possibility to switch to the active treatment when they were diagnosed with CDMS or after they completed the RCT. The participant allocated to the active treatment could decide to enter the OLE study at the end of the RCT and continue taking the treatment. The consequences of the OLE design were that original allocation concealment was lost, participants entering the extension were clearly selected, for example, those who had treatment benefit and did not discontinue treatment due to adverse events. Moreover, participants and outcome assessors were not blinded in the OLE phases. For these reasons, we considered OLE studies at high risk of bias for random sequence generation, allocation concealment and blinding of participants and outcome assessors. We reported the 'Risk of bias' assessments for RTC and OLE studies separately. </p> </section> <section id="CD012200-sec-0060"> <h5 class="title">Cohort studies</h5> <p>We assessed the risk of bias in the cohort studies using the <a href="https://sites.google.com/site/riskofbiastool/" target="_blank">ROBINS‐I tool for NRS</a> (<a href="./references#CD012200-bbs2-0118" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ (Clinical Research Ed.)2016; Vol. 355:i4919. [PUBMED: 27733354] ">Sterne 2016</a>) that includes the following bias domains: confounding, selection of participants into the study, classification of interventions, deviations from intended interventions, missing data, measurement of outcomes and selection of reported result. We judged each domain as pertaining to low, moderate, serious, critical risk of bias or no information about risk of bias and performed an overall 'Risk of bias' assessment for each study according to the criteria reported in the <a href="https://sites.google.com/site/riskofbiastool/" target="_blank">ROBINS‐I tool for NRS</a> (<a href="./references#CD012200-bbs2-0118" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ (Clinical Research Ed.)2016; Vol. 355:i4919. [PUBMED: 27733354] ">Sterne 2016</a>). </p> </section> <section id="CD012200-sec-0061"> <h5 class="title">Adverse events</h5> <p>We evaluated the methods of monitoring and detecting adverse events in each included study answering to the following two questions: firstly, did researchers actively monitor for adverse events, or did they simply provide spontaneous reporting of adverse events that arose; and secondly, did study authors define serious adverse events according to an accepted international classification and report the number of serious adverse events? (<a href="./references#CD012200-bbs2-0115" title="SinghJA , WellsGA , ChristensenR , Tanjong GhogomuE , MaxwellL , MacDonaldJK , et al. Adverse effects of biologics: a network meta‐analysis and Cochrane overview. Cochrane Database of Systematic Reviews2011, Issue 2. [DOI: 10.1002/14651858.CD008794] ">Singh 2011</a>). We have reported answers to these questions in a table 'Assessment of adverse events monitoring, definition and reporting of serious adverse events'. We used the resulting answers to decide indirectness in GRADE. </p> <p>MC, MM and AS independently assessed the risk of bias of each RCT and OLE study and resolved disagreements by discussion. OB, FP and GF independently assessed risk of bias of the cohort studies and resolved disagreements by discussion. The final judgments were established by GF and CDG. </p> </section> </section> <section id="CD012200-sec-0062"> <h4 class="title">Measures of treatment effect</h4> <p>We estimated, through pairwise meta‐analysis, treatment effects of competing interventions by using odds ratios (ORs) with 95% confidence intervals (95% CIs) for each binary outcome at each time point and HR with 95% CIs for conversion to CDMS. We estimated the absolute effects for primary outcomes included in the 'Summary of fIndings' table. We presented the results from NMA of RCTs as summary relative effect sizes according to the type of outcome. </p> </section> <section id="CD012200-sec-0063"> <h4 class="title">Unit of analysis issues</h4> <p>For multi‐arm trials, intervention groups are all those that can be included in a pairwise comparison of intervention groups, which, if investigated alone, would meet the inclusion criteria. For example, if a study compares 'interferon beta versus natalizumab versus interferon beta plus natalizumab' only one comparison ('interferon beta vs natalizumab') addresses the review objectives. We merged data from study arms involving the same drug at different doses. For outcomes for which data were available as treatment effects (i.e. HR), we used the data from the arm trial at highest dose. </p> </section> <section id="CD012200-sec-0064"> <h4 class="title">Dealing with missing data</h4> <p>We considered missing outcome data in the 'Risk of bias' assessment. In some of the studies included in the review, missing outcome rates were considerable and we accounted for the their impact on the outcomes assuming that they were not missing at random. We assumed a relationship between the unknown outcome among missing participants and the known outcome among observed participants by using the 'informative missingness odds ratios' (IMORs) approach, allowing for uncertainty in the missing data imputations (<a href="./references#CD012200-bbs2-0088" title="HigginsJP , WhiteIR , WoodAM . Imputation methods for missing outcome data in meta‐analysis of clinical trials. Clinical Trials2008;5(3):225–39. [PUBMED: 18559412] ">Higgins 2008</a>; <a href="./references#CD012200-bbs2-0124" title="WhiteIR , HigginsJPT , WoodAM . Allowing for uncertainty due to missing data in meta‐analysis. 1. Two‐stage methods. Statistics in Medicine2008;27(5):711‐27. [PUBMED: 17703496] ">White 2008</a>). We assumed in both groups that the odds of relapses or disability‐worsening in missing participants were roughly 6 times times the odds in the observed participants with 95% CI from 3 to 7 (IMOR = 5.95, 95% CI 3 to 7). We set these values after discussion with clinicians, who suggested that missing outcomes are most probably unfavourable outcomes. To implement the approach we used the '<i>metamiss</i>' command in Stata v14 (available from <a href="https://www.mrc-bsu.cam.ac.uk/software/stata-software/" target="_blank">https://www.mrc‐bsu.cam.ac.uk/software/stata‐software/</a>). </p> </section> <section id="CD012200-sec-0065"> <h4 class="title">Assessment of heterogeneity</h4> <p>In standard pairwise meta‐analyses, we estimated different heterogeneity variances for each pairwise comparison. In NMA, we assumed a common estimate for the heterogeneity variance for all comparisons. We assessed the presence of statistical heterogeneity within each pairwise comparison by visual inspection of the forest plots and by calculating the I<sup>2</sup> statistic (<a href="./references#CD012200-bbs2-0087" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. [PUBMED: 12958120] ">Higgins 2003</a>). The type of drug used in the various studies was a suspected source of heterogeneity and we performed all pairwise meta‐analyses in subgroups, considering the P value from the subgroup analyses as an indication of differences between interventions. </p> </section> <section id="CD012200-sec-0066"> <h4 class="title">Assessment of reporting biases</h4> <p>We were not able to assess the possibility of reporting bias as the number of studies were fewer than 10 in all the analyses. </p> </section> <section id="CD012200-sec-0067"> <h4 class="title">Data synthesis</h4> <p>We performed pairwise meta‐analyses using a random‐effects model (using the Mantel‐Haenszel estimator for Q) for any treatment versus placebo and for early versus delayed treatment. We performed NMA using a random‐effects model for outcomes evaluated in RCTs over 24 months of follow‐up. The validity of network estimates in NMA is based on the assumption of transitivity (<a href="./references#CD012200-bbs2-0109" title="SalantiG . Indirect and mixed‐treatment comparison, network, or multiple‐treatments meta‐analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Research Synthesis Methods2012;3(2):80. [PUBMED: 26062083] ">Salanti 2012</a>). We had planned to assess whether the distribution of potential effect modifiers (among those reported extracted data in <a href="#CD012200-sec-0055">Data extraction and management</a>) were balanced across comparisons (<a href="./references#CD012200-bbs2-0092" title="JansenJP , NaciH . Is network meta‐analysis as valid as standard pairwise meta‐analysis? It all depends on the distribution of effect modifiers. BMC Medicine2013;4(11):1‐8. [PUBMED: 23826681] ">Jansen 2013</a>), however, none of the networks that we identified presented enough data to evaluate the assumptions. We conducted pairwise meta‐analyses in Review Manager 5 (RevMan 5) software (<a href="./references#CD012200-bbs2-0108" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2017. ">RevMan 2017</a>) and NMA in Stata v14 using the <i>network</i> and <i>network_graphs</i> packages in Stata v14 (available from <a href="https://www.mrc-bsu.cam.ac.uk/software/stata-software/" target="_blank">https://www.mrc‐bsu.cam.ac.uk/software/stata‐software/</a>). </p> </section> <section id="CD012200-sec-0068"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We used the test for subgroup differences to assess the statistical heterogeneity across comparisons with different active agents within standard pairwise meta‐analyses. In the context of NMA, we did not have enough information to assess incoherence, defined as the statistical disagreements between direct and indirect effect sizes, as only indirect evidence was available. </p> </section> <section id="CD012200-sec-0069"> <h4 class="title">Sensitivity analysis</h4> <p>We re‐ran the analyses of excluding observational studies when relevant.</p> <section id="CD012200-sec-0070"> <h5 class="title">'Summary of findings' table</h5> <p>We have presented the main results of the review in two 'Summary of findings' tables, according to recommendations provided in Chapter 11 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (version 5.1.0) (<a href="./references#CD012200-bbs2-0113" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Schunemann 2011</a>). We judged the credibility of the evidence from pairwise meta‐analysis in accordance with the methods of the GRADE Working Group (<a href="./references#CD012200-bbs2-0086" title="GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490‐4. [PUBMED: 15205295] ">GRADE Working Group 2004</a>). For each outcome the assumed risk in the control group was based on the proportion of events in the included studies. </p> <p>In the first 'Summary of findings' table we included an overall grading of the evidence for four patient‐important outcomes with regards to the review question 'Are disease‐modifying drugs for a first attack suggestive of MS effective and safe compared to placebo?' </p> <p> <ul id="CD012200-list-0016"> <li> <p>Disability‐worsening during 24 months of treatment</p> </li> <li> <p>Relapse during 24 months of treatment</p> </li> <li> <p>Occurrence of at least one serious adverse event during 24 months of treatment</p> </li> <li> <p>Withdrawing from the study or discontinuing the drug due to adverse events during 24 months of treatment </p> </li> </ul> </p> <p>In the second 'Summary of findings' table we included an overall grading of the evidence for two patient‐important outcomes with regards to the review question 'Is early treatment with disease‐modifying drugs more efficacious and safe than delayed treatment?' </p> <p> <ul id="CD012200-list-0017"> <li> <p>Disability‐worsening at a maximum of five years' follow‐up from randomisation</p> </li> <li> <p>Relapse at a maximum of five years' follow‐up from randomisation</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012200-sec-0071" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012200-sec-0071"></div> <section id="CD012200-sec-0072"> <h3 class="title">Description of studies</h3> <section id="CD012200-sec-0073"> <h4 class="title">Results of the search</h4> <p>A flow diagram describes the results of the electronic search (<a href="#CD012200-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012200-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram.  DMD: disease‐modifying drugs; OLEs: open label extension studies; RCTs: randomised controlled trials" data-id="CD012200-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.<br/> <b>DMD</b> : disease‐modifying drugs; <b>OLEs</b> : open label extension studies; <b>RCTs</b>: randomised controlled trials </p> </div> </div> </div> </section> <section id="CD012200-sec-0074"> <h4 class="title">Included studies</h4> <p><a href="./references#CD012200-sec-0173" title="">Characteristics of included studies</a> and <a href="#CD012200-tbl-0003">Table 1</a> provide details on the characteristics of the included studies. We included 10 RCTs involving 3745 participants and published between 2000 and 2014 (<a href="./references#CD012200-bbs2-0001" title="AchironA , KishnerI , Sarova‐PinhasI , RazH , FaibelM , SternY , et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double‐blind, placebo‐controlled trial. Archives of Neurology2004;61(10):1515‐20. [PUBMED: 15477504] ">Achiron 2004</a>; <a href="./references#CD012200-bbs2-0003" title="KapposL , PolmanCH , FreedmanMS , EdanG , HartungHP , MillerDH , et al. Treatment with interferon beta‐1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006;67(7):1242‐9. [PUBMED: 16914693] ">BENEFIT 2006</a>; <a href="./references#CD012200-bbs2-0008" title="CHAMPS Study Group. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High‐Risk Subjects Avonex Multiple Sclerosis Prevention Study. Multiple Sclerosis2002;8(4):330‐8. [PUBMED: 12166504] JacobsLD , BeckRW , SimonJH , KinkelRP , BrownscheidleCM , MurrayTJ , et al. Intramuscular interferon beta‐1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine2000;343(13):898‐904. [PUBMED: 11006365] ">CHAMPS 2000</a>; <a href="./references#CD012200-bbs2-0011" title="ComiG , FilippiM , BarkhofF , DurelliL , EdanG , FernándezO , et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet2001;357(9268):1576‐82. [PUBMED: 11377645] ">ETOMS 2001</a>; <a href="./references#CD012200-bbs2-0013" title="MotamedMR , NajimiN , FereshtehnejadSM . The effect of interferon‐beta‐1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis. Clinical Neurology and Neurosurgery2007;109(4):344‐9. [PUBMED: 17300863] ">Motamed 2007</a>; <a href="./references#CD012200-bbs2-0015" title="LeistTP , ComiG , CreeBA , CoylePK , FreedmanMS , HartungHP , et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology2014;13(3):257‐67. [PUBMED: 24502830] ">ORACLE 2014</a>; <a href="./references#CD012200-bbs2-0016" title="PakdamanH , SahraianMA , FallahA , PakdamanR , GhareghozliK , GhafarpourM , et al. Effect of early interferon beta‐1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. Acta Neurologica Scandinavica2007;115(6):429‐31. [PUBMED: 17511854] ">Pakdaman 2007</a>; <a href="./references#CD012200-bbs2-0017" title="ComiG , MartinelliV , RodegherM , MoiolaL , BajenaruO , CarraA , et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double‐blind, placebo‐controlled trial. Lancet2009;374(9700):1503‐11. [PUBMED: 19815268] ">PRECISE 2009</a>; <a href="./references#CD012200-bbs2-0019" title="ComiG , DeStefanoN , FreedmanMS , BarkhofF , PolmanCH , UitdehaagBM , et al. Comparison of two dosing frequencies of subcutaneous interferon beta‐1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology2012;11(1):33‐41. [PUBMED: 22146409] ">REFLEX 2012</a>; <a href="./references#CD012200-bbs2-0022" title="MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. [PUBMED: 25192851] ">TOPIC 2014</a>); eight OLEs involving 1868 participants and published between 2006 and 2016 (<a href="./references#CD012200-bbs2-0004" title="KapposL , FreedmanMS , PolmanCH , EdanG , HartungHP , MillerDH , et al. Effect of early versus delayed interferon beta‐1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3‐year follow‐up analysis of the BENEFIT study. Lancet2007;370(9585):389‐97. [PUBMED: 17679016] ">BENEFIT 2007 (3 years FU)</a>; <a href="./references#CD012200-bbs2-0005" title="KapposL , FreedmanMS , PolmanCH , EdanG , HartungHP , MillerDH , et al. Long‐term effect of early treatment with interferon beta‐1bafter a first clinical event suggestive of multiple sclerosis: 5‐year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology2009;8(11):987–97. [PUBMED: 19748319] ">BENEFIT 2009 (5 years FU)</a>; <a href="./references#CD012200-bbs2-0006" title="EdanG , KapposL , MontalbánX , PolmanC , FreedmanM , HartungH , et al. Long‐term impact of interferon beta‐1b in patients with CIS: 8‐year follow‐up of BENEFIT. Journal of Neurology, Neurosurgery, and Psychiatry2014;85:1183–9. [PUBMED: 24218527] ">BENEFIT 2014 (8.7 years FU)</a>; <a href="./references#CD012200-bbs2-0007" title="KapposL , EdanG , FreedmanMS , MontalbánX , HartungHP , HemmerB , et al. The 11‐year long‐term follow‐up study from the randomized BENEFIT CIS trial. Neurology2016;87(10):978‐87. [PUBMED: 27511182] ">BENEFIT 2016 (11 years FU)</a>; <a href="./references#CD012200-bbs2-0009" title="KinkelRP , KollmanC , O'ConnorP , MurrayTJ , SimonJ , ArnoldD , et al. IM interferon beta‐1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology2006;66(5):678‐84. [PUBMED: 16436649] ">CHAMPS 2006 (5 years FU)</a>; <a href="./references#CD012200-bbs2-0010" title="KinkelRP , DontchevM , KollmanC , SkaramagasTT , O'ConnorPW , SimonJH , et al. Association between immediate initiation of intramuscular interferon beta‐1a at the time of a clinically isolated syndrome and long‐term outcomes: a 10‐year follow‐up of the Controlled High‐Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Archives of Neurology2012;69(2):183‐90. [PUBMED: 21987393] SimonJH , KinkelRP , KollmanC , O'ConnorP , FisherE , YouX , et al. Ten‐year follow‐up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial. Multiple Sclerosis2015;21(4):415‐22. [PUBMED: 25344370] ">CHAMPS 2012 (10 years FU)</a>; <a href="./references#CD012200-bbs2-0018" title="ComiG , MartinelliV , RodegherM , MoiolaL , LeocaniL , BajenaruO , et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Multiple Sclerosis2013;19(8):1074‐83. [PUBMED: 23234810] ">PRECISE 2013 (5 years FU)</a>; <a href="./references#CD012200-bbs2-0020" title="ComiG , DeStefanoN , FreedmanM , BarkhofF , UitdehaagB , deVosM , et al. Subcutaneous interferon β‐1a in the treatment of clinically isolated syndromes: 3‐year and 5‐year results of the phase III dosing frequency‐blind multicentre REFLEXION study. Journal of Neurology, Neurosurgery, and Psychiatry2016;88(4):285‐94. [PUBMED: 28039317] ">REFLEX 2016 (3 and 5 years FU)</a>); and four cohort studies involving 4775 participants and published between 2010 and 2016 (<a href="./references#CD012200-bbs2-0002" title="FazekasF , BaumhacklU , BergerT , DeisenhammerF , FuchsS , KristoferitschW , et al. Decision‐making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS). European Journal of Neurology2010;17(6):852‐60. [PUBMED: 20100231] ">ACISS 2010</a>; <a href="./references#CD012200-bbs2-0012" title="D'AlessandroR , VignatelliL , LugaresiA , BaldinE , GranellaF , TolaMR , et al. Risk of multiple sclerosis following clinically isolated syndrome: a 4‐year prospective study. Journal of Neurology2013;260(6):1583‐93. [PUBMED: 23377434] ">GERONIMUS 2013</a>; <a href="./references#CD012200-bbs2-0014" title="SpelmanT , MeynielC , RojasJI , LugaresiA , IzquierdoG , Grand'MaisonF , et al. Quantifying risk of early relapse in patients with first demyelinating events: prediction in clinical practice. Multiple Sclerosis Journal2016;1:1‐12. [PUBMED: 27885062] ">MSBASIS 2016</a>; <a href="./references#CD012200-bbs2-0021" title="TintoreM , RoviraÀ , RíoJ , Otero‐RomeroS , ArrambideG , TurC , et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain2015;138:1863‐74. [PUBMED: 25902415] ">Tintore 2015</a>). </p> <div class="table" id="CD012200-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Route</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RCTs</b> </p> <p><b>N = 10</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OLEs</b> </p> <p><b>N = 8</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cohort studies</b> </p> <p><b>N = 4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interferon beta‐1b sc (Betaseron®)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sc</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 OLEs at a maximum follow‐up of 3, 5, 8.7, and 11 years</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interferon beta‐1a (Avonex®)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>im</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 OLEs at a maximum follow‐up of 5 and 10 years</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interferon beta‐1a (Rebif®)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sc</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 OLE at a maximum follow‐up of 3 and 5 years</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glatiramer acetate sc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sc</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 OLE at a maximum follow‐up of 5 years</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cladribine os</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>os</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Teriflunomide os</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>os</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immunoglobulins iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>iv</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>disease‐modifying drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>follow‐up from 2 to 6 years</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>im</b> : intramuscular; <b>iv</b> : intravenously; <b>OLEs</b> : open‐label extension studies; <b>os</b> : oral; <b>RCTs</b> : randomised controlled studies; <b>sc</b>: subcutaneous </p> </div> </div> <p>All RCTs were placebo‐controlled studies with a median of two years follow‐up. Six (60%) of the 10 included RCTs assessed interferons in people with a first attack suggestive of MS. <a href="./references#CD012200-bbs2-0003" title="KapposL , PolmanCH , FreedmanMS , EdanG , HartungHP , MillerDH , et al. Treatment with interferon beta‐1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006;67(7):1242‐9. [PUBMED: 16914693] ">BENEFIT 2006</a> provided data of four OLEs at maximum follow‐up of three, five, eight and 11 years from randomisation (<a href="./references#CD012200-bbs2-0004" title="KapposL , FreedmanMS , PolmanCH , EdanG , HartungHP , MillerDH , et al. Effect of early versus delayed interferon beta‐1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3‐year follow‐up analysis of the BENEFIT study. Lancet2007;370(9585):389‐97. [PUBMED: 17679016] ">BENEFIT 2007 (3 years FU)</a>; <a href="./references#CD012200-bbs2-0005" title="KapposL , FreedmanMS , PolmanCH , EdanG , HartungHP , MillerDH , et al. Long‐term effect of early treatment with interferon beta‐1bafter a first clinical event suggestive of multiple sclerosis: 5‐year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology2009;8(11):987–97. [PUBMED: 19748319] ">BENEFIT 2009 (5 years FU)</a>; <a href="./references#CD012200-bbs2-0006" title="EdanG , KapposL , MontalbánX , PolmanC , FreedmanM , HartungH , et al. Long‐term impact of interferon beta‐1b in patients with CIS: 8‐year follow‐up of BENEFIT. Journal of Neurology, Neurosurgery, and Psychiatry2014;85:1183–9. [PUBMED: 24218527] ">BENEFIT 2014 (8.7 years FU)</a>; <a href="./references#CD012200-bbs2-0007" title="KapposL , EdanG , FreedmanMS , MontalbánX , HartungHP , HemmerB , et al. The 11‐year long‐term follow‐up study from the randomized BENEFIT CIS trial. Neurology2016;87(10):978‐87. [PUBMED: 27511182] ">BENEFIT 2016 (11 years FU)</a>); <a href="./references#CD012200-bbs2-0008" title="CHAMPS Study Group. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High‐Risk Subjects Avonex Multiple Sclerosis Prevention Study. Multiple Sclerosis2002;8(4):330‐8. [PUBMED: 12166504] JacobsLD , BeckRW , SimonJH , KinkelRP , BrownscheidleCM , MurrayTJ , et al. Intramuscular interferon beta‐1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine2000;343(13):898‐904. [PUBMED: 11006365] ">CHAMPS 2000</a> provided data of two OLEs with a maximum follow‐up of five and 10 years (<a href="./references#CD012200-bbs2-0009" title="KinkelRP , KollmanC , O'ConnorP , MurrayTJ , SimonJ , ArnoldD , et al. IM interferon beta‐1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology2006;66(5):678‐84. [PUBMED: 16436649] ">CHAMPS 2006 (5 years FU)</a>; <a href="./references#CD012200-bbs2-0010" title="KinkelRP , DontchevM , KollmanC , SkaramagasTT , O'ConnorPW , SimonJH , et al. Association between immediate initiation of intramuscular interferon beta‐1a at the time of a clinically isolated syndrome and long‐term outcomes: a 10‐year follow‐up of the Controlled High‐Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Archives of Neurology2012;69(2):183‐90. [PUBMED: 21987393] SimonJH , KinkelRP , KollmanC , O'ConnorP , FisherE , YouX , et al. Ten‐year follow‐up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial. Multiple Sclerosis2015;21(4):415‐22. [PUBMED: 25344370] ">CHAMPS 2012 (10 years FU)</a>); <a href="./references#CD012200-bbs2-0017" title="ComiG , MartinelliV , RodegherM , MoiolaL , BajenaruO , CarraA , et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double‐blind, placebo‐controlled trial. Lancet2009;374(9700):1503‐11. [PUBMED: 19815268] ">PRECISE 2009</a> provided data of one OLE with a maximum follow‐up of five years (<a href="./references#CD012200-bbs2-0018" title="ComiG , MartinelliV , RodegherM , MoiolaL , LeocaniL , BajenaruO , et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Multiple Sclerosis2013;19(8):1074‐83. [PUBMED: 23234810] ">PRECISE 2013 (5 years FU)</a>); and <a href="./references#CD012200-bbs2-0019" title="ComiG , DeStefanoN , FreedmanMS , BarkhofF , PolmanCH , UitdehaagBM , et al. Comparison of two dosing frequencies of subcutaneous interferon beta‐1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology2012;11(1):33‐41. [PUBMED: 22146409] ">REFLEX 2012</a> provided data of two OLEs with at maximum follow‐up of three and five years (<a href="./references#CD012200-bbs2-0020" title="ComiG , DeStefanoN , FreedmanM , BarkhofF , UitdehaagB , deVosM , et al. Subcutaneous interferon β‐1a in the treatment of clinically isolated syndromes: 3‐year and 5‐year results of the phase III dosing frequency‐blind multicentre REFLEXION study. Journal of Neurology, Neurosurgery, and Psychiatry2016;88(4):285‐94. [PUBMED: 28039317] ">REFLEX 2016 (3 and 5 years FU)</a>). Follow‐up of the cohort studies ranged from two to six years. </p> <p>We identified two ongoing cohort studies (<a href="./references#CD012200-bbs2-0050" title="NCT01371071 . Cohort study of clinically isolated syndrome and early multiple sclerosis (CIS‐COHORT) [Clinically isolated syndrome and newly diagnosed multiple sclerosis: diagnostic, prognostic and therapy ‐ response markers ‐ a Prospective Observational Study (Berlin CIS‐COHORT)]. clinicaltrials.gov/show/NCT01371071 (first received 8 June 2011). ">NCT01371071</a>; <a href="./references#CD012200-bbs2-0049" title="NCT01013350 . Prospective observational long‐term safety registry of multiple sclerosis patients who have participated in cladribine clinical trials (PREMIERE). (first received 11 November 2009). ">NCT01013350</a>). We will include these studies in a future update of this review. <a href="./references#CD012200-sec-0175" title="">Characteristics of ongoing studies</a> provides details on the characteristics of the two studies. </p> </section> <section id="CD012200-sec-0075"> <h4 class="title">Excluded studies</h4> <p>After full‐text review we excluded 26 studies (see <a href="./references#CD012200-sec-0174" title="">Characteristics of excluded studies</a>): 14 studies reported sub‐analysis of original trials (<a href="./references#CD012200-bbs2-0023" title="BarkhofF , PolmanCH , RadueEW , KapposL , FreedmanMS , EdanG , et al. Magnetic resonance imaging effects of interferon beta‐1b in the BENEFIT study: integrated 2‐year results. Archives of Neurology2007;64(9):1292‐8. [PUBMED: 17846268] ">BENEFIT 2007</a>; <a href="./references#CD012200-bbs2-0024" title="PolmanC , KapposL , FreedmanMS , EdanG , HartungHP , MillerDH , et al. Subgroups of the BENEFIT study: risk of developing MS and treatment effect of interferon beta‐1b. Journal of Neurology2008;255(4):480‐7. [PUBMED: 18004635] ">BENEFIT 2008</a>; <a href="./references#CD012200-bbs2-0025" title="HartungHP , FreedmanMS , PolmanCH , EdanG , KapposL , MillerDH , et al. Interferon β‐1b‐neutralizing antibodies 5 years after clinically isolated syndrome. Neurology2011;77(9):835‐43. [PUBMED: 21849647] ">BENEFIT 2011</a>; <a href="./references#CD012200-bbs2-0026" title="PennerIK , StemperB , CalabreseP , FreedmanMS , PolmanCH , EdanG , et al. Effects of interferon beta‐1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. Multiple Sclerosis2012;18(10):1466‐71. [PUBMED: 22492127] ">BENEFIT 2012</a>; <a href="./references#CD012200-bbs2-0027" title="AscherioA , MungerKL , WhiteR , KöchertK , SimonKC , PolmanCH , et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA2014;71(3):306‐14. [PUBMED: 24445558] ">BENEFIT 2014a</a>; <a href="./references#CD012200-bbs2-0030" title="CHAMPS Study Group. Interferon ‐1a for optic neuritis patients at high risk for multiple sclerosis. American Journal of Ophthalmology2001;132(4):463‐71. [PUBMED: 11589865] ">CHAMPS 2001</a>; <a href="./references#CD012200-bbs2-0031" title="CHAMPS Study Group. Predictors of short‐term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group. Multiple Sclerosis2002;8(5):405‐9. [PUBMED: 12356207] ">CHAMPS 2002a</a>; <a href="./references#CD012200-bbs2-0032" title="BeckRW , ChandlerDL , ColeSR , SimonJH , JacobsLD , KinkelRP , et al. Interferon beta‐1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Annals of Neurology2002;51(4):481‐90. [PUBMED: 11921054] ">CHAMPS 2002b</a>; <a href="./references#CD012200-bbs2-0033" title="CHAMPS Study Group. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Multiple Sclerosis2002;8(4):330‐8. [PUBMED: 12166504] ">CHAMPS 2002c</a>; <a href="./references#CD012200-bbs2-0034" title="O'ConnorP . The effects of intramuscular interferon beta‐1a in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS. Clinical Therapeutics2003;25(11):2865‐74. [PUBMED: 14693310] ">CHAMPS 2003</a>; <a href="./references#CD012200-bbs2-0037" title="BarkhofF , RoccaM , FrancisG , VanWaesbergheJH , UitdehaagBM , HommesOR , et al. Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. Annals of Neurology2003;53(6):718‐24. [PUBMED: 12783417] ">ETOMS 2003</a>; <a href="./references#CD012200-bbs2-0038" title="FilippiM , RovarisM , IngleseM , BarkhofF , DeStefanoN , SmithS , et al. Interferon beta‐1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double‐blind, placebo‐controlled trial. Lancet2004;364(9444):1489‐96. [PUBMED: 15500893] ">Filippi 2004</a>; <a href="./references#CD012200-bbs2-0045" title="FreedmanMS , DeStefanoN , BarkhofF , PolmanCH , ComiG , UitdehaagBM , et al. Patient subgroup analyses of the treatment effect of subcutaneous interferon β‐1a on development of multiple sclerosis in the randomized controlled REFLEX study. Journal of Neurology2014;261(3):490‐9. [PUBMED: 24413638] ">REFLEX 2014a</a>; <a href="./references#CD012200-bbs2-0046" title="DeStefanoN , ComiG , KapposL , FreedmanMS , PolmanCH , UitdehaagBM , et al. Efficacy of subcutaneous interferon β‐1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. Journal of Neurology Neurosurgery and Psychiatry2914;85(6):647‐53. [PUBMED: 24292999] ">REFLEX 2014b</a>) and four studies reported re‐analysis of original trials (<a href="./references#CD012200-bbs2-0028" title="NagtegaalGJ , PohlC , WattjesMP , HulstHE , FreedmanMS , HartungHP , et al. Interferon beta‐1b reduces black holes in a randomised trial of clinically isolated syndrome. Multiple Sclerosis2014;20(2):234‐42. [PUBMED: 23842212] ">BENEFIT 2014b</a>; <a href="./references#CD012200-bbs2-0029" title="SimonJH , KinkelRP , KollmanC , O'ConnorP , FisherE , YouX , et al. Ten‐year follow‐up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial. Multiple Sclerosis2015;21(4):415‐22. [PUBMED: 25344370 ] ">CHAMPIONS 2015</a>; <a href="./references#CD012200-bbs2-0035" title="O'ConnorP , KinkelRP , KremenchutzkyM . Efficacy of intramuscular interferon beta‐1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria. Multiple sclerosis2009;15(6):728‐34. [PUBMED: 19482863] ">CHAMPS 2009</a>; <a href="./references#CD012200-bbs2-0042" title="MoraalB , PohlC , UitdehaagBM , PolmanCH , EdanG , FreedmanMS , et al. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Archives of Neurology2009;66(11):1345‐52. [PUBMED: 19901165] ">Moraal 2009</a>); in four studies participants with a first clinical attack suggestive of MS were not reported separately from participants with relapsing‐remitting MS at the time of their first disease‐modifying drugs commencement (<a href="./references#CD012200-bbs2-0041" title="MeynielC , SpelmanT , JokubaitisVG , TrojanoM , IzquierdoG , Grand'MaisonF , et al. Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome. PLoS One2012;7(6):e38661. [PUBMED: 22768046] ">Meyniel 2012</a>; <a href="./references#CD012200-bbs2-0043" title="MowryEM , PesicM , GrimesB , DeenSR , BacchettiP , WaubantE . Clinical predictors of early second event in patients with clinically isolated syndrome. Journal of Neurology2009;256(7):1061‐6. [PUBMED: 19252775] ">Mowry 2009</a>; <a href="./references#CD012200-bbs2-0044" title="JokubaitisVG , SpelmanT , KalincikT , IzquierdoG , Grand'MaisonF , DuquetteP , et al. Predictors of disability worsening in clinically isolated syndrome. Annals of Clinical and Translational Neurology2015;2(5):479‐91. [PUBMED: 26000321] ">MSBASIS 2015</a>; <a href="./references#CD012200-bbs2-0047" title="GobbiC , ZeccaC , LinnebankM , MüllerS , YouX , MeierR , et al. Swiss analysis of multiple sclerosis: a multicenter, non‐interventional, retrospective cohort study of disease‐modifying therapies. European Neurology2013;70(1‐2):35‐41. [PUBMED: 23689307] ">SWISS COHORT STUDY 2013</a>); two studies did not include efficacy or safety outcome (<a href="./references#CD012200-bbs2-0036" title="CurkendallSM , WangC , JohnsonBH , CaoZ , PreblickR , TorresAM , et al. Potential health care cost savings associated with early treatment of multiple sclerosis using disease‐modifying therapy. Clinical Therapeutics2011;33(7):914‐25. [PUBMED: 21684600] ">Curkendall 2011</a>; <a href="./references#CD012200-bbs2-0048" title="DisantoG , BenkertP , LorscheiderJ , MuellerS , VehoffJ , ZeccaC , et al. The Swiss Multiple Sclerosis Cohort‐Study (SMSC): a prospective Swiss wide investigation of key phases in disease evolution and new treatment options. PLoS One2016;11(3):e0152347. [PUBMED: 27032105] ">SWISS COHORT STUDY 2016</a>); one cohort study did not evaluate disease‐modifying drugs (<a href="./references#CD012200-bbs2-0039" title="KuhleJ , DisantoG , DobsonR , AdiutoriR , BianchiL , ToppingJ , et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Multiple Sclerosis2015;21(8):1013‐24. [PUBMED: 25680984] ">Kuhle 2015</a>); and one study reported a cohort model based on characteristics of participants enrolled into the BENEFIT trial (<a href="./references#CD012200-bbs2-0040" title="LazzaroC , BianchiC , PeracinoL , ZacchettiP , UccelliA . Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta‐1b. Neurological Sciences2009;30(1):21‐31. [PUBMED: 19169625] ">Lazzaro 2009</a>). </p> </section> </section> <section id="CD012200-sec-0076"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias assessments are summarised separately for RCTs and OLEs in <a href="#CD012200-fig-0002">Figure 2</a>. Details on the judgement for each RCT and OLE study and the reason for that judgement are reported in <a href="./references#CD012200-sec-0173" title="">Characteristics of included studies</a>. Risk of bias in the included cohort studies was assessed by ROBINS‐I and it is reported in <a href="#CD012200-tbl-0004">Table 2</a>. </p> <div class="figure" id="CD012200-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Review authors' judgements about each risk of bias item presented as percentages across all included studies and review authors' judgements about each risk of bias item for each included study" data-id="CD012200-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Review authors' judgements about each risk of bias item presented as percentages across all included studies and review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="table" id="CD012200-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias in included cohort studies (ROBINS‐I)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0002" title="FazekasF , BaumhacklU , BergerT , DeisenhammerF , FuchsS , KristoferitschW , et al. Decision‐making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS). European Journal of Neurology2010;17(6):852‐60. [PUBMED: 20100231] ">ACISS 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors’ judgment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All known important domains were not appropriately controlled for</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection of participants into the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants who would have been eligible for the target trial were likely included in the study and for each participant start of follow up and start of intervention likely coincided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Classification of interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention status was well defined and intervention definition was based on information collected at the time of intervention </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deviations from intended interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information was reported on whether there was deviation from the intended intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were critical differences between early, delayed or no treatment in participants with missing data and an appropriate analysis to address missing data was not done </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measurement of outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outcome measures were subjective and assessed by assessors aware of the intervention received by study participants. This judgment is applicable to all the three outcomes reported in the article </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection of the reported result</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was evidence that reported results corresponded to all intended outcomes and analyses </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study judged to be at critical risk of bias in one domain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0012" title="D'AlessandroR , VignatelliL , LugaresiA , BaldinE , GranellaF , TolaMR , et al. Risk of multiple sclerosis following clinically isolated syndrome: a 4‐year prospective study. Journal of Neurology2013;260(6):1583‐93. [PUBMED: 23377434] ">GERONIMUS 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Authors’ judgment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding expected, all known important confounding domains appropriately measured and controlled for, and reliability and validity of measurement of important domains were sufficient, such that we do not expect serious residual confounding </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection of participants into the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants who would have been eligible for the target trial were likely included in the study and for each participant start of follow up and start of intervention likely coincided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Classification of interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention status was not well defined</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deviations from intended interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information was reported on whether there was deviation from the intended intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data were reasonably complete</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measurement of outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDMS was assessed by assessors aware of the intervention received by study participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection of the reported result</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was evidence that reported results corresponded to all intended outcomes and analyses </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study judged to be at serious risk of bias in two domains, but not at critical risk of bias in any domain </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0014" title="SpelmanT , MeynielC , RojasJI , LugaresiA , IzquierdoG , Grand'MaisonF , et al. Quantifying risk of early relapse in patients with first demyelinating events: prediction in clinical practice. Multiple Sclerosis Journal2016;1:1‐12. [PUBMED: 27885062] ">MSBASIS 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Authors’ judgment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Important domains were not appropriately controlled for</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Selection of participants into the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Critical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Selection into the study was very strongly related to intervention and outcome and this could not be adjusted for in analyses </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Classification of interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention status was not well defined</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deviations from intended interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information was reported on whether there was deviation from the intended intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information was reported on missing data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measurement of outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The outcome measures were subjective and they were assessed by assessors aware of the intervention received by study participants. Follow‐up duration not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Selection of the reported result</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was evidence that reported results corresponded to all intended outcomes and analyses </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Critical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study judged to be at critical risk of bias in one domain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0021" title="TintoreM , RoviraÀ , RíoJ , Otero‐RomeroS , ArrambideG , TurC , et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain2015;138:1863‐74. [PUBMED: 25902415] ">Tintore 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors’ judgment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Important domains were not appropriately controlled for</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection of participants into the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants who would have been eligible for the target trial were likely included in the study and for each participant start of follow up and start of intervention likely coincided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Classification of interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention status was not well defined</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deviations from intended interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information was reported on whether there was deviation from the intended intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reasons for missing data differed substantially across interventions, and the analysis is unlikely to have removed the risk of bias arising from the missing data </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measurement of outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The outcome measures were subjective and assessed by assessors aware of the intervention received by study participants. This judgment is applicable to all outcomes reported in the article </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection of the reported result</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was evidence that reported results corresponded to all intended outcomes and analyses </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study judged to be at serious risk of bias in four domains, but not at critical risk of bias in any domain </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ROBINS‐I is a tool to evaluate Risk Of Bias In Non‐randomised Studies ‐ of Interventions (<a href="./references#CD012200-bbs2-0118" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ (Clinical Research Ed.)2016; Vol. 355:i4919. [PUBMED: 27733354] ">Sterne 2016</a>) </p> </div> </div> <section id="CD012200-sec-0077"> <h4 class="title">RCTs</h4> <section id="CD012200-sec-0078"> <h5 class="title">Random sequence generation</h5> <p>Eight out of 10 RCTs (80%) reported adequate methods for allocation sequence and we judged them to be at low risk of bias. Two RCTs (20%) did not provide enough information to assess allocation sequence and we judged the risk of bias to be unclear for these studies. </p> </section> <section id="CD012200-sec-0079"> <h5 class="title">Allocation concealment</h5> <p>Four out of 10 RCTs (40%) reported adequate methods for allocation concealment and we judged them to be at low risk of bias. Six RCTs (60%), did not provide enough information to assess allocation concealment and we judged the risk of bias to be unclear for these studies. </p> </section> <section id="CD012200-sec-0080"> <h5 class="title">Other major baseline imbalance</h5> <p>Eight out of 10 RCTs (80%) were adequate in terms of baseline balance and we judged them to be at low risk of bias. Two RCTs (20%) did not provide enough information to assess the presence of other baseline imbalance and we judged the risk of bias to be unclear for these studies. </p> </section> <section id="CD012200-sec-0081"> <h5 class="title">Blinding of participants and personnel</h5> <p>Only one RCT (10%) reported adequate methods for blinding participants and personnel to treatment allocation. Two RCTs (20%) did not provide enough information and we judged the risk of bias to be unclear for these studies. We judged seven RCTs (70%) to be at high risk of bias (<a href="./references#CD012200-bbs2-0003" title="KapposL , PolmanCH , FreedmanMS , EdanG , HartungHP , MillerDH , et al. Treatment with interferon beta‐1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006;67(7):1242‐9. [PUBMED: 16914693] ">BENEFIT 2006</a>; <a href="./references#CD012200-bbs2-0011" title="ComiG , FilippiM , BarkhofF , DurelliL , EdanG , FernándezO , et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet2001;357(9268):1576‐82. [PUBMED: 11377645] ">ETOMS 2001</a>; <a href="./references#CD012200-bbs2-0013" title="MotamedMR , NajimiN , FereshtehnejadSM . The effect of interferon‐beta‐1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis. Clinical Neurology and Neurosurgery2007;109(4):344‐9. [PUBMED: 17300863] ">Motamed 2007</a>; <a href="./references#CD012200-bbs2-0015" title="LeistTP , ComiG , CreeBA , CoylePK , FreedmanMS , HartungHP , et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology2014;13(3):257‐67. [PUBMED: 24502830] ">ORACLE 2014</a>; <a href="./references#CD012200-bbs2-0017" title="ComiG , MartinelliV , RodegherM , MoiolaL , BajenaruO , CarraA , et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double‐blind, placebo‐controlled trial. Lancet2009;374(9700):1503‐11. [PUBMED: 19815268] ">PRECISE 2009</a>; <a href="./references#CD012200-bbs2-0019" title="ComiG , DeStefanoN , FreedmanMS , BarkhofF , PolmanCH , UitdehaagBM , et al. Comparison of two dosing frequencies of subcutaneous interferon beta‐1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology2012;11(1):33‐41. [PUBMED: 22146409] ">REFLEX 2012</a>; <a href="./references#CD012200-bbs2-0022" title="MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. [PUBMED: 25192851] ">TOPIC 2014</a>). </p> </section> <section id="CD012200-sec-0082"> <h5 class="title">Blinding of outcome assessors</h5> <p>Four out of 10 RCTs (40%) reported adequate methods for blinding outcome assessors to treatment allocation. Five RCTs (50%) did not provide enough information and we judged the risk of bias to be unclear for these studies. We judged one open‐label study to be at high risk of bias for blinding of outcome assessors (<a href="./references#CD012200-bbs2-0013" title="MotamedMR , NajimiN , FereshtehnejadSM . The effect of interferon‐beta‐1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis. Clinical Neurology and Neurosurgery2007;109(4):344‐9. [PUBMED: 17300863] ">Motamed 2007</a>). </p> </section> <section id="CD012200-sec-0083"> <h5 class="title">Incomplete outcome data</h5> <p>We judged four out of 10 RCTs (40%) to be at low risk of bias because missing outcome data were balanced in numbers across intervention groups with similar reasons for missing data across groups. Two (20%) studies (<a href="./references#CD012200-bbs2-0013" title="MotamedMR , NajimiN , FereshtehnejadSM . The effect of interferon‐beta‐1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis. Clinical Neurology and Neurosurgery2007;109(4):344‐9. [PUBMED: 17300863] ">Motamed 2007</a>; <a href="./references#CD012200-bbs2-0016" title="PakdamanH , SahraianMA , FallahA , PakdamanR , GhareghozliK , GhafarpourM , et al. Effect of early interferon beta‐1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. Acta Neurologica Scandinavica2007;115(6):429‐31. [PUBMED: 17511854] ">Pakdaman 2007</a>) reported insufficient information so that it was uncertain whether or not the handling of incomplete data was appropriate. We judged risk of bias for these two trials to be unclear. We judged four trials (40%) to be at a high risk of bias, of which three (<a href="./references#CD012200-bbs2-0008" title="CHAMPS Study Group. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High‐Risk Subjects Avonex Multiple Sclerosis Prevention Study. Multiple Sclerosis2002;8(4):330‐8. [PUBMED: 12166504] JacobsLD , BeckRW , SimonJH , KinkelRP , BrownscheidleCM , MurrayTJ , et al. Intramuscular interferon beta‐1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine2000;343(13):898‐904. [PUBMED: 11006365] ">CHAMPS 2000</a>; <a href="./references#CD012200-bbs2-0015" title="LeistTP , ComiG , CreeBA , CoylePK , FreedmanMS , HartungHP , et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology2014;13(3):257‐67. [PUBMED: 24502830] ">ORACLE 2014</a>; <a href="./references#CD012200-bbs2-0017" title="ComiG , MartinelliV , RodegherM , MoiolaL , BajenaruO , CarraA , et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double‐blind, placebo‐controlled trial. Lancet2009;374(9700):1503‐11. [PUBMED: 19815268] ">PRECISE 2009</a>) were stopped before the scheduled period of follow‐up because the studies had ended prematurely and a low percentage of participants completed the studies. The fourth study (<a href="./references#CD012200-bbs2-0022" title="MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. [PUBMED: 25192851] ">TOPIC 2014</a>) showed more than 40% of participants lost to follow‐up. </p> </section> <section id="CD012200-sec-0084"> <h5 class="title">Selective outcome reporting</h5> <p>We judged the majority of included studies (six of 10; 60%) to be at low risk of bias. The study protocols were available or the published reports included those outcomes that had been pre‐specified in the methods section of primary articles. One study did not provide enough information to assess this item and the risk of bias was judged to be unclear. In three trials (30%), we judged risk of bias to be high (<a href="./references#CD012200-bbs2-0001" title="AchironA , KishnerI , Sarova‐PinhasI , RazH , FaibelM , SternY , et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double‐blind, placebo‐controlled trial. Archives of Neurology2004;61(10):1515‐20. [PUBMED: 15477504] ">Achiron 2004</a>; <a href="./references#CD012200-bbs2-0015" title="LeistTP , ComiG , CreeBA , CoylePK , FreedmanMS , HartungHP , et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology2014;13(3):257‐67. [PUBMED: 24502830] ">ORACLE 2014</a>; <a href="./references#CD012200-bbs2-0016" title="PakdamanH , SahraianMA , FallahA , PakdamanR , GhareghozliK , GhafarpourM , et al. Effect of early interferon beta‐1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. Acta Neurologica Scandinavica2007;115(6):429‐31. [PUBMED: 17511854] ">Pakdaman 2007</a>). </p> </section> <section id="CD012200-sec-0085"> <h5 class="title">Method of adverse event monitoring</h5> <p>Five included trials (5 out of 10; 50%) reported that adverse events were actively monitored. Four trials (40%) reported insufficient information about the method of adverse events monitoring so that it was uncertain whether or not adverse events were monitored appropriately. <a href="./references#CD012200-bbs2-0008" title="CHAMPS Study Group. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High‐Risk Subjects Avonex Multiple Sclerosis Prevention Study. Multiple Sclerosis2002;8(4):330‐8. [PUBMED: 12166504] JacobsLD , BeckRW , SimonJH , KinkelRP , BrownscheidleCM , MurrayTJ , et al. Intramuscular interferon beta‐1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine2000;343(13):898‐904. [PUBMED: 11006365] ">CHAMPS 2000</a> reported adverse events only during the first six months of treatment (<a href="#CD012200-tbl-0005">Table 3</a>). </p> <div class="table" id="CD012200-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Assessment of adverse events monitoring, definition and reporting of serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Did the researchers actively monitor for adverse events or did they simply provide spontaneous reporting of adverse events that arose?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Did the authors define serious adverse events according to an accepted international classification and report the number of serious adverse events?</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0001" title="AchironA , KishnerI , Sarova‐PinhasI , RazH , FaibelM , SternY , et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double‐blind, placebo‐controlled trial. Archives of Neurology2004;61(10):1515‐20. [PUBMED: 15477504] ">Achiron 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0002" title="FazekasF , BaumhacklU , BergerT , DeisenhammerF , FuchsS , KristoferitschW , et al. Decision‐making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS). European Journal of Neurology2010;17(6):852‐60. [PUBMED: 20100231] ">ACISS 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0003" title="KapposL , PolmanCH , FreedmanMS , EdanG , HartungHP , MillerDH , et al. Treatment with interferon beta‐1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006;67(7):1242‐9. [PUBMED: 16914693] ">BENEFIT 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes, active monitoring.“Regular visits were scheduled for safety assessments at months 3, 6, 9, 12, 18, and 24”<i>.</i> (page 1243) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0004" title="KapposL , FreedmanMS , PolmanCH , EdanG , HartungHP , MillerDH , et al. Effect of early versus delayed interferon beta‐1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3‐year follow‐up analysis of the BENEFIT study. Lancet2007;370(9585):389‐97. [PUBMED: 17679016] ">BENEFIT 2007 (3 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0005" title="KapposL , FreedmanMS , PolmanCH , EdanG , HartungHP , MillerDH , et al. Long‐term effect of early treatment with interferon beta‐1bafter a first clinical event suggestive of multiple sclerosis: 5‐year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology2009;8(11):987–97. [PUBMED: 19748319] ">BENEFIT 2009 (5 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0006" title="EdanG , KapposL , MontalbánX , PolmanC , FreedmanM , HartungH , et al. Long‐term impact of interferon beta‐1b in patients with CIS: 8‐year follow‐up of BENEFIT. Journal of Neurology, Neurosurgery, and Psychiatry2014;85:1183–9. [PUBMED: 24218527] ">BENEFIT 2014 (8.7 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0007" title="KapposL , EdanG , FreedmanMS , MontalbánX , HartungHP , HemmerB , et al. The 11‐year long‐term follow‐up study from the randomized BENEFIT CIS trial. Neurology2016;87(10):978‐87. [PUBMED: 27511182] ">BENEFIT 2016 (11 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0008" title="CHAMPS Study Group. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High‐Risk Subjects Avonex Multiple Sclerosis Prevention Study. Multiple Sclerosis2002;8(4):330‐8. [PUBMED: 12166504] JacobsLD , BeckRW , SimonJH , KinkelRP , BrownscheidleCM , MurrayTJ , et al. Intramuscular interferon beta‐1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine2000;343(13):898‐904. [PUBMED: 11006365] ">CHAMPS 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No active monitoring. "Each center was instructed to report all adverse events during the first six months of treatment, but thereafter to report only serious adverse events". (page 899) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0009" title="KinkelRP , KollmanC , O'ConnorP , MurrayTJ , SimonJ , ArnoldD , et al. IM interferon beta‐1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology2006;66(5):678‐84. [PUBMED: 16436649] ">CHAMPS 2006 (5 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0010" title="KinkelRP , DontchevM , KollmanC , SkaramagasTT , O'ConnorPW , SimonJH , et al. Association between immediate initiation of intramuscular interferon beta‐1a at the time of a clinically isolated syndrome and long‐term outcomes: a 10‐year follow‐up of the Controlled High‐Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Archives of Neurology2012;69(2):183‐90. [PUBMED: 21987393] SimonJH , KinkelRP , KollmanC , O'ConnorP , FisherE , YouX , et al. Ten‐year follow‐up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial. Multiple Sclerosis2015;21(4):415‐22. [PUBMED: 25344370] ">CHAMPS 2012 (10 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0011" title="ComiG , FilippiM , BarkhofF , DurelliL , EdanG , FernándezO , et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet2001;357(9268):1576‐82. [PUBMED: 11377645] ">ETOMS 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes, active monitoring<i>.</i> "Safety was assessed at 1, 6, 12, 18, 24 months". (page 1577) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes to both questions. <i>"</i>Serious adverse events were defined according to the guidelines of the International Conference on Harmonisation". (page 1580) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0012" title="D'AlessandroR , VignatelliL , LugaresiA , BaldinE , GranellaF , TolaMR , et al. Risk of multiple sclerosis following clinically isolated syndrome: a 4‐year prospective study. Journal of Neurology2013;260(6):1583‐93. [PUBMED: 23377434] ">GERONIMUS 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0013" title="MotamedMR , NajimiN , FereshtehnejadSM . The effect of interferon‐beta‐1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis. Clinical Neurology and Neurosurgery2007;109(4):344‐9. [PUBMED: 17300863] ">Motamed 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes, active monitoring."Safety assessments were performed at the end of months 1, 2, 3, 9, 15, and 21 by a neurologist". (page 345) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0014" title="SpelmanT , MeynielC , RojasJI , LugaresiA , IzquierdoG , Grand'MaisonF , et al. Quantifying risk of early relapse in patients with first demyelinating events: prediction in clinical practice. Multiple Sclerosis Journal2016;1:1‐12. [PUBMED: 27885062] ">MSBASIS 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0015" title="LeistTP , ComiG , CreeBA , CoylePK , FreedmanMS , HartungHP , et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology2014;13(3):257‐67. [PUBMED: 24502830] ">ORACLE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes, active monitoring<i>.</i> "Adverse events and laboratory findings were recorded at study visits and at regularly scheduled interim visits" (page 259). "International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use". (page 258) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes to both questions. "International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use". (page 258) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0016" title="PakdamanH , SahraianMA , FallahA , PakdamanR , GhareghozliK , GhafarpourM , et al. Effect of early interferon beta‐1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. Acta Neurologica Scandinavica2007;115(6):429‐31. [PUBMED: 17511854] ">Pakdaman 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0017" title="ComiG , MartinelliV , RodegherM , MoiolaL , BajenaruO , CarraA , et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double‐blind, placebo‐controlled trial. Lancet2009;374(9700):1503‐11. [PUBMED: 19815268] ">PRECISE 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear whether the researchers actively monitored for adverse events or they simply provided spontaneous reporting of adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0018" title="ComiG , MartinelliV , RodegherM , MoiolaL , LeocaniL , BajenaruO , et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Multiple Sclerosis2013;19(8):1074‐83. [PUBMED: 23234810] ">PRECISE 2013 (5 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear whether the researchers actively monitored for adverse events or they simply provided spontaneous reporting of adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0019" title="ComiG , DeStefanoN , FreedmanMS , BarkhofF , PolmanCH , UitdehaagBM , et al. Comparison of two dosing frequencies of subcutaneous interferon beta‐1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology2012;11(1):33‐41. [PUBMED: 22146409] ">REFLEX 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes, active monitoring<i>.</i> "Active monitoring by personnel was ensured via various testing". (page 34). "Adverse events were coded with the Medical Dictionary for Regulatory Activities (MedDRA) and analysed according to the preferred terms". (page 35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes to both questions."Adverse events were coded with the Medical Dictionary for Regulatory Activities (MedDRA) and analysed according to the preferred terms". (page 35) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0020" title="ComiG , DeStefanoN , FreedmanM , BarkhofF , UitdehaagB , deVosM , et al. Subcutaneous interferon β‐1a in the treatment of clinically isolated syndromes: 3‐year and 5‐year results of the phase III dosing frequency‐blind multicentre REFLEXION study. Journal of Neurology, Neurosurgery, and Psychiatry2016;88(4):285‐94. [PUBMED: 28039317] ">REFLEX 2016 (3 and 5 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear. "Adverse events (adverse events) were monitored at months 25 and 27 and then every 3 months to the study end". (page 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0021" title="TintoreM , RoviraÀ , RíoJ , Otero‐RomeroS , ArrambideG , TurC , et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain2015;138:1863‐74. [PUBMED: 25902415] ">Tintore 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0022" title="MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. [PUBMED: 25192851] ">TOPIC 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear. "Adverse events were reported by study participants or investigators throughout the study; investigators recorded all such events on case report forms". (page 979) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD012200-sec-0086"> <h5 class="title">Serious adverse event definitions</h5> <p>The majority of included studies (7 out of 10; 70%) gave insufficient information on serious adverse events definition, the remaining three trials (30%) provided this definition (<a href="#CD012200-tbl-0005">Table 3</a>). </p> </section> </section> <section id="CD012200-sec-0087"> <h4 class="title">OLEs</h4> <section id="CD012200-sec-0088"> <h5 class="title">Random sequence generation</h5> <p>We judged all eight OLEs to be at high risk of bias for sequence generation because there was no random assignment to the open‐label treatment groups. </p> </section> <section id="CD012200-sec-0089"> <h5 class="title">Allocation concealment</h5> <p>We judged all eight OLEs to be at high risk of bias because there was no allocation concealment with respect to assignment to the open‐label treatment groups. </p> </section> <section id="CD012200-sec-0090"> <h5 class="title">Other major baseline imbalance</h5> <p>Two out of eight OLEs (25%) were adequate in terms of baseline balance and we judged them to be at low risk of bias. Six OLEs (75%) did not provide enough information to assess the presence of other baseline imbalance and we judged the risk of bias to be unclear for these studies. </p> </section> <section id="CD012200-sec-0091"> <h5 class="title">Blinding of participants and personnel</h5> <p>None of the eight OLEs blinded participants or personnel to treatment allocation. We judged these studies to be at high risk of bias for blinding of participants and personnel. </p> </section> <section id="CD012200-sec-0092"> <h5 class="title">Blinding of outcome assessors</h5> <p>None of the eight OLEs blinded outcome assessors to treatment allocation. We judged these studies to be at high risk of bias for blinding of outcome assessors. </p> </section> <section id="CD012200-sec-0093"> <h5 class="title">Incomplete outcome data</h5> <p>Seven (87%) of the eight OLEs were likely to be at high risk of attrition bias as participants who dropped out ranged from 23% to 70% and proportions and reasons of missing participants differed substantially across intervention groups. Most of the participants who were lost to follow‐up may have not responded in the original RCT or have had adverse events that were not included in the analyses, which could overestimate the treatment benefit or underestimate the adverse effect estimates. In one OLE (<a href="./references#CD012200-bbs2-0004" title="KapposL , FreedmanMS , PolmanCH , EdanG , HartungHP , MillerDH , et al. Effect of early versus delayed interferon beta‐1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3‐year follow‐up analysis of the BENEFIT study. Lancet2007;370(9585):389‐97. [PUBMED: 17679016] ">BENEFIT 2007 (3 years FU)</a>) the majority of participants (about 80%) contributed outcome data and thus we judged this study to be at low risk of attrition bias. </p> </section> <section id="CD012200-sec-0094"> <h5 class="title">Selective outcome reporting</h5> <p>We judged most of the included studies (six of eight; 75%) to be at high risk of selective reporting bias. We did not find study protocols in the ClinicalTrials.gov database or in the FDA or EMA databases, and judged published reports to be at high risk of this type of reporting bias if they did not report all expected outcomes, including treatment discontinuation due to adverse events or serious adverse events, that were primary outcomes pre‐specified in the methods section. The six OLEs were likely to be at high risk of selective reporting bias because these studies did not specify in the methods that they intended to report adverse events and treatment discontinuation due to adverse events or serious adverse events were not reported. </p> </section> <section id="CD012200-sec-0095"> <h5 class="title">Method of adverse event monitoring</h5> <p>All the included OLEs reported insufficient information to judge if adverse events were monitored appropriately or not (<a href="#CD012200-tbl-0005">Table 3</a>). </p> </section> <section id="CD012200-sec-0096"> <h5 class="title">Serious adverse event definitions</h5> <p>All the included OLEs did not clearly define ‘serious adverse events’ (<a href="#CD012200-tbl-0005">Table 3</a>). </p> </section> </section> <section id="CD012200-sec-0097"> <h4 class="title">Cohort studies</h4> <p>We assessed risk of bias according to ROBINS‐I tool for non‐randomised studies of interventions (<a href="./references#CD012200-bbs2-0118" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ (Clinical Research Ed.)2016; Vol. 355:i4919. [PUBMED: 27733354] ">Sterne 2016</a>). We judged two (<a href="./references#CD012200-bbs2-0002" title="FazekasF , BaumhacklU , BergerT , DeisenhammerF , FuchsS , KristoferitschW , et al. Decision‐making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS). European Journal of Neurology2010;17(6):852‐60. [PUBMED: 20100231] ">ACISS 2010</a>; <a href="./references#CD012200-bbs2-0014" title="SpelmanT , MeynielC , RojasJI , LugaresiA , IzquierdoG , Grand'MaisonF , et al. Quantifying risk of early relapse in patients with first demyelinating events: prediction in clinical practice. Multiple Sclerosis Journal2016;1:1‐12. [PUBMED: 27885062] ">MSBASIS 2016</a>) of the four included cohort studies at critical risk of bias, and the other two studies (<a href="./references#CD012200-bbs2-0012" title="D'AlessandroR , VignatelliL , LugaresiA , BaldinE , GranellaF , TolaMR , et al. Risk of multiple sclerosis following clinically isolated syndrome: a 4‐year prospective study. Journal of Neurology2013;260(6):1583‐93. [PUBMED: 23377434] ">GERONIMUS 2013</a>; <a href="./references#CD012200-bbs2-0021" title="TintoreM , RoviraÀ , RíoJ , Otero‐RomeroS , ArrambideG , TurC , et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain2015;138:1863‐74. [PUBMED: 25902415] ">Tintore 2015</a>) at serious risk of bias (<a href="#CD012200-tbl-0004">Table 2</a>). None of the cohort studies reported the method they used to monitor and detect adverse events or to define serious adverse events (<a href="#CD012200-tbl-0005">Table 3</a>). </p> </section> </section> <section id="CD012200-sec-0098"> <h3 class="title" id="CD012200-sec-0098">Effects of interventions</h3> <p>See: <a href="./full#CD012200-tbl-0001"><b>Summary of findings for the main comparison</b> Are disease‐modifying drugs for a first attack suggestive of multiple sclerosis (MS) effective and safe compared to placebo?</a>; <a href="./full#CD012200-tbl-0002"><b>Summary of findings 2</b> Is early treatment with disease‐modifying drugs more efficacious and safer than delayed treatment?</a> </p> <section id="CD012200-sec-0099"> <h4 class="title">Research question 1: is early treatment efficacious and safe compared to placebo or no treatment? </h4> <p>Ten RCTs and two cohort studies compared early intervention versus placebo or no treatment.</p> <p>Their results are synthesised and presented in <a href="./full#CD012200-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD012200-sec-0100"> <h5 class="title">Primary outcomes</h5> <section id="CD012200-sec-0101"> <h6 class="title">Disability‐worsening</h6> <p>The number of participants who had disability‐worsening during 24 months was available from two RCTs (<a href="./references#CD012200-bbs2-0011" title="ComiG , FilippiM , BarkhofF , DurelliL , EdanG , FernándezO , et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet2001;357(9268):1576‐82. [PUBMED: 11377645] ">ETOMS 2001</a>, <a href="./references#CD012200-bbs2-0022" title="MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. [PUBMED: 25192851] ">TOPIC 2014</a>) and 927 participants (25% of those included in the 10 RCTs). The summary OR, which takes into account the missing outcome data, suggested a non‐significant reduction of the odds of disability‐worsening in early treatment with interferon beta‐1a (Rebif®) (<a href="./references#CD012200-bbs2-0011" title="ComiG , FilippiM , BarkhofF , DurelliL , EdanG , FernándezO , et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet2001;357(9268):1576‐82. [PUBMED: 11377645] ">ETOMS 2001</a>) or teriflunomide (<a href="./references#CD012200-bbs2-0022" title="MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. [PUBMED: 25192851] ">TOPIC 2014</a>) compared with placebo (OR 0.74, 95% CI 0.49 to 1.14, P = 0.696) with very little heterogeneity (I² = 0%) (<a href="#CD012200-fig-0003">Figure 3</a>). In one cohort study (<a href="./references#CD012200-bbs2-0002" title="FazekasF , BaumhacklU , BergerT , DeisenhammerF , FuchsS , KristoferitschW , et al. Decision‐making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS). European Journal of Neurology2010;17(6):852‐60. [PUBMED: 20100231] ">ACISS 2010</a>) participants treated with disease‐modifying drugs at their first attack had greater mean score of EDSS measured at 24 months than participants who were never treated (<a href="#CD012200-tbl-0006">Table 4</a>). </p> <div class="figure" id="CD012200-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: treatment with disease‐modifying drugs compared with placebo. Random‐effects meta‐analysis results of proportion of participants with disability‐worsening over 24 months in RCT studies. We assumed in both groups that the odds of disability‐worsening in missing participants were 5.95 times the odds in the observed participants with 95% CI from 3 to 7" data-id="CD012200-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: treatment with disease‐modifying drugs compared with placebo. Random‐effects meta‐analysis results of proportion of participants with disability‐worsening over 24 months in RCT studies. We assumed in both groups that the odds of disability‐worsening in missing participants were 5.95 times the odds in the observed participants with 95% CI from 3 to 7 </p> </div> </div> </div> <div class="table" id="CD012200-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Outcome data from cohort studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012200-bbs2-0002" title="FazekasF , BaumhacklU , BergerT , DeisenhammerF , FuchsS , KristoferitschW , et al. Decision‐making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS). European Journal of Neurology2010;17(6):852‐60. [PUBMED: 20100231] "><b>ACISS 2010</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Early DMDs treatment (N = 49)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Delayed DMDs treatment (N = 57)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No treatment</b> </p> <p><b>(N = 52)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EDSS score over 24 months' follow‐up</b> </p> <p>Mean (SD)</p> <p>Median (range)</p> <p>Kruskal–Wallis H‐Test P value &lt;0.001</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (0.9)</p> <p>1.5 (0‐3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (1.2)</p> <p>1.5 (0‐6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 (0.8)</p> <p>1.0 (0‐3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value versus no treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.016</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value early versus delayed treatment (Wilcoxon matched pair test)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.055</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapses</b> </p> <p>Mean (SD)</p> <p>Median (range)</p> <p>Kruskal–Wallis H‐Test P value &lt; 0.001</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (0.8)</p> <p>0.0 (0‐4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 (1.1)</p> <p>1.0 (0‐4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 (0.5)</p> <p>0.0 (0‐3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value versus no treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.059</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value early versus delayed treatment (Wilcoxon matched pair test)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012200-bbs2-0021" title="TintoreM , RoviraÀ , RíoJ , Otero‐RomeroS , ArrambideG , TurC , et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain2015;138:1863‐74. [PUBMED: 25902415] ">Tintore 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Risk of attaining an EDSS score of 3.0 with early DMDs compared with delayed DMDs treatment. </p> <p>Adjusted hazard ratio: 0.5 (95% CI 0.3 to 0.9)</p> <p>Unadjusted hazard ratio: 1.1 (95% CI 0.7 to 1.9)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>DMDs</b> : disease‐modifying drugs. <b>EDSS:</b> expanded disability status scale; NA: not applicable; <b>SD:</b> standard deviation </p> </div> </div> </section> <section id="CD012200-sec-0102"> <h6 class="title">Relapses</h6> <p>Data from only one trial (<a href="./references#CD012200-bbs2-0022" title="MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. [PUBMED: 25192851] ">TOPIC 2014</a>) with 618 participants (16.5%) were available to calculate the number of participants who continued to have relapses during the first 24 months of treatment with teriflunomide. The result obtained applying the IMOR method indicated a lower but not significant odds of relapse compared to placebo (OR 0.65, 95% CI 0.38 to 1.12). In one cohort study (<a href="./references#CD012200-bbs2-0002" title="FazekasF , BaumhacklU , BergerT , DeisenhammerF , FuchsS , KristoferitschW , et al. Decision‐making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS). European Journal of Neurology2010;17(6):852‐60. [PUBMED: 20100231] ">ACISS 2010</a>) there was no difference during the first 24 months of treatment in the number of relapses among participants who took disease‐modifying drugs for their first attack compared to participants who were not treated (<a href="#CD012200-tbl-0006">Table 4</a>). </p> </section> <section id="CD012200-sec-0103"> <h6 class="title">Occurrence of at least one serious adverse event</h6> <p>Data on adverse events over 24 months were available from seven RCTs (<a href="./references#CD012200-bbs2-0003" title="KapposL , PolmanCH , FreedmanMS , EdanG , HartungHP , MillerDH , et al. Treatment with interferon beta‐1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006;67(7):1242‐9. [PUBMED: 16914693] ">BENEFIT 2006</a>; <a href="./references#CD012200-bbs2-0008" title="CHAMPS Study Group. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High‐Risk Subjects Avonex Multiple Sclerosis Prevention Study. Multiple Sclerosis2002;8(4):330‐8. [PUBMED: 12166504] JacobsLD , BeckRW , SimonJH , KinkelRP , BrownscheidleCM , MurrayTJ , et al. Intramuscular interferon beta‐1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine2000;343(13):898‐904. [PUBMED: 11006365] ">CHAMPS 2000</a>; <a href="./references#CD012200-bbs2-0011" title="ComiG , FilippiM , BarkhofF , DurelliL , EdanG , FernándezO , et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet2001;357(9268):1576‐82. [PUBMED: 11377645] ">ETOMS 2001</a>; <a href="./references#CD012200-bbs2-0015" title="LeistTP , ComiG , CreeBA , CoylePK , FreedmanMS , HartungHP , et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology2014;13(3):257‐67. [PUBMED: 24502830] ">ORACLE 2014</a>; <a href="./references#CD012200-bbs2-0017" title="ComiG , MartinelliV , RodegherM , MoiolaL , BajenaruO , CarraA , et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double‐blind, placebo‐controlled trial. Lancet2009;374(9700):1503‐11. [PUBMED: 19815268] ">PRECISE 2009</a>; <a href="./references#CD012200-bbs2-0019" title="ComiG , DeStefanoN , FreedmanMS , BarkhofF , PolmanCH , UitdehaagBM , et al. Comparison of two dosing frequencies of subcutaneous interferon beta‐1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology2012;11(1):33‐41. [PUBMED: 22146409] ">REFLEX 2012</a>; <a href="./references#CD012200-bbs2-0022" title="MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. [PUBMED: 25192851] ">TOPIC 2014</a>) (3385 participants; 90%).The summary OR was 0.78 (95% CI 0.60 to 1.03, P = 0.08) (<a href="./references#CD012200-fig-0009" title="">Analysis 1.1</a>) suggesting, with very little heterogeneity (I<sup>2</sup> = 0%), that the odds of occurrence of at least one serious adverse event were lower in the active interventions compared with placebo. One trial (<a href="./references#CD012200-bbs2-0016" title="PakdamanH , SahraianMA , FallahA , PakdamanR , GhareghozliK , GhafarpourM , et al. Effect of early interferon beta‐1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. Acta Neurologica Scandinavica2007;115(6):429‐31. [PUBMED: 17511854] ">Pakdaman 2007</a>) with 202 participants (5%) suggested that the odds of occurrence of at least one serious adverse event were greater with interferon beta 1‐a (Avonex®) compared with placebo over 36 months of follow‐up; however this difference was very imprecise (OR 1.23, 95% CI 0.44 to 3.45, P = 0.69, <a href="./references#CD012200-fig-0010" title="">Analysis 1.2</a>). </p> </section> <section id="CD012200-sec-0104"> <h6 class="title">Withdrawing from the study or discontinuing the drug due to adverse events</h6> <p>Data from five RCTs (<a href="./references#CD012200-bbs2-0003" title="KapposL , PolmanCH , FreedmanMS , EdanG , HartungHP , MillerDH , et al. Treatment with interferon beta‐1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006;67(7):1242‐9. [PUBMED: 16914693] ">BENEFIT 2006</a>; <a href="./references#CD012200-bbs2-0015" title="LeistTP , ComiG , CreeBA , CoylePK , FreedmanMS , HartungHP , et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology2014;13(3):257‐67. [PUBMED: 24502830] ">ORACLE 2014</a>; <a href="./references#CD012200-bbs2-0017" title="ComiG , MartinelliV , RodegherM , MoiolaL , BajenaruO , CarraA , et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double‐blind, placebo‐controlled trial. Lancet2009;374(9700):1503‐11. [PUBMED: 19815268] ">PRECISE 2009</a>; <a href="./references#CD012200-bbs2-0022" title="MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. [PUBMED: 25192851] ">TOPIC 2014</a>; <a href="./references#CD012200-bbs2-0019" title="ComiG , DeStefanoN , FreedmanMS , BarkhofF , PolmanCH , UitdehaagBM , et al. Comparison of two dosing frequencies of subcutaneous interferon beta‐1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology2012;11(1):33‐41. [PUBMED: 22146409] ">REFLEX 2012</a>) with 2693 participants (72%) were reported for this outcome over 24 months. Overall, treatment was associated with greater odds of withdrawal or discontinuation compared with placebo (OR 2.43, 95% CI 0.91 to 6.49, P = 0.08) (<a href="./references#CD012200-fig-0011" title="">Analysis 1.3</a>). There was considerable heterogeneity (I² = 78%); compared to placebo, interferon beta 1‐b (Betaseon®) (<a href="./references#CD012200-bbs2-0003" title="KapposL , PolmanCH , FreedmanMS , EdanG , HartungHP , MillerDH , et al. Treatment with interferon beta‐1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006;67(7):1242‐9. [PUBMED: 16914693] ">BENEFIT 2006</a>), glatiramer acetate (<a href="./references#CD012200-bbs2-0017" title="ComiG , MartinelliV , RodegherM , MoiolaL , BajenaruO , CarraA , et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double‐blind, placebo‐controlled trial. Lancet2009;374(9700):1503‐11. [PUBMED: 19815268] ">PRECISE 2009</a>) and cladribine (<a href="./references#CD012200-bbs2-0015" title="LeistTP , ComiG , CreeBA , CoylePK , FreedmanMS , HartungHP , et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology2014;13(3):257‐67. [PUBMED: 24502830] ">ORACLE 2014</a>) were associated with significantly more withdrawals due to adverse events, while interferon beta‐1a (Rebif®) (<a href="./references#CD012200-bbs2-0019" title="ComiG , DeStefanoN , FreedmanMS , BarkhofF , PolmanCH , UitdehaagBM , et al. Comparison of two dosing frequencies of subcutaneous interferon beta‐1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology2012;11(1):33‐41. [PUBMED: 22146409] ">REFLEX 2012</a>) and teriflunomide (<a href="./references#CD012200-bbs2-0022" title="MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. [PUBMED: 25192851] ">TOPIC 2014</a>) were not significantly different from placebo. Interferon beta 1‐a (Avonex®) was shown to be associated with fewer withdrawals and discontinuations compared with placebo during the first 12 months of treatment (OR 0.14, 95% CI 0.02 to 1.12) (<a href="./references#CD012200-bbs2-0008" title="CHAMPS Study Group. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High‐Risk Subjects Avonex Multiple Sclerosis Prevention Study. Multiple Sclerosis2002;8(4):330‐8. [PUBMED: 12166504] JacobsLD , BeckRW , SimonJH , KinkelRP , BrownscheidleCM , MurrayTJ , et al. Intramuscular interferon beta‐1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine2000;343(13):898‐904. [PUBMED: 11006365] ">CHAMPS 2000</a>) (<a href="./references#CD012200-fig-0012" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD012200-sec-0105"> <h5 class="title">Secondary outcomes</h5> <section id="CD012200-sec-0106"> <h6 class="title">Time to conversion to CDMS</h6> <p>Seven RCTS reported this outcome at 24 months (<a href="./references#CD012200-bbs2-0003" title="KapposL , PolmanCH , FreedmanMS , EdanG , HartungHP , MillerDH , et al. Treatment with interferon beta‐1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006;67(7):1242‐9. [PUBMED: 16914693] ">BENEFIT 2006</a>; <a href="./references#CD012200-bbs2-0008" title="CHAMPS Study Group. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High‐Risk Subjects Avonex Multiple Sclerosis Prevention Study. Multiple Sclerosis2002;8(4):330‐8. [PUBMED: 12166504] JacobsLD , BeckRW , SimonJH , KinkelRP , BrownscheidleCM , MurrayTJ , et al. Intramuscular interferon beta‐1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine2000;343(13):898‐904. [PUBMED: 11006365] ">CHAMPS 2000</a>; <a href="./references#CD012200-bbs2-0011" title="ComiG , FilippiM , BarkhofF , DurelliL , EdanG , FernándezO , et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet2001;357(9268):1576‐82. [PUBMED: 11377645] ">ETOMS 2001</a>; <a href="./references#CD012200-bbs2-0015" title="LeistTP , ComiG , CreeBA , CoylePK , FreedmanMS , HartungHP , et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology2014;13(3):257‐67. [PUBMED: 24502830] ">ORACLE 2014</a>; <a href="./references#CD012200-bbs2-0017" title="ComiG , MartinelliV , RodegherM , MoiolaL , BajenaruO , CarraA , et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double‐blind, placebo‐controlled trial. Lancet2009;374(9700):1503‐11. [PUBMED: 19815268] ">PRECISE 2009</a>; <a href="./references#CD012200-bbs2-0019" title="ComiG , DeStefanoN , FreedmanMS , BarkhofF , PolmanCH , UitdehaagBM , et al. Comparison of two dosing frequencies of subcutaneous interferon beta‐1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology2012;11(1):33‐41. [PUBMED: 22146409] ">REFLEX 2012</a>; <a href="./references#CD012200-bbs2-0022" title="MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. [PUBMED: 25192851] ">TOPIC 2014</a>) (3385 participants; 90%) and in two cohort studies (<a href="./references#CD012200-bbs2-0002" title="FazekasF , BaumhacklU , BergerT , DeisenhammerF , FuchsS , KristoferitschW , et al. Decision‐making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS). European Journal of Neurology2010;17(6):852‐60. [PUBMED: 20100231] ">ACISS 2010</a>; <a href="./references#CD012200-bbs2-0014" title="SpelmanT , MeynielC , RojasJI , LugaresiA , IzquierdoG , Grand'MaisonF , et al. Quantifying risk of early relapse in patients with first demyelinating events: prediction in clinical practice. Multiple Sclerosis Journal2016;1:1‐12. [PUBMED: 27885062] ">MSBASIS 2016</a>) with 3592 participants (75% of those included in the four cohort studies). Overall there was a significant advantage of early treatment compared to control groups in reducing the hazard of CDMS during the first 24 months of treatment (HR 0.53, 95% CI 0.47 to 0.60; P &lt; 0.001). There was no evidence of heterogeneity (I² = 0%) (<a href="./references#CD012200-fig-0013" title="">Analysis 1.5</a>). Immunoglobulins (<a href="./references#CD012200-bbs2-0001" title="AchironA , KishnerI , Sarova‐PinhasI , RazH , FaibelM , SternY , et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double‐blind, placebo‐controlled trial. Archives of Neurology2004;61(10):1515‐20. [PUBMED: 15477504] ">Achiron 2004</a>) were associated with a significantly lower hazard to conversion compared with placebo during the first 12 months of treatment (HR 0.36, 95% CI 0.15 to 0.86; P = 0.02, <a href="./references#CD012200-fig-0014" title="">Analysis 1.6</a>). </p> </section> <section id="CD012200-sec-0107"> <h6 class="title">Withdrawing from the study or discontinuing the drug for any reason</h6> <p>Data at 24 months were available from six RCTs (<a href="./references#CD012200-bbs2-0003" title="KapposL , PolmanCH , FreedmanMS , EdanG , HartungHP , MillerDH , et al. Treatment with interferon beta‐1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006;67(7):1242‐9. [PUBMED: 16914693] ">BENEFIT 2006</a>; <a href="./references#CD012200-bbs2-0008" title="CHAMPS Study Group. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High‐Risk Subjects Avonex Multiple Sclerosis Prevention Study. Multiple Sclerosis2002;8(4):330‐8. [PUBMED: 12166504] JacobsLD , BeckRW , SimonJH , KinkelRP , BrownscheidleCM , MurrayTJ , et al. Intramuscular interferon beta‐1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine2000;343(13):898‐904. [PUBMED: 11006365] ">CHAMPS 2000</a>; <a href="./references#CD012200-bbs2-0011" title="ComiG , FilippiM , BarkhofF , DurelliL , EdanG , FernándezO , et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet2001;357(9268):1576‐82. [PUBMED: 11377645] ">ETOMS 2001</a>; <a href="./references#CD012200-bbs2-0015" title="LeistTP , ComiG , CreeBA , CoylePK , FreedmanMS , HartungHP , et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology2014;13(3):257‐67. [PUBMED: 24502830] ">ORACLE 2014</a>; <a href="./references#CD012200-bbs2-0019" title="ComiG , DeStefanoN , FreedmanMS , BarkhofF , PolmanCH , UitdehaagBM , et al. Comparison of two dosing frequencies of subcutaneous interferon beta‐1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology2012;11(1):33‐41. [PUBMED: 22146409] ">REFLEX 2012</a>; <a href="./references#CD012200-bbs2-0022" title="MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. [PUBMED: 25192851] ">TOPIC 2014</a>) (2931 participants; 78%). On average placebo and active drugs showed similar odds of discontinuation and dropout (OR 1.00, 95% CI 0.61 to 1.62, P = 0.99, <a href="./references#CD012200-fig-0015" title="">Analysis 1.7</a>) but there was considerable heterogeneity (I² = 84%). Compared to placebo, interferon beta 1‐b (Betaseron®) (<a href="./references#CD012200-bbs2-0003" title="KapposL , PolmanCH , FreedmanMS , EdanG , HartungHP , MillerDH , et al. Treatment with interferon beta‐1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006;67(7):1242‐9. [PUBMED: 16914693] ">BENEFIT 2006</a>) and cladribine (<a href="./references#CD012200-bbs2-0015" title="LeistTP , ComiG , CreeBA , CoylePK , FreedmanMS , HartungHP , et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology2014;13(3):257‐67. [PUBMED: 24502830] ">ORACLE 2014</a>) were associated with a greater proportion of participants who discontinued treatment or were lost to follow‐up for any reason (OR 1.50, 95% CI 0.95 to 2.3; OR 2.30, 95% CI 1.49 to 3.56), while interferon beta 1a (Rebif®) and teriflunomide were on average better than placebo. One study showed a very imprecise advantage of placebo over immunoglobulins (<a href="./references#CD012200-bbs2-0001" title="AchironA , KishnerI , Sarova‐PinhasI , RazH , FaibelM , SternY , et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double‐blind, placebo‐controlled trial. Archives of Neurology2004;61(10):1515‐20. [PUBMED: 15477504] ">Achiron 2004</a>) during the first 12 months of treatment (OR 2.15, 95% CI 0.37 to 12.35, <a href="./references#CD012200-fig-0016" title="">Analysis 1.8</a>). </p> </section> </section> </section> <section id="CD012200-sec-0108"> <h4 class="title">Research question 2: are there differences in efficacy and safety between the various drugs administered as early treatments? </h4> <p>To examine the comparative effect of one disease‐modifying drug against another we considered the results from the NMA of RCTs. Evidence was scarce and the assumptions underlying NMA impossible to evaluate. </p> <section id="CD012200-sec-0109"> <h5 class="title">Primary outcomes</h5> <section id="CD012200-sec-0110"> <h6 class="title">Disability‐worsening</h6> <p>Only two RCTs reported this outcome over 24 months, one for interferon beta‐1a (Rebif ®) (<a href="./references#CD012200-bbs2-0011" title="ComiG , FilippiM , BarkhofF , DurelliL , EdanG , FernándezO , et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet2001;357(9268):1576‐82. [PUBMED: 11377645] ">ETOMS 2001</a>) and one for teriflunomide (<a href="./references#CD012200-bbs2-0022" title="MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. [PUBMED: 25192851] ">TOPIC 2014</a>) compared to placebo. Indirect comparison did not indicate a difference between the interventions (interferon beta‐1a (Rebif ®) versus teriflunomide: OR 0.84 95% CI 0.43 to 1.66) in reducing disability‐worsening. </p> </section> <section id="CD012200-sec-0111"> <h6 class="title">Relapses</h6> <p>Only one study was available for teriflunomide compared with placebo over 24 months (<a href="./references#CD012200-bbs2-0022" title="MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. [PUBMED: 25192851] ">TOPIC 2014</a>). </p> </section> <section id="CD012200-sec-0112"> <h6 class="title">Occurrence of at least one serious adverse event</h6> <p>There were no important differences between active drugs with respect to the odds of serious adverse events. The effect sizes from studies examining various drugs were not heterogeneous (in <a href="./references#CD012200-fig-0009" title="">Analysis 1.1</a>, I² = 0% and P = 0.72 for subgroup differences). We did not estimate relative treatment effects between active drugs in an NMA because there was important variation in the definition of serious adverse events violating the transitivity assumption. </p> </section> <section id="CD012200-sec-0113"> <h6 class="title">Withdrawing from the study or discontinuing the drug due to adverse events</h6> <p>We identified important differences between the drugs, as shown in <a href="./references#CD012200-fig-0011" title="">Analysis 1.3</a> (test for subgroup differences P = 0.003). The ORs between active drugs estimated from NMA along with the network plot are shown in <a href="#CD012200-fig-0004">Figure 4</a>. As only one study per comparison was available the results pertain to a fixed‐effect model. Two treatments, interferon beta‐1a (Rebif®) and teriflunomide, were associated with significantly fewer withdrawals or discontinuation due to adverse events compared to other treatments. Odds of withdrawing from the study or discontinuing Rebif® were significantly lower compared with Betaseron® (OR 0.03, 95% CI 0.00 to 0.33), cladribine (OR 0.18, 95% CI 0.04 to 0.79) and glatiramer acetate (OR 0.21, 95% CI 0.04 to 0.96). Teriflunomide presented fewer withdrawals and discontinuations than Betaseron® (OR 0.05, 95% CI 0.01 to 0.38), cladribine (OR 0.25, 95% CI 0.07 to 0.82) and glatiramer acetate (OR 0.29, 95% CI 0.08 to 1.01). All these estimates have large variations around them. As only placebo‐controlled trials were available we were unable to evaluate the plausibility of the transitivity assumption and hence the confidence in the results from NMA is very low. </p> <div class="figure" id="CD012200-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Network plot of comparisons and network meta‐analysis estimates for the proportion of participants who withdrew from the study because of adverse events in RCT studies. The estimate is located at the intersection of the column‐defining treatment and the row‐defining treatment. In the lower triangle the comparisons should be read from left to right, a OR value less than 1 favours the column‐defining treatment. In the upper triangle the comparisons should be read from right to left, a OR value larger 1 favours the row‐defining treatment. Significant results are in italic" data-id="CD012200-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Network plot of comparisons and network meta‐analysis estimates for the proportion of participants who withdrew from the study because of adverse events in RCT studies. The estimate is located at the intersection of the column‐defining treatment and the row‐defining treatment. In the lower triangle the comparisons should be read from left to right, a OR value less than 1 favours the column‐defining treatment. In the upper triangle the comparisons should be read from right to left, a OR value larger 1 favours the row‐defining treatment. Significant results are in italic </p> </div> </div> </div> </section> </section> <section id="CD012200-sec-0114"> <h5 class="title">Secondary outcomes</h5> <section id="CD012200-sec-0115"> <h6 class="title">Time to conversion to CDMS</h6> <p>All interventions were associated with beneficial effects compared with placebo and there were no significant differences between them (test for subgroup differences P = 0.79, <a href="./references#CD012200-fig-0013" title="">Analysis 1.5</a>). This was confirmed by a NMA synthesising data over 24 months (<a href="#CD012200-fig-0005">Figure 5</a>). Note that we were unable to evaluate the transitivity assumption because few studies and only indirect comparisons were available, and hence NMA results have low credibility. </p> <div class="figure" id="CD012200-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Network plot of comparisons and network meta‐analysis estimates for the time to conversion to CDMS in RCT studies over 24 months. The estimate is located at the intersection of the column‐defining treatment and the row‐defining treatment. In the lower triangle the comparisons should be read from left to right, a HR value less than 1 favours the column‐defining treatment. In the upper triangle the comparisons should be read from right to left, a HR value larger than 1 favours the row‐defining treatment. Significant results are in italic" data-id="CD012200-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Network plot of comparisons and network meta‐analysis estimates for the time to conversion to CDMS in RCT studies over 24 months. The estimate is located at the intersection of the column‐defining treatment and the row‐defining treatment. In the lower triangle the comparisons should be read from left to right, a HR value less than 1 favours the column‐defining treatment. In the upper triangle the comparisons should be read from right to left, a HR value larger than 1 favours the row‐defining treatment. Significant results are in italic </p> </div> </div> </div> </section> <section id="CD012200-sec-0116"> <h6 class="title">Withdrawing from the study or discontinuing the drug for any reason</h6> <p>Important differences existed between drugs with respect to the odds of discontinuing or withdrawing from the study for any reason (test for subgroup differences P = 0.005, <a href="./references#CD012200-fig-0015" title="">Analysis 1.7</a>). The network plot and results from NMA are presented in <a href="#CD012200-fig-0006">Figure 6</a>. Indirect comparisons were very imprecise due to the low number of events. Note that we were unable to evaluate the transitivity assumption because few studies and only indirect comparisons were available, and hence NMA results have very low credibility. </p> <div class="figure" id="CD012200-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Network plot of comparisons and network meta‐analysis estimates for the proportion of participants who discontinued treatment and were followed up to the end of the study or who were lost to follow‐up for any reason in RCT studies. The estimate is located at the intersection of the column‐defining treatment and the row‐defining treatment. In the lower triangle the comparisons should be read from left to right, a HR value less than 1 favours the column‐defining treatment. In the upper triangle the comparisons should be read from right to left, a HR value larger 1 favours the row‐defining treatment" data-id="CD012200-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Network plot of comparisons and network meta‐analysis estimates for the proportion of participants who discontinued treatment and were followed up to the end of the study or who were lost to follow‐up for any reason in RCT studies. The estimate is located at the intersection of the column‐defining treatment and the row‐defining treatment. In the lower triangle the comparisons should be read from left to right, a HR value less than 1 favours the column‐defining treatment. In the upper triangle the comparisons should be read from right to left, a HR value larger 1 favours the row‐defining treatment </p> </div> </div> </div> </section> </section> </section> <section id="CD012200-sec-0117"> <h4 class="title">Research question 3: is early treatment more effective and safe than delayed treatment?</h4> <p>Eight OLE studies provided data for this comparison. Delayed treatment was defined as treatment given only after a second clinically confirmed attack or at two years after randomisation. The study‐specific time until the delayed treatment after randomisation is presented in <a href="#CD012200-tbl-0007">Table 5</a>. In the description of results below, the follow‐up time is the time after randomisation. </p> <div class="table" id="CD012200-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Time until the delayed treatment in open‐label extension studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time until the delayed treatment after randomisation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012200-bbs2-0003" title="KapposL , PolmanCH , FreedmanMS , EdanG , HartungHP , MillerDH , et al. Treatment with interferon beta‐1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006;67(7):1242‐9. [PUBMED: 16914693] ">BENEFIT 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD): 1.5 (0.73) years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012200-bbs2-0008" title="CHAMPS Study Group. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High‐Risk Subjects Avonex Multiple Sclerosis Prevention Study. Multiple Sclerosis2002;8(4):330‐8. [PUBMED: 12166504] JacobsLD , BeckRW , SimonJH , KinkelRP , BrownscheidleCM , MurrayTJ , et al. Intramuscular interferon beta‐1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine2000;343(13):898‐904. [PUBMED: 11006365] ">CHAMPS 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (interquartile range): 30 (24‐35) months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012200-bbs2-0017" title="ComiG , MartinelliV , RodegherM , MoiolaL , BajenaruO , CarraA , et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double‐blind, placebo‐controlled trial. Lancet2009;374(9700):1503‐11. [PUBMED: 19815268] ">PRECISE 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (range): 29 (0.5 –38) months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012200-bbs2-0019" title="ComiG , DeStefanoN , FreedmanMS , BarkhofF , PolmanCH , UitdehaagBM , et al. Comparison of two dosing frequencies of subcutaneous interferon beta‐1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology2012;11(1):33‐41. [PUBMED: 22146409] ">REFLEX 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not reported</p> </td> </tr> </tbody> </table> </div> <p>The results are synthesised and presented in <a href="./full#CD012200-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD012200-sec-0118"> <h5 class="title">Primary outcomes</h5> <section id="CD012200-sec-0119"> <h6 class="title">Disability‐worsening</h6> <p>Data were available at a maximum of three (<a href="./references#CD012200-bbs2-0004" title="KapposL , FreedmanMS , PolmanCH , EdanG , HartungHP , MillerDH , et al. Effect of early versus delayed interferon beta‐1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3‐year follow‐up analysis of the BENEFIT study. Lancet2007;370(9585):389‐97. [PUBMED: 17679016] ">BENEFIT 2007 (3 years FU)</a>; <a href="./references#CD012200-bbs2-0020" title="ComiG , DeStefanoN , FreedmanM , BarkhofF , UitdehaagB , deVosM , et al. Subcutaneous interferon β‐1a in the treatment of clinically isolated syndromes: 3‐year and 5‐year results of the phase III dosing frequency‐blind multicentre REFLEXION study. Journal of Neurology, Neurosurgery, and Psychiatry2016;88(4):285‐94. [PUBMED: 28039317] ">REFLEX 2016 (3 and 5 years FU)</a>), five (<a href="./references#CD012200-bbs2-0009" title="KinkelRP , KollmanC , O'ConnorP , MurrayTJ , SimonJ , ArnoldD , et al. IM interferon beta‐1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology2006;66(5):678‐84. [PUBMED: 16436649] ">CHAMPS 2006 (5 years FU)</a>; <a href="./references#CD012200-bbs2-0005" title="KapposL , FreedmanMS , PolmanCH , EdanG , HartungHP , MillerDH , et al. Long‐term effect of early treatment with interferon beta‐1bafter a first clinical event suggestive of multiple sclerosis: 5‐year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology2009;8(11):987–97. [PUBMED: 19748319] ">BENEFIT 2009 (5 years FU)</a>; <a href="./references#CD012200-bbs2-0018" title="ComiG , MartinelliV , RodegherM , MoiolaL , LeocaniL , BajenaruO , et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Multiple Sclerosis2013;19(8):1074‐83. [PUBMED: 23234810] ">PRECISE 2013 (5 years FU)</a>; <a href="./references#CD012200-bbs2-0020" title="ComiG , DeStefanoN , FreedmanM , BarkhofF , UitdehaagB , deVosM , et al. Subcutaneous interferon β‐1a in the treatment of clinically isolated syndromes: 3‐year and 5‐year results of the phase III dosing frequency‐blind multicentre REFLEXION study. Journal of Neurology, Neurosurgery, and Psychiatry2016;88(4):285‐94. [PUBMED: 28039317] ">REFLEX 2016 (3 and 5 years FU)</a>), 8.7 (<a href="./references#CD012200-bbs2-0006" title="EdanG , KapposL , MontalbánX , PolmanC , FreedmanM , HartungH , et al. Long‐term impact of interferon beta‐1b in patients with CIS: 8‐year follow‐up of BENEFIT. Journal of Neurology, Neurosurgery, and Psychiatry2014;85:1183–9. [PUBMED: 24218527] ">BENEFIT 2014 (8.7 years FU)</a>), 10 and 11 years of follow‐up (<a href="./references#CD012200-bbs2-0010" title="KinkelRP , DontchevM , KollmanC , SkaramagasTT , O'ConnorPW , SimonJH , et al. Association between immediate initiation of intramuscular interferon beta‐1a at the time of a clinically isolated syndrome and long‐term outcomes: a 10‐year follow‐up of the Controlled High‐Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Archives of Neurology2012;69(2):183‐90. [PUBMED: 21987393] SimonJH , KinkelRP , KollmanC , O'ConnorP , FisherE , YouX , et al. Ten‐year follow‐up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial. Multiple Sclerosis2015;21(4):415‐22. [PUBMED: 25344370] ">CHAMPS 2012 (10 years FU)</a>; <a href="./references#CD012200-bbs2-0007" title="KapposL , EdanG , FreedmanMS , MontalbánX , HartungHP , HemmerB , et al. The 11‐year long‐term follow‐up study from the randomized BENEFIT CIS trial. Neurology2016;87(10):978‐87. [PUBMED: 27511182] ">BENEFIT 2016 (11 years FU)</a>). We undertook data synthesis accounting for the large amounts of missing outcome data. Overall, the benefit of early compared to delayed treatment was very imprecise with high heterogeneity (<a href="#CD012200-fig-0007">Figure 7</a>). Early treatment with interferon beta‐1b (Betaseron®) appeared to significantly reduce the odds of participants with disability‐worsening compared with delayed treatment at a maximum of three and five years' follow‐up (<a href="./references#CD012200-bbs2-0004" title="KapposL , FreedmanMS , PolmanCH , EdanG , HartungHP , MillerDH , et al. Effect of early versus delayed interferon beta‐1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3‐year follow‐up analysis of the BENEFIT study. Lancet2007;370(9585):389‐97. [PUBMED: 17679016] ">BENEFIT 2007 (3 years FU)</a>; <a href="./references#CD012200-bbs2-0005" title="KapposL , FreedmanMS , PolmanCH , EdanG , HartungHP , MillerDH , et al. Long‐term effect of early treatment with interferon beta‐1bafter a first clinical event suggestive of multiple sclerosis: 5‐year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology2009;8(11):987–97. [PUBMED: 19748319] ">BENEFIT 2009 (5 years FU)</a>). Results of the <a href="./references#CD012200-bbs2-0020" title="ComiG , DeStefanoN , FreedmanM , BarkhofF , UitdehaagB , deVosM , et al. Subcutaneous interferon β‐1a in the treatment of clinically isolated syndromes: 3‐year and 5‐year results of the phase III dosing frequency‐blind multicentre REFLEXION study. Journal of Neurology, Neurosurgery, and Psychiatry2016;88(4):285‐94. [PUBMED: 28039317] ">REFLEX 2016 (3 and 5 years FU)</a> study suggested a non‐significant reduction of the odds of participants with disability‐worsening in delayed compared with early treatment with interferon beta‐1a (Rebif®) at a maximum of three and five years' follow‐up. Results on interferon beta‐1a (Avonex®) (<a href="./references#CD012200-bbs2-0009" title="KinkelRP , KollmanC , O'ConnorP , MurrayTJ , SimonJ , ArnoldD , et al. IM interferon beta‐1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology2006;66(5):678‐84. [PUBMED: 16436649] ">CHAMPS 2006 (5 years FU)</a>; <a href="./references#CD012200-bbs2-0010" title="KinkelRP , DontchevM , KollmanC , SkaramagasTT , O'ConnorPW , SimonJH , et al. Association between immediate initiation of intramuscular interferon beta‐1a at the time of a clinically isolated syndrome and long‐term outcomes: a 10‐year follow‐up of the Controlled High‐Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Archives of Neurology2012;69(2):183‐90. [PUBMED: 21987393] SimonJH , KinkelRP , KollmanC , O'ConnorP , FisherE , YouX , et al. Ten‐year follow‐up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial. Multiple Sclerosis2015;21(4):415‐22. [PUBMED: 25344370] ">CHAMPS 2012 (10 years FU)</a>) or glatiramer acetate (<a href="./references#CD012200-bbs2-0018" title="ComiG , MartinelliV , RodegherM , MoiolaL , LeocaniL , BajenaruO , et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Multiple Sclerosis2013;19(8):1074‐83. [PUBMED: 23234810] ">PRECISE 2013 (5 years FU)</a>) were imprecise. We did not include the outcome data for interferon beta‐1b (Betaseron®) during 11 years' follow‐up (<a href="./references#CD012200-bbs2-0007" title="KapposL , EdanG , FreedmanMS , MontalbánX , HartungHP , HemmerB , et al. The 11‐year long‐term follow‐up study from the randomized BENEFIT CIS trial. Neurology2016;87(10):978‐87. [PUBMED: 27511182] ">BENEFIT 2016 (11 years FU)</a>) in the analysis as this was a cross‐sectional reassessment of the original RCT (investigators conducted participant assessments at their respective centers or via a structured interview by phone) and not appropriate to be combined with the other data (OR 0.82, 95% CI 0.46 to 1.47, as estimated from the original study data). One cohort study (<a href="./references#CD012200-bbs2-0021" title="TintoreM , RoviraÀ , RíoJ , Otero‐RomeroS , ArrambideG , TurC , et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain2015;138:1863‐74. [PUBMED: 25902415] ">Tintore 2015</a>) reported that participants who received early treatment had a lower hazard of attaining an EDSS score of 3.0 compared with delayed treatment (adjusted HR 0.5, 95% CI 0.3 to 0.9) during a mean follow‐up time of three years and nine months (<a href="#CD012200-tbl-0006">Table 4</a>). </p> <div class="figure" id="CD012200-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: early treatment compared with delayed treatment with disease‐modifying drugs. Random‐effects meta‐analysis results of proportions of participants with disability‐worsening at a maximum of 3 years, 5 years and 10 years of follow‐up in open‐label extension studies. We assumed in both groups that the odds of disability‐worsening in missing participants were 5.95 times the odds in the observed participants with 95% CI from 3 to 7" data-id="CD012200-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: early treatment compared with delayed treatment with disease‐modifying drugs. Random‐effects meta‐analysis results of proportions of participants with disability‐worsening at a maximum of 3 years, 5 years and 10 years of follow‐up in open‐label extension studies. We assumed in both groups that the odds of disability‐worsening in missing participants were 5.95 times the odds in the observed participants with 95% CI from 3 to 7 </p> </div> </div> </div> </section> <section id="CD012200-sec-0120"> <h6 class="title">Relapses</h6> <p>Data at a maximum of five years' follow‐up were available in three OLE studies. We undertook data synthesis accounting for the large amounts of missing outcome data. Early treatment with interferon beta 1‐b (<a href="./references#CD012200-bbs2-0005" title="KapposL , FreedmanMS , PolmanCH , EdanG , HartungHP , MillerDH , et al. Long‐term effect of early treatment with interferon beta‐1bafter a first clinical event suggestive of multiple sclerosis: 5‐year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology2009;8(11):987–97. [PUBMED: 19748319] ">BENEFIT 2009 (5 years FU)</a>), interferon beta 1‐a (Rebif®) (<a href="./references#CD012200-bbs2-0020" title="ComiG , DeStefanoN , FreedmanM , BarkhofF , UitdehaagB , deVosM , et al. Subcutaneous interferon β‐1a in the treatment of clinically isolated syndromes: 3‐year and 5‐year results of the phase III dosing frequency‐blind multicentre REFLEXION study. Journal of Neurology, Neurosurgery, and Psychiatry2016;88(4):285‐94. [PUBMED: 28039317] ">REFLEX 2016 (3 and 5 years FU)</a>) and glatiramer acetate (<a href="./references#CD012200-bbs2-0018" title="ComiG , MartinelliV , RodegherM , MoiolaL , LeocaniL , BajenaruO , et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Multiple Sclerosis2013;19(8):1074‐83. [PUBMED: 23234810] ">PRECISE 2013 (5 years FU)</a>) significantly reduced the odds of participants with relapses compared to delayed treatment (OR 0.35, 95% CI 0.26 to 0.48, I² = 0.0%) (<a href="#CD012200-fig-0008">Figure 8</a>). At a maximum of three years' follow‐up early treatment with interferon beta 1‐a (Rebif®) (<a href="./references#CD012200-bbs2-0020" title="ComiG , DeStefanoN , FreedmanM , BarkhofF , UitdehaagB , deVosM , et al. Subcutaneous interferon β‐1a in the treatment of clinically isolated syndromes: 3‐year and 5‐year results of the phase III dosing frequency‐blind multicentre REFLEXION study. Journal of Neurology, Neurosurgery, and Psychiatry2016;88(4):285‐94. [PUBMED: 28039317] ">REFLEX 2016 (3 and 5 years FU)</a>) decreased the odds of participants with relapse compared to delayed treatment (OR 0.51, 95% CI 0.33 to 0.81). Between five and 10 years' follow‐up, the early interferon beta 1‐a (Avonex®) group was less likely than the delayed group to experience relapses (OR 0.51, 95% CI 0.25 to 1.04) (<a href="./references#CD012200-bbs2-0010" title="KinkelRP , DontchevM , KollmanC , SkaramagasTT , O'ConnorPW , SimonJH , et al. Association between immediate initiation of intramuscular interferon beta‐1a at the time of a clinically isolated syndrome and long‐term outcomes: a 10‐year follow‐up of the Controlled High‐Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Archives of Neurology2012;69(2):183‐90. [PUBMED: 21987393] SimonJH , KinkelRP , KollmanC , O'ConnorP , FisherE , YouX , et al. Ten‐year follow‐up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial. Multiple Sclerosis2015;21(4):415‐22. [PUBMED: 25344370] ">CHAMPS 2012 (10 years FU)</a>). </p> <div class="figure" id="CD012200-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: Early treatment compared with delayed treatment with disease‐modifying drugs. Random‐effects meta‐analysis results for proportion of participants with relapse over 5 years follow‐up in OLE studies. We assumed in both groups that the odds of relapses in missing participants were 5.95 times the odds in the observed participants with 95% CI from 3 to 7" data-id="CD012200-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: Early treatment compared with delayed treatment with disease‐modifying drugs. Random‐effects meta‐analysis results for proportion of participants with relapse over 5 years follow‐up in OLE studies. We assumed in both groups that the odds of relapses in missing participants were 5.95 times the odds in the observed participants with 95% CI from 3 to 7 </p> </div> </div> </div> </section> <section id="CD012200-sec-0121"> <h6 class="title">Occurrence of at least one serious adverse event</h6> <p>Definition of serious adverse events according to an accepted international classification was not specified in any of the OLE studies and there was important variation across studies. Additionally, the process of including participants in the OLE phases was likely associated with the occurrence of adverse events and hence the risk of selections bias was very high. Consequently, we presented the data as reported in the studies in <a href="#CD012200-tbl-0008">Table 6</a> but we did not draw any conclusions. </p> <div class="table" id="CD012200-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Safety outcome data from open‐label extension studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interferon beta‐1b</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intramuscular interferon beta 1‐a (Avonex)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subcutaneous interferon beta 1‐a (Rebif)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Glatiramer acetate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>487</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>383</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>517</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>481</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ number of participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinued treatment for any adverse events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinued treatment or were lost to follow‐up for any reason</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>146</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Years of follow‐up</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD012200-sec-0122"> <h6 class="title">Withdrawing from the study or discontinuing the drug due to adverse events</h6> <p>The method of monitoring adverse events was not specified in any of the extension studies and there was varying reliability of the different monitoring approaches. For these reasons and because there was selection of participants in the extension studies we presented results in <a href="#CD012200-tbl-0008">Table 6</a> only and we did not draw any conclusions. </p> </section> </section> <section id="CD012200-sec-0123"> <h5 class="title">Secondary outcomes</h5> <section id="CD012200-sec-0124"> <h6 class="title">Time to conversion to clinically definite multiple sclerosis</h6> <p>Early treatment with any drug reduced the hazard to conversion to CDMS over any follow‐up period (<a href="./references#CD012200-fig-0017" title="">Analysis 2.1</a>). Summary hazard ratios were 0.62 (95% CI 0.48 to 0.81, I² = 0%) from five studies reporting the outcome at a maximum follow‐up between two and four years, 0.62 (95% CI 0.53 to 0.73, I² = 0%) from four studies reporting the outcome at a maximum of five years and 0.65 (95% CI 0.54 to 0.79, I² = 0%) from two studies reporting the outcome between 8.7 and 10 years. This beneficial effect of early treatment was also present for longer follow‐up; <a href="./references#CD012200-bbs2-0007" title="KapposL , EdanG , FreedmanMS , MontalbánX , HartungHP , HemmerB , et al. The 11‐year long‐term follow‐up study from the randomized BENEFIT CIS trial. Neurology2016;87(10):978‐87. [PUBMED: 27511182] ">BENEFIT 2016 (11 years FU)</a> reported an HR of 0.67 (95% CI 0.53 to 0.85) at 11 years (this result was not included in the meta‐analysis for the same reason explained above). </p> </section> <section id="CD012200-sec-0125"> <h6 class="title">Withdrawing from the study or discontinuing the drug for any reason</h6> <p>In OLE studies participants were selected according to their willingness to take an active intervention or continue with the active intervention they were initially randomised to and hence this outcome cannot be measured. We presented results reported in these studies in <a href="#CD012200-tbl-0008">Table 6</a> but we did not draw any conclusions. </p> </section> </section> </section> <section id="CD012200-sec-0126"> <h4 class="title">Subgroup and sensitivity analyses</h4> <p>We conducted the simple meta‐analysis for the conversion to CDMS for the first and third research question excluding cohort studies. In both cases the conclusions did not change compared with the main analyses (HR 0.53, 95% CI 0.46 to 0.61 and HR 0.58, 95% CI 0.46 to 0.73, respectively). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012200-sec-0127" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012200-sec-0127"></div> <section id="CD012200-sec-0128"> <h3 class="title" id="CD012200-sec-0128">Summary of main results</h3> <p>We analysed all RCTs and open‐label extension studies undertaken so far on the use of disease‐modifying drugs in participants with a first clinical attack. The review included ten RCTs (3745 participants) with a median of two years' follow‐up, and eight open‐label extension studies (1868 participants) ranging from three to 11 years' follow‐up. Most extension studies had major methodological shortcomings. The most common flaws were lack of blinding of outcome assessors and high dropout rates, combined with failure to do an intention‐to‐treat analysis, even though most trialists specifically declared their intention to do such an analysis. The review also included four cohort studies involving 4775 participants. These cohort studies had serious defects and we judged them to be at critical or serious risk of bias by the ROBINS‐I tool. </p> <section id="CD012200-sec-0129"> <h4 class="title">Disability‐worsening</h4> <section id="CD012200-sec-0130"> <h5 class="title">Is early treatment efficacious and safe compared to placebo or no treatment?</h5> <p>Data were available from two RCTs. The odds of disability‐worsening decreased but were not significantly reduced during the first 24 months of interferon beta‐1a (Rebif®) or teriflunomide treatment compared to placebo. A small cohort study showed a greater mean score of EDSS measured at 24 months' follow‐up in participants receiving an early treatment compared with those who did not receive any treatment. </p> </section> <section id="CD012200-sec-0131"> <h5 class="title">Are there differences in efficacy and safety between the various drugs administered for early treatment? </h5> <p>There was not enough evidence to answer this question with confidence.</p> </section> <section id="CD012200-sec-0132"> <h5 class="title">Is early treatment better than delayed treatment?</h5> <p>Information to answer this question for disability‐worsening was available in the open‐label extension studies of four RCTs. The available evidence indicated a protective effect of early treatment with interferon beta‐1b (Betaseron®) compared with delayed treatment during three and five years' follow‐up. Early treatment with interferon beta‐1a (Rebif®), interferon beta‐1a (Avonex®), or glatiramer acetate was not beneficial compared to delayed treatment at any time of follow‐up. It is not clear from our analysis why this may be although in view of the great variability of the included extension studies these findings should be interpreted with caution. Early treatment with interferon beta‐1b (Betaseron®) or interferon beta‐1a (Avonex®) was no different from delayed treatment in terms of the proportion of participants who had disability‐worsening during 10 years' follow‐up. </p> </section> </section> <section id="CD012200-sec-0133"> <h4 class="title">Relapses</h4> <section id="CD012200-sec-0134"> <h5 class="title">Is early treatment efficacious and safe compared to placebo or no treatment?</h5> <p>In a single trial the odds of relapses were less but not significantly smaller with early teriflunomide treatment compared with placebo. In one cohort study relapses were not reduced in participants on early disease‐modifying drugs compared with participants who were not treated. </p> </section> <section id="CD012200-sec-0135"> <h5 class="title">Are there differences in efficacy and safety between the various drugs administered for early treatment? </h5> <p>There was not enough evidence to answer this question with confidence.</p> </section> <section id="CD012200-sec-0136"> <h5 class="title">Is early treatment better than delayed treatment?</h5> <p>The results of open‐label extension studies showed that early treatment was associated with lower odds of recurrence of relapses during three and five years of follow‐up. </p> </section> </section> <section id="CD012200-sec-0137"> <h4 class="title">Occurence of at least one serious adverse event</h4> <section id="CD012200-sec-0138"> <h5 class="title">Is early treatment efficacious and safe compared to placebo or no treatment?</h5> <p>Early treatment was associated with fewer chances of having at least one serious adverse event compared with placebo, although this difference was not significant. Information on serious adverse events was scanty and poorly reported in the included randomised trials. </p> </section> <section id="CD012200-sec-0139"> <h5 class="title">Are there differences in efficacy and safety between the various drugs administered for early treatment? </h5> <p>No evidence was available.</p> </section> <section id="CD012200-sec-0140"> <h5 class="title">Is early treatment better than delayed treatment?</h5> <p>This review cannot conclude on long‐term serious adverse events because of inadequacies in the available data both in the included open‐label extension studies and cohort studies. </p> </section> </section> <section id="CD012200-sec-0141"> <h4 class="title">Treatment discontinuation or dropout due to adverse events</h4> <section id="CD012200-sec-0142"> <h5 class="title">Is early treatment efficacious and safe compared to placebo or no treatment?</h5> <p>Interferon beta 1‐b (Betaseron®), glatiramer acetate, and cladribine were associated with significantly higher proportion of participants who withdrew due to adverse events compared to placebo during 24 months of treatment. </p> </section> <section id="CD012200-sec-0143"> <h5 class="title">Are there differences in efficacy and safety between the various drugs administered for early treatment? </h5> <p>Indirect comparisons revealed that interferon beta 1‐a (Rebif®) and teriflunomide were associated with significantly lower proportions of participants who withdrew due to adverse events compared to interferon beta 1‐b (Betaseron®), glatiramer acetate and cladribine. The estimates are very uncertain and it is possible that these differences reflect differences in the methods of monitoring and recording adverse events across studies. </p> </section> <section id="CD012200-sec-0144"> <h5 class="title">Is early treatment better than delayed treatment?</h5> <p>This review cannot conclude on long‐term adverse events because of inadequate data reported both in the included open‐label extension studies and the cohort studies. </p> </section> </section> <section id="CD012200-sec-0145"> <h4 class="title">Conversion to CDMS</h4> <section id="CD012200-sec-0146"> <h5 class="title">Is early treatment efficacious and safe compared to placebo or no treatment?</h5> <p>Early treatment was associated with significantly lower hazard of conversion to CDMS over 24 months of follow‐up. </p> </section> <section id="CD012200-sec-0147"> <h5 class="title">Are there differences in efficacy and safety between the various drugs administered for early treatment? </h5> <p>Indirect comparisons and subgroup differences showed that the disease‐modifying drugs did not differ in their effects on efficacy and safety. </p> </section> <section id="CD012200-sec-0148"> <h5 class="title">Is early treatment better than delayed treatment?</h5> <p>Open‐label extension studies and cohort studies showed that early treatment reduced the hazard of conversion to CDMS at any follow‐up up to 10 years. </p> </section> </section> <section id="CD012200-sec-0149"> <h4 class="title">Treatment discontinuation or dropout for any reason</h4> <section id="CD012200-sec-0150"> <h5 class="title">Is early treatment efficacious and safe compared to placebo or no treatment?</h5> <p>Compared to placebo, interferon beta 1‐b (Betaseron®), and cladribine were associated with significantly higher proportion of participants who discontinued treatment or were lost to follow‐up for any reason during 24 months of treatment. These results are very uncertain therefore these findings should be interpreted with caution. </p> </section> <section id="CD012200-sec-0151"> <h5 class="title">Are there differences in efficacy and safety between the various drugs administered for early treatment? </h5> <p>Indirect comparisons revealed that the disease‐modifying drugs did not differ from each other with regards to this outcome over 24 months of follow‐up and it is possible that these differences reflect differences in the methods of monitoring and recording adverse events across studies. </p> </section> <section id="CD012200-sec-0152"> <h5 class="title">Is early treatment better than delayed treatment?</h5> <p>This review cannot conclude on this outcome because of inadequate data reported both in the included open‐label extension studies and the cohort studies. </p> </section> </section> </section> <section id="CD012200-sec-0153"> <h3 class="title" id="CD012200-sec-0153">Overall completeness and applicability of evidence</h3> <p>All eligible RCTs, their open‐label extensions and cohort studies up to December 2016 were included. Unfortunately, only a small number of included studies reported data on the predefined primary outcomes of the review, that is, short‐ and long‐term disability‐worsening and recurrence of relapses. This is an unwelcome finding considering that according to the new MS diagnostic criteria (<a href="./references#CD012200-bbs2-0106" title="PolmanC , ReingoldS , BanwellB , ClanetM , CohenJ , FilippiM , et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology2011;69(2):292‐302. [PUBMED: 21387374] ">Polman 2011</a>) most of the participants included in this review currently receive a diagnosis of MS at their first attack and they need evidence about benefit of early disease‐modifying treatment with regards to disability‐worsening and recurrence of relapses that are the most important outcomes. We decided to include open‐label extension studies and cohort studies aiming to collect evidence on the long‐term safety of early treatment with disease‐modifying drugs, but unfortunately the studies included in the review reported scanty and poorly detailed safety data that did not allow us to draw conclusions, leading to uncertainty about the long‐term risk profile of these treatments. </p> </section> <section id="CD012200-sec-0154"> <h3 class="title" id="CD012200-sec-0154">Quality of the evidence</h3> <p>There were 10 RCTs with 3745 participants included in this review. We only judged one of the included trials (10%) to be at low risk of bias, when criteria for allocation concealment, blinding of outcome assessors, and complete outcome data were met. In the majority of trials, we judged allocation concealment to be ‘unclear’ due to lack of details provided in the study reports. Blinding of outcome assessors was also not clearly described in many of the included studies. We judged four studies to have a high risk of bias for incomplete outcome data. Most studies were judged to have a low risk of bias due to major baseline imbalances. </p> <p>The majority of trials in this review did not provide sufficient information on how a serious adverse event was defined in the study. We combined data on serious adverse events in pairwise meta‐analysis, regardless of the definition and whether it was provided, so caution is needed in interpreting this outcome. We assessed whether trials reported undertaking active monitoring for adverse events. Fifty percent of included trials reported that they monitored for adverse effects, however many different monitoring techniques may have been used with great variation of the different approaches. </p> <p>We included eight open‐label extension studies (1868 participants) of four RCTs. Given the design of extension studies, in which a highly selected group of participants continued on from the RCT and the majority of participants and outcome assessors were unblinded, we judged most of these studies to be at high risk of bias. We also judged 90% of the included studies to be at high risk of attrition bias because dropouts ranged from 23% to 70% and proportions and reasons for missing participants differed substantially across intervention groups. Serious adverse events were not clearly defined in most extension studies and the majority of them reported insufficient information to judge if adverse events were monitored appropriately or not. </p> <p>We included four cohort studies with 4775 participants. We assessed risk of bias of these studies according to ROBINS‐I tool for non‐randomised studies of interventions (<a href="./references#CD012200-bbs2-0118" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ (Clinical Research Ed.)2016; Vol. 355:i4919. [PUBMED: 27733354] ">Sterne 2016</a>). We judged two studies at critical risk of bias, and the other two studies at serious risk of bias. None of the included cohort studies defined or reported serious adverse events, or whether adverse events were monitored appropriately or not. </p> <p>For the overall results of disease‐modifying drugs as a group versus placebo for the four primary outcomes of disability‐worsening, recurrence of relapse, serious adverse events and withdrawals due to adverse events during 24 months of treatment, we graded our confidence in the results as 'very low’ or ’low’ using the GRADE approach (<a href="./full#CD012200-tbl-0001">summary of findings Table for the main comparison</a>). For the results of early treatment compared to delayed treatment for the two primary outcomes of disability‐worsening and recurrence of relapses during five years' follow‐up, we graded our confidence in the results as ’very low’ or ’low’ (<a href="./full#CD012200-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD012200-sec-0155"> <h3 class="title" id="CD012200-sec-0155">Potential biases in the review process</h3> <p>This review has several differences compared to its protocol. We have broadened the research question as a result of the identified data. The initial protocol was focused on detecting differences between the intervention (research question 2) but we realised that we would not be able to answer this question and we added two other aims that we considered clinically important. We also added an outcome (time to conversion to CDMS). Although these decisions were guided by data availability, we think that this has not introduced bias in our review because its scope has become wider rather than narrower. </p> </section> <section id="CD012200-sec-0156"> <h3 class="title" id="CD012200-sec-0156">Agreements and disagreements with other studies or reviews</h3> <p>In this review that included RCTs of seven disease‐modifying drugs used in participants who had a first clinical attack suggestive of MS, we found that participants who received interferons, glatiramer acetate, teriflunomide, cladribine had significantly lower hazard of conversion to MS compared to placebo and the effects of these drugs did not differ from each other. Compared with placebo, disease‐modifying drugs did not increase the risk of serious adverse events. Interferon beta 1‐a (Rebif®) and teriflunomide were associated with a lower risk of withdrawals due to adverse events, compared with placebo and the other drugs. </p> <p>Our findings extend the findings of a previous Cochrane Review that examined only three RCTs of 24 months' duration of interferon beta 1‐b (Betaseron®), interferon beta 1‐a (Rebif®) and interferon beta 1‐a (Avonex®) (<a href="./references#CD012200-bbs2-0056" title="ClericoM , FaggianoF , PalaceJ , RiceG , TintorèM , DurelliL . Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD005278.pub3] ">Clerico 2008</a>). They reported that interferons had lower‐than‐placebo risk of conversion to CDMS, the frequency of serious adverse events was not significantly different in interferon groups compared to placebo, but active treatment was more likely than placebo to lead to withdrawals due to adverse events. Similar observations have been made by one qualitative review, <a href="./references#CD012200-bbs2-0083" title="FreedmanMS , ComiG , DeStefanoN , BarkhofF , PolmanCH , UitdehaagBM , et al. Moving toward earlier treatment of multiple sclerosis: findings from a decade of clinical trials and implications for clinical practice. Multiple Sclerosis and Related Disorders2014;3(2):147‐55. [PUBMED: 25878002] ">Freedman 2014</a> of the same three RCTs of interferons. In one review (<a href="./references#CD012200-bbs2-0116" title="SmithB , CarsonS , FuR , McDonaghM , DanaT , ChanBKS , et al. Drug Class Review: Disease‐modifying Drugs for Multiple Sclerosis: Final Update 1 Report. 2010 Aug. Portland (OR): Oregon Health &amp; Science University, 2010. [PUBMED: 21348046 ] ">Smith 2010</a>) of five RCTs of disease‐modifying drugs, which included some of the same RCTs with their extensions during five years' follow‐up, the authors concluded that all the three interferons and glatiramer acetate reduced the probability of converting from clinically isolated syndrome to CDMS over a period of two to five years. They reported that the included studies did not describe methods of ascertaining adverse events and that their reporting was sparse. The incidence of adverse events was significantly higher in the interferon and glatiramer acetate groups compared with the placebo groups for most commonly occurring adverse events such as influenza‐like syndrome and injection‐site reactions. Rates of serious adverse events were no different from placebo in any trial. Most of our findings from direct and indirect comparisons cannot be compared to previous studies since most of them reported only a qualitative description of the trials focusing on efficacy outcomes. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012200-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram.  DMD: disease‐modifying drugs; OLEs: open label extension studies; RCTs: randomised controlled trials" data-id="CD012200-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.<br/> <b>DMD</b> : disease‐modifying drugs; <b>OLEs</b> : open label extension studies; <b>RCTs</b>: randomised controlled trials </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Review authors' judgements about each risk of bias item presented as percentages across all included studies and review authors' judgements about each risk of bias item for each included study" data-id="CD012200-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Review authors' judgements about each risk of bias item presented as percentages across all included studies and review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: treatment with disease‐modifying drugs compared with placebo. Random‐effects meta‐analysis results of proportion of participants with disability‐worsening over 24 months in RCT studies. We assumed in both groups that the odds of disability‐worsening in missing participants were 5.95 times the odds in the observed participants with 95% CI from 3 to 7" data-id="CD012200-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: treatment with disease‐modifying drugs compared with placebo. Random‐effects meta‐analysis results of proportion of participants with disability‐worsening over 24 months in RCT studies. We assumed in both groups that the odds of disability‐worsening in missing participants were 5.95 times the odds in the observed participants with 95% CI from 3 to 7 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Network plot of comparisons and network meta‐analysis estimates for the proportion of participants who withdrew from the study because of adverse events in RCT studies. The estimate is located at the intersection of the column‐defining treatment and the row‐defining treatment. In the lower triangle the comparisons should be read from left to right, a OR value less than 1 favours the column‐defining treatment. In the upper triangle the comparisons should be read from right to left, a OR value larger 1 favours the row‐defining treatment. Significant results are in italic" data-id="CD012200-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Network plot of comparisons and network meta‐analysis estimates for the proportion of participants who withdrew from the study because of adverse events in RCT studies. The estimate is located at the intersection of the column‐defining treatment and the row‐defining treatment. In the lower triangle the comparisons should be read from left to right, a OR value less than 1 favours the column‐defining treatment. In the upper triangle the comparisons should be read from right to left, a OR value larger 1 favours the row‐defining treatment. Significant results are in italic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Network plot of comparisons and network meta‐analysis estimates for the time to conversion to CDMS in RCT studies over 24 months. The estimate is located at the intersection of the column‐defining treatment and the row‐defining treatment. In the lower triangle the comparisons should be read from left to right, a HR value less than 1 favours the column‐defining treatment. In the upper triangle the comparisons should be read from right to left, a HR value larger than 1 favours the row‐defining treatment. Significant results are in italic" data-id="CD012200-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Network plot of comparisons and network meta‐analysis estimates for the time to conversion to CDMS in RCT studies over 24 months. The estimate is located at the intersection of the column‐defining treatment and the row‐defining treatment. In the lower triangle the comparisons should be read from left to right, a HR value less than 1 favours the column‐defining treatment. In the upper triangle the comparisons should be read from right to left, a HR value larger than 1 favours the row‐defining treatment. Significant results are in italic </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Network plot of comparisons and network meta‐analysis estimates for the proportion of participants who discontinued treatment and were followed up to the end of the study or who were lost to follow‐up for any reason in RCT studies. The estimate is located at the intersection of the column‐defining treatment and the row‐defining treatment. In the lower triangle the comparisons should be read from left to right, a HR value less than 1 favours the column‐defining treatment. In the upper triangle the comparisons should be read from right to left, a HR value larger 1 favours the row‐defining treatment" data-id="CD012200-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Network plot of comparisons and network meta‐analysis estimates for the proportion of participants who discontinued treatment and were followed up to the end of the study or who were lost to follow‐up for any reason in RCT studies. The estimate is located at the intersection of the column‐defining treatment and the row‐defining treatment. In the lower triangle the comparisons should be read from left to right, a HR value less than 1 favours the column‐defining treatment. In the upper triangle the comparisons should be read from right to left, a HR value larger 1 favours the row‐defining treatment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: early treatment compared with delayed treatment with disease‐modifying drugs. Random‐effects meta‐analysis results of proportions of participants with disability‐worsening at a maximum of 3 years, 5 years and 10 years of follow‐up in open‐label extension studies. We assumed in both groups that the odds of disability‐worsening in missing participants were 5.95 times the odds in the observed participants with 95% CI from 3 to 7" data-id="CD012200-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: early treatment compared with delayed treatment with disease‐modifying drugs. Random‐effects meta‐analysis results of proportions of participants with disability‐worsening at a maximum of 3 years, 5 years and 10 years of follow‐up in open‐label extension studies. We assumed in both groups that the odds of disability‐worsening in missing participants were 5.95 times the odds in the observed participants with 95% CI from 3 to 7 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: Early treatment compared with delayed treatment with disease‐modifying drugs. Random‐effects meta‐analysis results for proportion of participants with relapse over 5 years follow‐up in OLE studies. We assumed in both groups that the odds of relapses in missing participants were 5.95 times the odds in the observed participants with 95% CI from 3 to 7" data-id="CD012200-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: Early treatment compared with delayed treatment with disease‐modifying drugs. Random‐effects meta‐analysis results for proportion of participants with relapse over 5 years follow‐up in OLE studies. We assumed in both groups that the odds of relapses in missing participants were 5.95 times the odds in the observed participants with 95% CI from 3 to 7 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Active intervention versus placebo, Outcome 1 Occurrence of at least one serious adverse event over 24 months." data-id="CD012200-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Active intervention versus placebo, Outcome 1 Occurrence of at least one serious adverse event over 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/references#CD012200-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Active intervention versus placebo, Outcome 2 Occurrence of at least one serious adverse event over 36 months." data-id="CD012200-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Active intervention versus placebo, Outcome 2 Occurrence of at least one serious adverse event over 36 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/references#CD012200-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Active intervention versus placebo, Outcome 3 Withdrawing from the study or discontinuing the drug due to adverse events over 24 months." data-id="CD012200-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Active intervention versus placebo, Outcome 3 Withdrawing from the study or discontinuing the drug due to adverse events over 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/references#CD012200-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Active intervention versus placebo, Outcome 4 Withdrawing from the study or discontinuing the drug due to adverse events over 12 months." data-id="CD012200-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Active intervention versus placebo, Outcome 4 Withdrawing from the study or discontinuing the drug due to adverse events over 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/references#CD012200-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Active intervention versus placebo, Outcome 5 Time to conversion to CDMS over 24 months." data-id="CD012200-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Active intervention versus placebo, Outcome 5 Time to conversion to CDMS over 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/references#CD012200-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Active intervention versus placebo, Outcome 6 Time to conversion to CDMS over 12 months." data-id="CD012200-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Active intervention versus placebo, Outcome 6 Time to conversion to CDMS over 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/references#CD012200-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Active intervention versus placebo, Outcome 7 Withdrawing from the study or discontinuing the drug for any reason over 24 months." data-id="CD012200-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Active intervention versus placebo, Outcome 7 Withdrawing from the study or discontinuing the drug for any reason over 24 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/references#CD012200-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Active intervention versus placebo, Outcome 8 Withdrawing from the study or discontinuing the drug for any reason over 12 months." data-id="CD012200-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Active intervention versus placebo, Outcome 8 Withdrawing from the study or discontinuing the drug for any reason over 12 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/references#CD012200-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012200-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/urn:x-wiley:14651858:media:CD012200:CD012200-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_t/tCD012200-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Early versus delayed treatment, Outcome 1 Time to conversion to CDMS at different follow‐up years." data-id="CD012200-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Early versus delayed treatment, Outcome 1 Time to conversion to CDMS at different follow‐up years. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/references#CD012200-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/media/CDSR/CD012200/image_n/nCD012200-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012200-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Are disease‐modifying drugs for a first attack suggestive of multiple sclerosis (MS) effective and safe compared to placebo?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> adults with first attack suggestive of MS<br/> <b>Setting:</b> MS centres<br/> <b>Intervention:</b> early disease‐modifying drug treatment<br/> <b>Comparison:</b> placebo </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>With early disease‐modifying drugs treatment</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Disability‐worsening</b> </p> <p>Proportion of participants with disability‐worsening, assessed by EDSS** during 24 months of treatment<br/> Participants: N = 927<br/> (2 RCTs) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.74<br/> (0.49 to 1.14) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.7%</p> <p>(20.2 to 37.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4% fewer (13.9 fewer to 3 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The risk of disability‐worsening is less with disease‐modifying drugs than with placebo, but there is a lot of uncertainty in the effect </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Relapse</b> </p> <p>Proportion of participants with relapse during 24 months of treatment<br/> Participants: N = 618<br/> (1 RCT) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.65<br/> (0.38 to 1.12) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>41.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.7%</p> <p>(21.3 to 44.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.0% fewer (20.3 fewer to 2.8 more)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,c,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The risk of relapse is less with disease‐modifying drugs than with placebo, but there is a lot of uncertainty in the effects </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Occurrence of at least one serious adverse event</b> Proportion of participants with at least one serious adverse event during 24 months of treatment<br/> Participants: N = 3385<br/> (7 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.78<br/> (0.60 to 1.03) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>8.0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.3%<br/> (5.0 to 8.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6% fewer<br/> (3 fewer to 0.2 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo, disease‐modifying drugs were associated with less risk of serious adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawls or drug discontinuation due to adverse events</b> </p> <p>during 24 months of treatment<br/> Participants: N = 2693<br/> (5 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 2.43<br/> (0.91 to 6.49) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>3.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.0%<br/> (3.2 to 18.9) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6% more<br/> (0.3 fewer to 15.4 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,f,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to placebo interferon beta 1‐b, glatiramer acetate, and cladribine were associated with higher risk of withdrawals due to adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p>**<b>EDSS:</b> expanded disability status scale<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup>High risk of bias for blinding of participants and outcome assessment and incomplete outcome data.<br/> <sup>b</sup>Surrogate outcome in both studies contributing to this estimate.<br/> <sup>c</sup>The confidence interval does not rule out a null effect or benefit.<br/> <sup>d</sup>Only one study contributed to this estimate.<br/> <sup>e</sup>Definition and methods of monitoring and detecting serious adverse events not reported in most trials.<br/> <sup>f</sup>High heterogeneity (I² = 78%, P = 0.001) not explained; high subgroup differences (I² = 75%, P = 0.003).<br/> <sup>g</sup>Definition and methods of monitoring and detecting adverse events not reported in most trials. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Are disease‐modifying drugs for a first attack suggestive of multiple sclerosis (MS) effective and safe compared to placebo?</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012200-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Is early treatment with disease‐modifying drugs more efficacious and safer than delayed treatment?</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> adults with first attack suggestive of MS<br/> <b>Setting:</b> MS centres<br/> <b>Intervention:</b> early disease‐modifying drug treatment<br/> <b>Comparison:</b> delayed disease‐modifying drug treatment; after the second attack or diagnosis with clinically definitive MS </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Without early disease‐modifying drug treatment</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>With early disease‐modifying drug treatment</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Disability‐worsening</b> </p> <p>Proportion of participants with disability‐worsening at a maximum of five years' follow‐up (assessed by EDSS**)<br/> Participants: N = 1868<br/> (4 open‐label extension studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.88<br/> (0.50 to 1.57) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40.2%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37.2%<br/> (25.2 to 51.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.0% fewer<br/> (15 fewer to 11.1 more) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c, d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No significant effect of early treatment compared to delayed treatment during five years' follow‐up; however there is a significant heterogeneity between the studies </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b> </p> <p>Proportion of participants with relapse at a maximum of five years' follow‐up<br/> Participants: N = 1485<br/> (3 open‐label extension studies) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>OR 0.35<br/> (0.26 to 0.48) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63.8%<br/> (56.7 to 70.7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.6% fewer<br/> (26.7 fewer to 12.7 fewer) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early treatment reduced the risk of relapses compared to delayed treatment during five years' follow‐up </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> **<b>EDSS:</b> expanded disability status scale<br/> <b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>High risk of bias for allocation concealment, blinding of outcome assessment and incomplete outcome data.<br/> <sup>b</sup>Surrogate outcome in two out of four studies contributing to this estimate.<br/> <sup>c</sup>High heterogeneity (I² = 67%, P = 0.03).<br/> <sup>d</sup>The confidence interval fails to exclude important benefit or important harms. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Is early treatment with disease‐modifying drugs more efficacious and safer than delayed treatment?</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012200-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Route</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RCTs</b> </p> <p><b>N = 10</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>OLEs</b> </p> <p><b>N = 8</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Cohort studies</b> </p> <p><b>N = 4</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interferon beta‐1b sc (Betaseron®)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sc</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 OLEs at a maximum follow‐up of 3, 5, 8.7, and 11 years</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interferon beta‐1a (Avonex®)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>im</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 OLEs at a maximum follow‐up of 5 and 10 years</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Interferon beta‐1a (Rebif®)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sc</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 OLE at a maximum follow‐up of 3 and 5 years</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glatiramer acetate sc</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>sc</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 OLE at a maximum follow‐up of 5 years</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cladribine os</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>os</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Teriflunomide os</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>os</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Immunoglobulins iv</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>iv</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>disease‐modifying drugs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>follow‐up from 2 to 6 years</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><b>im</b> : intramuscular; <b>iv</b> : intravenously; <b>OLEs</b> : open‐label extension studies; <b>os</b> : oral; <b>RCTs</b> : randomised controlled studies; <b>sc</b>: subcutaneous </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012200-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias in included cohort studies (ROBINS‐I)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0002" title="FazekasF , BaumhacklU , BergerT , DeisenhammerF , FuchsS , KristoferitschW , et al. Decision‐making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS). European Journal of Neurology2010;17(6):852‐60. [PUBMED: 20100231] ">ACISS 2010</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors’ judgment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All known important domains were not appropriately controlled for</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection of participants into the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants who would have been eligible for the target trial were likely included in the study and for each participant start of follow up and start of intervention likely coincided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Classification of interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention status was well defined and intervention definition was based on information collected at the time of intervention </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deviations from intended interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information was reported on whether there was deviation from the intended intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were critical differences between early, delayed or no treatment in participants with missing data and an appropriate analysis to address missing data was not done </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measurement of outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The outcome measures were subjective and assessed by assessors aware of the intervention received by study participants. This judgment is applicable to all the three outcomes reported in the article </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection of the reported result</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was evidence that reported results corresponded to all intended outcomes and analyses </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Critical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study judged to be at critical risk of bias in one domain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0012" title="D'AlessandroR , VignatelliL , LugaresiA , BaldinE , GranellaF , TolaMR , et al. Risk of multiple sclerosis following clinically isolated syndrome: a 4‐year prospective study. Journal of Neurology2013;260(6):1583‐93. [PUBMED: 23377434] ">GERONIMUS 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Authors’ judgment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding expected, all known important confounding domains appropriately measured and controlled for, and reliability and validity of measurement of important domains were sufficient, such that we do not expect serious residual confounding </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection of participants into the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All participants who would have been eligible for the target trial were likely included in the study and for each participant start of follow up and start of intervention likely coincided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Classification of interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention status was not well defined</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deviations from intended interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information was reported on whether there was deviation from the intended intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data were reasonably complete</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measurement of outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CDMS was assessed by assessors aware of the intervention received by study participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection of the reported result</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was evidence that reported results corresponded to all intended outcomes and analyses </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study judged to be at serious risk of bias in two domains, but not at critical risk of bias in any domain </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0014" title="SpelmanT , MeynielC , RojasJI , LugaresiA , IzquierdoG , Grand'MaisonF , et al. Quantifying risk of early relapse in patients with first demyelinating events: prediction in clinical practice. Multiple Sclerosis Journal2016;1:1‐12. [PUBMED: 27885062] ">MSBASIS 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Authors’ judgment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Important domains were not appropriately controlled for</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Selection of participants into the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Critical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Selection into the study was very strongly related to intervention and outcome and this could not be adjusted for in analyses </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Classification of interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention status was not well defined</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Deviations from intended interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information was reported on whether there was deviation from the intended intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information was reported on missing data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measurement of outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The outcome measures were subjective and they were assessed by assessors aware of the intervention received by study participants. Follow‐up duration not reported </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Selection of the reported result</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>There was evidence that reported results corresponded to all intended outcomes and analyses </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overall bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Critical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study judged to be at critical risk of bias in one domain</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0021" title="TintoreM , RoviraÀ , RíoJ , Otero‐RomeroS , ArrambideG , TurC , et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain2015;138:1863‐74. [PUBMED: 25902415] ">Tintore 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bias</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Authors’ judgment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Support for judgement</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Important domains were not appropriately controlled for</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection of participants into the study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>All participants who would have been eligible for the target trial were likely included in the study and for each participant start of follow up and start of intervention likely coincided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Classification of interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Intervention status was not well defined</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Deviations from intended interventions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information was reported on whether there was deviation from the intended intervention</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Missing data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reasons for missing data differed substantially across interventions, and the analysis is unlikely to have removed the risk of bias arising from the missing data </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Measurement of outcomes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The outcome measures were subjective and assessed by assessors aware of the intervention received by study participants. This judgment is applicable to all outcomes reported in the article </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection of the reported result</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There was evidence that reported results corresponded to all intended outcomes and analyses </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall bias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study judged to be at serious risk of bias in four domains, but not at critical risk of bias in any domain </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>ROBINS‐I is a tool to evaluate Risk Of Bias In Non‐randomised Studies ‐ of Interventions (<a href="./references#CD012200-bbs2-0118" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ (Clinical Research Ed.)2016; Vol. 355:i4919. [PUBMED: 27733354] ">Sterne 2016</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias in included cohort studies (ROBINS‐I)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012200-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Assessment of adverse events monitoring, definition and reporting of serious adverse events</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Did the researchers actively monitor for adverse events or did they simply provide spontaneous reporting of adverse events that arose?</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b> Did the authors define serious adverse events according to an accepted international classification and report the number of serious adverse events?</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0001" title="AchironA , KishnerI , Sarova‐PinhasI , RazH , FaibelM , SternY , et al. Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double‐blind, placebo‐controlled trial. Archives of Neurology2004;61(10):1515‐20. [PUBMED: 15477504] ">Achiron 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0002" title="FazekasF , BaumhacklU , BergerT , DeisenhammerF , FuchsS , KristoferitschW , et al. Decision‐making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS). European Journal of Neurology2010;17(6):852‐60. [PUBMED: 20100231] ">ACISS 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0003" title="KapposL , PolmanCH , FreedmanMS , EdanG , HartungHP , MillerDH , et al. Treatment with interferon beta‐1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006;67(7):1242‐9. [PUBMED: 16914693] ">BENEFIT 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes, active monitoring.“Regular visits were scheduled for safety assessments at months 3, 6, 9, 12, 18, and 24”<i>.</i> (page 1243) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0004" title="KapposL , FreedmanMS , PolmanCH , EdanG , HartungHP , MillerDH , et al. Effect of early versus delayed interferon beta‐1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3‐year follow‐up analysis of the BENEFIT study. Lancet2007;370(9585):389‐97. [PUBMED: 17679016] ">BENEFIT 2007 (3 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0005" title="KapposL , FreedmanMS , PolmanCH , EdanG , HartungHP , MillerDH , et al. Long‐term effect of early treatment with interferon beta‐1bafter a first clinical event suggestive of multiple sclerosis: 5‐year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology2009;8(11):987–97. [PUBMED: 19748319] ">BENEFIT 2009 (5 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0006" title="EdanG , KapposL , MontalbánX , PolmanC , FreedmanM , HartungH , et al. Long‐term impact of interferon beta‐1b in patients with CIS: 8‐year follow‐up of BENEFIT. Journal of Neurology, Neurosurgery, and Psychiatry2014;85:1183–9. [PUBMED: 24218527] ">BENEFIT 2014 (8.7 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0007" title="KapposL , EdanG , FreedmanMS , MontalbánX , HartungHP , HemmerB , et al. The 11‐year long‐term follow‐up study from the randomized BENEFIT CIS trial. Neurology2016;87(10):978‐87. [PUBMED: 27511182] ">BENEFIT 2016 (11 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0008" title="CHAMPS Study Group. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High‐Risk Subjects Avonex Multiple Sclerosis Prevention Study. Multiple Sclerosis2002;8(4):330‐8. [PUBMED: 12166504] JacobsLD , BeckRW , SimonJH , KinkelRP , BrownscheidleCM , MurrayTJ , et al. Intramuscular interferon beta‐1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine2000;343(13):898‐904. [PUBMED: 11006365] ">CHAMPS 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No active monitoring. "Each center was instructed to report all adverse events during the first six months of treatment, but thereafter to report only serious adverse events". (page 899) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0009" title="KinkelRP , KollmanC , O'ConnorP , MurrayTJ , SimonJ , ArnoldD , et al. IM interferon beta‐1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology2006;66(5):678‐84. [PUBMED: 16436649] ">CHAMPS 2006 (5 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0010" title="KinkelRP , DontchevM , KollmanC , SkaramagasTT , O'ConnorPW , SimonJH , et al. Association between immediate initiation of intramuscular interferon beta‐1a at the time of a clinically isolated syndrome and long‐term outcomes: a 10‐year follow‐up of the Controlled High‐Risk Avonex Multiple Sclerosis Prevention Study in Ongoing Neurological Surveillance. Archives of Neurology2012;69(2):183‐90. [PUBMED: 21987393] SimonJH , KinkelRP , KollmanC , O'ConnorP , FisherE , YouX , et al. Ten‐year follow‐up of the 'minimal MRI lesion' subgroup from the original CHAMPS Multiple Sclerosis Prevention Trial. Multiple Sclerosis2015;21(4):415‐22. [PUBMED: 25344370] ">CHAMPS 2012 (10 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0011" title="ComiG , FilippiM , BarkhofF , DurelliL , EdanG , FernándezO , et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet2001;357(9268):1576‐82. [PUBMED: 11377645] ">ETOMS 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes, active monitoring<i>.</i> "Safety was assessed at 1, 6, 12, 18, 24 months". (page 1577) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes to both questions. <i>"</i>Serious adverse events were defined according to the guidelines of the International Conference on Harmonisation". (page 1580) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0012" title="D'AlessandroR , VignatelliL , LugaresiA , BaldinE , GranellaF , TolaMR , et al. Risk of multiple sclerosis following clinically isolated syndrome: a 4‐year prospective study. Journal of Neurology2013;260(6):1583‐93. [PUBMED: 23377434] ">GERONIMUS 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0013" title="MotamedMR , NajimiN , FereshtehnejadSM . The effect of interferon‐beta‐1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis. Clinical Neurology and Neurosurgery2007;109(4):344‐9. [PUBMED: 17300863] ">Motamed 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes, active monitoring."Safety assessments were performed at the end of months 1, 2, 3, 9, 15, and 21 by a neurologist". (page 345) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0014" title="SpelmanT , MeynielC , RojasJI , LugaresiA , IzquierdoG , Grand'MaisonF , et al. Quantifying risk of early relapse in patients with first demyelinating events: prediction in clinical practice. Multiple Sclerosis Journal2016;1:1‐12. [PUBMED: 27885062] ">MSBASIS 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0015" title="LeistTP , ComiG , CreeBA , CoylePK , FreedmanMS , HartungHP , et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurology2014;13(3):257‐67. [PUBMED: 24502830] ">ORACLE 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes, active monitoring<i>.</i> "Adverse events and laboratory findings were recorded at study visits and at regularly scheduled interim visits" (page 259). "International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use". (page 258) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes to both questions. "International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use". (page 258) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0016" title="PakdamanH , SahraianMA , FallahA , PakdamanR , GhareghozliK , GhafarpourM , et al. Effect of early interferon beta‐1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. Acta Neurologica Scandinavica2007;115(6):429‐31. [PUBMED: 17511854] ">Pakdaman 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0017" title="ComiG , MartinelliV , RodegherM , MoiolaL , BajenaruO , CarraA , et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double‐blind, placebo‐controlled trial. Lancet2009;374(9700):1503‐11. [PUBMED: 19815268] ">PRECISE 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear whether the researchers actively monitored for adverse events or they simply provided spontaneous reporting of adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0018" title="ComiG , MartinelliV , RodegherM , MoiolaL , LeocaniL , BajenaruO , et al. Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Multiple Sclerosis2013;19(8):1074‐83. [PUBMED: 23234810] ">PRECISE 2013 (5 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear whether the researchers actively monitored for adverse events or they simply provided spontaneous reporting of adverse events </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0019" title="ComiG , DeStefanoN , FreedmanMS , BarkhofF , PolmanCH , UitdehaagBM , et al. Comparison of two dosing frequencies of subcutaneous interferon beta‐1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology2012;11(1):33‐41. [PUBMED: 22146409] ">REFLEX 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes, active monitoring<i>.</i> "Active monitoring by personnel was ensured via various testing". (page 34). "Adverse events were coded with the Medical Dictionary for Regulatory Activities (MedDRA) and analysed according to the preferred terms". (page 35) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes to both questions."Adverse events were coded with the Medical Dictionary for Regulatory Activities (MedDRA) and analysed according to the preferred terms". (page 35) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0020" title="ComiG , DeStefanoN , FreedmanM , BarkhofF , UitdehaagB , deVosM , et al. Subcutaneous interferon β‐1a in the treatment of clinically isolated syndromes: 3‐year and 5‐year results of the phase III dosing frequency‐blind multicentre REFLEXION study. Journal of Neurology, Neurosurgery, and Psychiatry2016;88(4):285‐94. [PUBMED: 28039317] ">REFLEX 2016 (3 and 5 years FU)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear. "Adverse events (adverse events) were monitored at months 25 and 27 and then every 3 months to the study end". (page 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0021" title="TintoreM , RoviraÀ , RíoJ , Otero‐RomeroS , ArrambideG , TurC , et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain2015;138:1863‐74. [PUBMED: 25902415] ">Tintore 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012200-bbs2-0022" title="MillerAE , WolinskyJS , KapposL , ComiG , FreedmanMS , OlssonTP , et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet Neurology2014;13(10):977‐86. [PUBMED: 25192851] ">TOPIC 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unclear. "Adverse events were reported by study participants or investigators throughout the study; investigators recorded all such events on case report forms". (page 979) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No information</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Assessment of adverse events monitoring, definition and reporting of serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012200-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Outcome data from cohort studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012200-bbs2-0002" title="FazekasF , BaumhacklU , BergerT , DeisenhammerF , FuchsS , KristoferitschW , et al. Decision‐making for and impact of early immunomodulatory treatment: the Austrian Clinically Isolated Syndrome Study (ACISS). European Journal of Neurology2010;17(6):852‐60. [PUBMED: 20100231] "><b>ACISS 2010</b> </a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Early DMDs treatment (N = 49)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Delayed DMDs treatment (N = 57)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No treatment</b> </p> <p><b>(N = 52)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>EDSS score over 24 months' follow‐up</b> </p> <p>Mean (SD)</p> <p>Median (range)</p> <p>Kruskal–Wallis H‐Test P value &lt;0.001</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (0.9)</p> <p>1.5 (0‐3)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.6 (1.2)</p> <p>1.5 (0‐6)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 (0.8)</p> <p>1.0 (0‐3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value versus no treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.016</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value early versus delayed treatment (Wilcoxon matched pair test)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.055</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapses</b> </p> <p>Mean (SD)</p> <p>Median (range)</p> <p>Kruskal–Wallis H‐Test P value &lt; 0.001</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (0.8)</p> <p>0.0 (0‐4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 (1.1)</p> <p>1.0 (0‐4)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.2 (0.5)</p> <p>0.0 (0‐3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value versus no treatment</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.059</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>P value early versus delayed treatment (Wilcoxon matched pair test)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012200-bbs2-0021" title="TintoreM , RoviraÀ , RíoJ , Otero‐RomeroS , ArrambideG , TurC , et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain2015;138:1863‐74. [PUBMED: 25902415] ">Tintore 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Risk of attaining an EDSS score of 3.0 with early DMDs compared with delayed DMDs treatment. </p> <p>Adjusted hazard ratio: 0.5 (95% CI 0.3 to 0.9)</p> <p>Unadjusted hazard ratio: 1.1 (95% CI 0.7 to 1.9)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><b>DMDs</b> : disease‐modifying drugs. <b>EDSS:</b> expanded disability status scale; NA: not applicable; <b>SD:</b> standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Outcome data from cohort studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012200-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Time until the delayed treatment in open‐label extension studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time until the delayed treatment after randomisation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012200-bbs2-0003" title="KapposL , PolmanCH , FreedmanMS , EdanG , HartungHP , MillerDH , et al. Treatment with interferon beta‐1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology2006;67(7):1242‐9. [PUBMED: 16914693] ">BENEFIT 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD): 1.5 (0.73) years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012200-bbs2-0008" title="CHAMPS Study Group. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. Controlled High‐Risk Subjects Avonex Multiple Sclerosis Prevention Study. Multiple Sclerosis2002;8(4):330‐8. [PUBMED: 12166504] JacobsLD , BeckRW , SimonJH , KinkelRP , BrownscheidleCM , MurrayTJ , et al. Intramuscular interferon beta‐1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine2000;343(13):898‐904. [PUBMED: 11006365] ">CHAMPS 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (interquartile range): 30 (24‐35) months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012200-bbs2-0017" title="ComiG , MartinelliV , RodegherM , MoiolaL , BajenaruO , CarraA , et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double‐blind, placebo‐controlled trial. Lancet2009;374(9700):1503‐11. [PUBMED: 19815268] ">PRECISE 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (range): 29 (0.5 –38) months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012200-bbs2-0019" title="ComiG , DeStefanoN , FreedmanMS , BarkhofF , PolmanCH , UitdehaagBM , et al. Comparison of two dosing frequencies of subcutaneous interferon beta‐1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurology2012;11(1):33‐41. [PUBMED: 22146409] ">REFLEX 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data not reported</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Time until the delayed treatment in open‐label extension studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012200-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Safety outcome data from open‐label extension studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Interferon beta‐1b</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Intramuscular interferon beta 1‐a (Avonex)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Subcutaneous interferon beta 1‐a (Rebif)</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Glatiramer acetate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>487</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>383</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>517</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>481</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events ‐ number of participants</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinued treatment for any adverse events</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Discontinued treatment or were lost to follow‐up for any reason</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>146</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>192</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Years of follow‐up</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.7</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Safety outcome data from open‐label extension studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/full#CD012200-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012200-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Active intervention versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Occurrence of at least one serious adverse event over 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3385</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.60, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Interferon beta‐1b (Betaseron) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.48, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Interferon beta‐1a (Avonex) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.28, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Interferon beta‐1a (Rebif) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>823</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.35, 1.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Glatiramer acetate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.25, 1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Teriflunomide versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.59, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Cladribine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.43, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Occurrence of at least one serious adverse event over 36 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Interferon beta‐1a (Avonex) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.44, 3.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Withdrawing from the study or discontinuing the drug due to adverse events over 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2693</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.43 [0.91, 6.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Interferon beta‐1b (Betaseron) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>468</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>21.54 [2.92, 159.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Interferon beta‐1a (Rebif) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>514</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.26, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Glatiramer acetate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.58 [1.16, 11.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Teriflunomide versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>614</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.58, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Cladribine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>616</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.13 [1.44, 11.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Withdrawing from the study or discontinuing the drug due to adverse events over 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Interferon beta‐1a (Avonex) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.02, 1.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Time to conversion to CDMS over 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.47, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Interferon beta‐1b (Betaseron) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.50 [0.36, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Interferon beta‐1a (Avonex) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.38, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Interferon beta‐1a (Rebif) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.43, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Glatiramer acetate versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.40, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Teriflunomide versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.38, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Cladribine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.25, 0.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 Any DMD vs no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.30, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Time to conversion to CDMS over 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Immunoglobulins versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [0.15, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Withdrawing from the study or discontinuing the drug for any reason over 24 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2931</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.61, 1.62]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Interferon beta‐1b (Betaseron) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>487</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [0.95, 2.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Interferon beta‐1a (Avonex) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>383</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.65, 1.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Interferon beta‐1a (Rebif) versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>826</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.18, 1.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.4 Teriflunomide versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>618</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.59, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.5 Cladribine versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>617</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [1.49, 3.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Withdrawing from the study or discontinuing the drug for any reason over 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Immunoglobulins versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.15 [0.37, 12.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Active intervention versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/references#CD012200-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012200-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Early versus delayed treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Time to conversion to CDMS at different follow‐up years <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 2‐4 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.48, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 5 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.53, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 8.7‐10 years' follow‐up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.54, 0.79]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Early versus delayed treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012200.pub2/references#CD012200-tbl-0010">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012200.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012200-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012200-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012200-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012200-note-0002">Français</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012200\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012200\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012200\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012200\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012200\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=mV7VuqgF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012200.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012200.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012200.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012200.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012200.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729084909"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012200.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729084912"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012200.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed4453ec4f56f',t:'MTc0MDcyOTA4NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 